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Abstract  
Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma with poor 
prognosis. RMS, and especially the embryonal subtype (ERMS), show activation of Hedgehog 
(HH) signaling. In patients with Gorlin syndrome, who have an increased susceptibility to 
ERMS, activation of the HH pathway is due to mutations in the HH receptor PATCHED 
(PTCH). This is different in sporadic RMS, in which mutations in components of the HH 
pathway are very rare.  
Because the HH pathway seems to be a good target for RMS therapy, we tested the effects of 
several SMOOTHENED (SMO) inhibitors on cell lines derived from sporadic human RMS. The 
response of the cells was very heterogeneous and some drugs paradoxically induced 
proliferation at certain concentrations or showed anti-proliferative effects without inhibition of 
HH signaling activity. Therefore we hypothesized that the antitumoral effects of SMO inhibitors 
may rely on off-target effects. In addition, our group found evidence for an interaction between 
HH and PI3K/AKT/mTOR signaling in RMS.  
Since the majority of RMS show phosphorylation of AKT or S6 and since an interaction 
between the PI3K/AKT/mTOR and HH signaling pathways is well described in the literature, 
this thesis elucidated the importance of PI3K/AKT/mTOR signaling in RMS and in regulation of 
HH signaling activity. Furthermore the effectiveness of PI3K/AKT/mTOR inhibitors alone and 
in combination with SMO inhibitors was analyzed. For this purpose cell lines from sporadic 
human ERMS and the Ptch+/- mouse model for ERMS were employed. In addition, we tried to 
unravel if the anti-cancer effects of SMO inhibitors that were not associated with a 
downregulation of HH signaling activity were off-target effects.  
The data show that cell lines from sporadic human ERMS are rather unresponsive to 
stimulation by the SHH ligand or SMO agonist. They are also only moderately responsive to 
SMO inhibitors, which apparently can exert off-target effects. However, they are highly 
responsive to PI3K/AKT/mTOR inhibitors, especially to the PI3K inhibitor pictilisib. 
Furthermore, PI3K/AKT/mTOR inhibitors can inhibit HH signaling activity in ERMS cells and 
when combined with SMO inhibitors they can induce cooperative anti-cancer effects.  
Because the investigated human ERMS cell lines in most likelihood do not harbor mutations 
that cause activation of HH signaling upstream of SMO and because the cells were only 
moderately responsive to SMO inhibitors, we hypothesized that SMO inhibitors alone are only 
useful in those ERMS that are caused by mutations upstream of SMO. To approach this 
hypothesis, we made use of ERMS-like tumors of Ptch mutant mice. Indeed, cultured Ptch+/- 
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ERMS cells respond to SMO inhibitors, which goes along with efficient reduction of Hh 
signaling activity. In addition, and as in human ERMS cells, efficient reduction of Hh signaling 
activity and antitumor effects are also seen with the PI3K inhibitor pictilisib. Furthermore, the 
combination of SMO inhibitors plus pictilisib synergistically induces anti-cancer effects. When 
applied orally to tumor bearing Ptch+/- mice, SMO inhibitors stop tumor growth and 
downregulate Gli1 expression, which correlates with reduction of tumor size. Tumor growth is 
also stopped by pictilisib. However, in contrast to cultured Ptch+/- ERMS cells and human 
ERMS cell lines and probably due to microenvironmental factors, pictilisib does not affect Gli1 
expression.  
In summary, the experiments of this thesis demonstrate that SMO inhibitors and concomitant 
reduction of HH signaling activity exhibit strong antitumoral effects in ERMS that harbor 
mutations upstream of SMO, whereas their antitumoral activity in cell lines derived from 
sporadic human ERMS (which most likely do not harbor mutations upstream of SMO) is very 
variable and not always associated with HH signaling inhibition. In contrast, PI3K/AKT/mTOR 
inhibitors e.g. pictilisib induce a strong antitumoral response irrespective of the mutational 
status of the HH pathway and in some cases also may allow for lowering the dose of SMO 
inhibitors. Together, these data suggest that PI3K/AKT/mTOR inhibitors are in general a better 
and probably a more secure therapeutic option in patients with sporadic ERMS and that a 
treatment with SMO inhibitors requires either pretesting e.g. in patient-derived short-term RMS 
cultures or a screen for PTCH mutations. 
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1 Introduction 
1.1 Rhabdomyosarcoma (RMS) 
RMS is the most common pediatric soft tissue sarcoma with an annual incidence rate of 5.4 
(males) and 4.2 (females) cases per one million children at the age of 0-19 years1,2. 
Originally RMS was supposed to develop from the skeletal muscle lineage. However, these 
tumors can also arise from non-skeletal muscle progenitor cells3,4. Hence, primary sites of 
RMS are not only skeletal muscle tissue i.e. the muscles of the limbs, but also the head and 
neck area, the genitourinary tract and the peritoneum1,5. 
The two major histological subtypes are embryonal RMS (ERMS, account for approx. 50 % 
of cases) and alveolar RMS (ARMS, account for approx. 40 % of cases). In addition, spindle 
cell RMS and botryoid RMS have been classified as the third and fourth accepted subtype6.  
On a molecular basis ARMS are further characterized by chromosomal reciprocal 
translocations of chromosome 13 and chromosome 2 or 1. These translocations, t(2;13)(q35-
37;q14) and t(1;13)(p36;q14), result in the expression of PAX3/FOXO1 and PAX7/FOXO1 
fusion proteins, respectively. Approximately 70 % of ARMS are fusion protein-positive tumors 
and the expression of the fusion proteins is associated with a poorer outcome7-9. In contrast, 
ERMS don’t show unique chromosomal alterations. However, they frequently show a loss of 
heterozygosity (LOH) at 11p15 locus10-12. Additionally ERMS often accumulate copy number 
variations and structural variants in typical cancer associated genes like NRAS, KRAS, 
TP53, FGFR4 and PIK3CA. For example, RAS pathway mutations occur in 75 % of high-risk 
ERMS13. In addition, 10 % of ERMS carry a c.365T>G mutation within the MYOD1 gene, 
which results in a p.Leu122Arg substitution that alters the DNA binding domain of this 
myogenic transcription factor and which is associated with a worse outcome14.  
Risk stratification for RMS is predicted based on age, tumor subtype and stage, primary site 
and number/sites of metastatic disease. Hence, the 10-year overall survival ranges between 
20 % for fusion gene-positive ARMS, 65 % for ERMS and 75 % for fusion gene-negative 
ARMS15. The current therapy of RMS consists of radiotherapy or surgery in combination with 
a multi-agent chemotherapy that includes vincristine, actinomycin D and cyclophosphamide 
(VAC). A trial with 617 intermediate-risk RMS patients receiving X-rays and VAC treatment 
resulted in a mean 4-year failure-free survival in 73 % of the patients. However, this 
therapeutic approach is highly toxic and can result in febrile neutropenia (85 %), anemia (55 
%), infectious diseases (54 %), leukopenia (60 %), lymphopenia (22 %), neutropenia (63 %) 
and thrombopenia (51 %). Besides, secondary hematologic malignancies or secondary solid 
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tumors can occur16. As these adverse effects of chemotherapy are especially detrimental for 
children, other therapy approaches including targeted therapy are highly requested. 
1.1.1 Current clinical trials for RMS 
Even though the 3-year failure-free survival for low-risk RMS with the current treatment 
options is > 90 %, patients with high-risk metastatic RMS have a long-term failure-free 
survival of < 30 %. Hence, clinical trials for low-risk RMS aim to sustain the effectiveness of 
current treatments while at the same time reducing toxicities. In contrast, clinical trials for 
intermediate- and high-risk RMS aim to improve the therapy effectiveness of the current 
chemotherapy17. In addition, trials for refractory or relapsed RMS after standard therapy often 
assess the effectiveness of alternative novel targeted therapies.  
Ongoing or recently completed clinical trials can be found in the ClinicalTrials.gov database 
(provided by the U.S. National Library of Medicine) and will be summarized in the following 
section.  
Currently, many clinical trials test agents targeting receptor tyrosine kinases or their ligands, 
either as single agent therapy or in combination with a chemotherapy backbone. Examples 
are the trials NCT01222715 and NCT00643565, which investigate the effectiveness of the 
monoclonal antibody bevacizumab, which targets the vascular endothelial growth factor 
(VEGF). However, the treatment did not show any benefits compared to the current 
therapy18. Other examples are the studies NCT01055314, NCT00642941 and 
NCT03041701, which investigate the effectiveness of cixutumumab, R1507 and ganitumab, 
which are three different monoclonal antibodies against insulin-like growth factor 1 receptor 
(IGF-1R). Whereas cixutumumab is applied in combination with a chemotherapy backbone, 
R1507 is applied as single drug and ganitumab is applied in combination with the tyrosine 
kinase inhibitor dasatinib. The study results are already published for R1507 and show that 
the drug is well tolerated but is not efficient in refractory or relapsed RMS19.  
Besides antibodies targeting receptors or ligands, small molecules are employed in RMS. 
Examples are the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib 
(NCT03210714) and the epidermal growth factor receptor (EGFR) inhibitors erlotinib and 
afatinib (NCT00077454, NCT02689336 and NCT 02372006). Additionally, VEGF signaling is 
repressed with multi-target receptor tyrosine kinase inhibitors that target its receptors 
(VEGFRs), e.g. regorafenib (NCT02048371 and NCT02085148), sorafenib (NCT01502410), 
cabozantinib (NCT02867592) and lanvatinib (NCT03245151).  
Additionally, several RMS clinical trials target more downstream kinases of common 
oncogenic pathways, which are the phosphatidylionsitide 3-kinase (PI3K) / protein kinase B 
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(AKT) / mammalian target of rapamycin (mTOR) signaling pathway. For instance the mTOR 
inhibitor temsirolimus, which is approved by the FDA and EMEA for renal cell carcinoma, 
entered a phase III clinical trial in combination with a chemotherapy backbone for 
intermediate-risk RMS patients (NCT02567435). Two additional mTOR inhibitors, rapamycin 
and everolimus, are also under investigation (NCT01331135, NCT02574728 and 
NCT01216839). Furthermore, the dual mTOR and PI3K inhibitor LY302314 as well as the 
PI3K inhibitor copanlisib are investigated (NCT03123678 and NCT03458728). Finally, results 
for a clinical phase II trial with perifosine, which supposedly inhibits AKT and also the MAPK 
and JNK pathways, have been published and show that this drug is not effective in RMS20.  
Together these data show that the effectiveness of the currently completed targeted therapy 
treatments using inhibitors of receptor tyrosine kinases or the PI3K/AKT/mTOR pathway 
stayed somewhat behind the expectations. Therefore current research also focuses on other 
therapy options. One pathway, which apparently is activated in RMS, but silenced in most 
adult human cells, is the Hedgehog (HH) signaling cascade21,22. Recently, results of a phase 
I clinical trial with the Smoothened (SMO) inhibitor sonidegib for pediatric and adult RMS, 
medulloblastoma, neuroblastoma, hepatoblastoma, glioma or astrocytoma were posted 
(NCT01125800). The maximal tolerated dose was 680 mg/m2 and oral application induced 
dose-limiting toxicities in only 1 of 60 pediatric participants who was is the group receiving 
372 mg/m2 sonidegib. Results from another phase II clinical trial using a SMO inhibitor called 
vismodegib (oral application of 150 mg per day) in combination with the γ-secretase/notch 
signaling pathway inhibitor RO4929097 were posted in 2016 (NCT01154452). The short-
term results (4 month) show that addition of vismodegib is of no benefit. However the results 
about the long-term effects are not available yet. Even though HH signaling plays an 
important role in tumorigenesis and tumor maintenance of RMS (see section 1.2.4), no 
further clinical trials targeting this pathway are under investigation. 
1.2 The Hedgehog (HH) signaling cascade 
The importance of HH proteins became obvious upon a mutational screen in Drosophila 
melanogaster larvae, performed back in 198023. The screen discovered a set of genetic 
mutations leading to segmentation defects. One of these larvae had duplicated denticles24. 
As this phenotype – in the view of the authors – resembled a hedgehog, the responsible 
gene in Drosophila melanogaster was called hedgehog as was the resulting protein. 
1.2.1 Canonical HH signaling  
In vertebrates, three Hh homologs exist, which are Desert hedgehog (DHH), Indian 
hedgehog (IHH) and Sonic hedgehog (SHH). SHH is the most important HH protein and 
Introduction 4 
 
 
 
plays a crucial role in several key developmental processes in the human embryo including 
patterning of the neural tube, the ventral somites and the anterior-posterior limb axis24. In 
addition, HH signaling is very important for regulation of tissue homeostasis and stem cell 
maintenance as well as for differentiation processes in the adult organism. As dysregulated 
cell growth is associated with the development of cancer, it is not surprising that aberrant HH 
signaling can induce tumorigenesis25. 
Although the mechanism of canonical HH signal transduction within eukaryotic cells is not 
fully understood, the main factors are known and a simplified scheme of the pathway is 
depicted in Fig. 1. Today it is known that binding of any of the three HH ligands to the 
transmembrane protein Patched 1 (PTCH) that is located in the primary cilium and represses 
SMO, releases the inhibition of SMO. The mechanism of SMO repression by PTCH in the 
absence of HH is not completely understood, but upon HH binding PTCH disappears from 
the primary cilium and subsequently SMO translocates into the primary cilium26. 
Accumulation of SMO in the primary cilium triggers an intracellular signaling cascade, which 
finally leads to conversion of the Glioma-associated Oncogene Homolog (GLI) transcription 
factors GLI2 and GLI3 into their active state. As a consequence GLI2/3 are translocated into 
the nucleus where they recognize and bind to specific promoter sequences. The latter 
process activates transcription of HH target genes, which are amongst others GLI1, PTCH 
and HHIP27,28. Whereas expression of GLI1 amplifies the signal in a positive feedback loop, 
expression of the two negative regulators PTCH and HHIP reflect negative feedback loops. 
HHIP is the abbreviation for HH interacting protein, which is a membrane protein that can 
compete with PTCH for binding of all three HH ligands29.  
Besides positive and negative feedback regulation, GLI proteins can regulate the expression 
of factors that are related to cell cycle progress, proliferation and cell survival, e.g. CyclinD1, 
IGF2 and N-Myc. However the cellular response upon GLI activation highly depends on the 
cell type, age, state and time28,30. 
Within the following, the three main components of HH signal transduction in a recipient cell, 
PTCH, SMO and GLI, are described in more detail, because they play an important role in 
cancers associated with aberrant HH signaling activity. 
PTCH is a 12-pass transmembrane protein with the N- and C-terminal parts located within 
the cytoplasm and six extracellular as well as five intracellular loops. The extracellular parts 
of PTCH interact with the three SHH co-receptors growth arrest-specific 1 (GAS1), cell 
adhesion molecule-related/down-regulated by oncogenes (CDO) and brother of CDO (BOC), 
which are essential for proper signal activation31,32.  
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Figure 1: The HH signaling pathway. (A) In absence of HH ligands, the transmembrane protein 
PTCH withholds SMO from entering the primary cilium. This triggers an intracellular signaling cascade 
resulting in the phosphorylation of GLI transcription factors. As a result GLI proteins are processed into 
their truncated repressor forms (GLI
R
) which enter the nucleus to inhibit target gene expression or are 
further degraded by the proteasome. (B) Upon binding of HH ligands to PTCH, the transmembrane 
protein exits the primary cilium and the repression of SMO is released. Hence SMO enters the primary 
cilium and the GLI transcription factors are activated and translocate into the nucleus where they 
induce the expression of HH target genes, e.g. GLI1 and PTCH. A more detailed description of the HH 
signaling pathway can be found in the main text. 
The mechanism of signal transduction from PTCH to SMO is not well understood. 
Nevertheless the N-terminal part of PTCH is important for ligand binding as well as SMO 
inhibition and the C-terminal cytosolic tail of PTCH is sufficient for localization of the protein 
within the primary cilium. In addition, the removal of PTCH from the primary cilium, in 
contrast to binding of HH ligands to PTCH, seems to be uncoupled from the activation of 
SMO. As a consequence, it is supposed that removal of PTCH from the primary cilium might 
rather enhance than induce the response to HH ligands33. 
PTCH plays a pivotal role in developmental processes and in cancer. Thus, in humans, 
germline mutations in PTCH result in Gorlin syndrome that is characterized by 
developmental anomalies and a variety of tumors (see section 1.2.2 for description). In mice, 
the homozygous deletion of Ptch leads to neural tube closure defects and Ptch mutants do 
not survive beyond embryonic day 9.0. Heterozygous deletion of Ptch can result in 
developmental anomalies like polydactyly and overgrowth34. In addition, these animals are 
prone to develop basal cell carcinoma, medulloblastoma and RMS34,35. 
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SMO is a G protein-coupled receptor that consists of 7 transmembrane domains, 3 
extracellular and 3 intracellular loops, an extracellular N- and an intracellular C-terminus. 
Although in research focus since several years, the mechanism of SMO repression by PTCH 
and the identity of cell endogenous SMO ligands remains elusive, as reviewed in36. However, 
it is known that HH ligands induce phosphorylation of SMO at the C- terminus37 that leads to 
a conformation change resulting in SMO activation38. In Drosophila melanogaster it was 
shown that Smo activation leads to ubiquitination and degradation of Ptch39. 
The transmembrane domain of SMO carries a binding pocket, which is accessible for small 
molecule inhibitors. The first described inhibitor was the natural SMO antagonist 
cyclopamine. Discovery of this drug began more than 50 years ago, when a series of lamb 
cyclops were born in sheep ranches in the United States. Within the following decades a 
causative compound was found in wildflowers. Offspring of sheep fed with these wildflowers 
developed malformations of the head and in the worst case were born as cyclops. Hence, 
the compound was named cyclopamine. Cyclopamine was shown to be the first SMO 
antagonist inhibiting HH signaling and evoking developmental problems40. Besides 
cyclopamine several SMO antagonists and agonists, which can bind to different sites of 
SMO’s binding pocket have been developed41. The SMO inhibitors that are used in this 
thesis are described in detail in section 1.3.1. 
In addition, the extracellular N-terminus of SMO possesses a cysteine-rich domain that is 
accessible to oxysterol binding. Interaction of oxysterols with this domain, albeit not fully 
understood on mechanistic basis, can modulate SMO activation as well42. 
The importance of SMO in development was discovered in Smo knock-out mouse embryos. 
These embryos suffer from severe developmental defects like holoprosencephaly, cyclopia 
and heart defects and do not survive beyond embryonic day 9.543. Opposite, activating SMO 
mutations result in activation of HH signaling and lead to basal cell carcinoma and other 
tumors both in humans and mice44,45. 
In vertebrates, three members of the GLI zinc-finger transcription factor family exist, which 
are GLI1, GLI2 and GLI3. Whereas GLI2/3 can occur in a repressor or activator form and 
serve as a first line of HH signal sensors, GLI1 is expressed when GLI2/3 activate its 
transcription. It therefore amplifies the initial response to the HH signal. 
GLI transcription factors consist of five zinc-finger DNA binding domains that recognize the 
DNA motif 5’-GACCACCCA-3’ 46,47. In the absence of HH ligands, GLI2/3 bind to a 
cytoplasmatic protein called Suppressor of Fused (SUFU), which represses the nuclear 
transport of GLI activator forms. Upon activation of the pathway, SUFU-bound GLI2/3 
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translocate into the primary cilium and their activator forms are released from SUFU at the tip 
of the cilium. Subsequently GLI2/3 translocate into the nucleus where they induce HH target 
gene expression48,49. Homozygous Sufu mutant embryos suffer from severe developmental 
abnormalities resulting in open fore-, mid- and hindbrain and neural tube closure defects as 
well as cardiac malformations. Sufu mutants die in utero at embryonic day 9.550-52, which is 
similar to Ptch mutant embryos that show a comparable phenotype as described above. This 
indicates the importance of SUFU’s function in proper HH signaling regulation. Hence it is not 
surprising that SUFU mutations were also found in patients with Gorlin syndrome and 
sporadic medulloblastoma53 and that Sufu+/- p53+/- animals are prone to medulloblastoma and 
RMS52. 
The regulation of transcriptional activity of GLI proteins is conducted by several 
posttranslational modification steps. Depending on the availability of HH ligands, GLI2/3 are 
phosphorylated at two different phosphorylation clusters, one N-terminal and the other C-
terminal of the zinc-finger DNA binding domains54. In the absence of HH ligands, protein 
kinase A (PKA), glycogen synthase kinase 3β (GSK3β) and casein kinase 1 (CK1) 
phosphorylate GLI2/3 at the C-terminus, triggering their ubiquitination and proteasomal 
degradation into the truncated repressor forms. Dephosphorylation of the C-terminus and 
additional phosphorylation at the N-terminus is essential for pathway activation in the 
presence of HH ligands. In this case, full length activator forms of GLI2/3 are stabilized, 
released from SUFU binding and translocate into the nucleus, where they activate target 
gene expression. The sensitive equilibrium between the activator and repressor form of 
GLI2/3 depends on the quantitative availability of ligands and is referred to as the GLI code55. 
Signal quantification is achieved by stepwise phosphorylation and dephosphorylation of 
GLI2/328,55 and regulates fate decision of HH morphogen recipient cells in developmental 
processes. GLI1, in contrast to GLI2/3, misses the N-terminal region that is necessary for the 
repressor form and can therefore only act as an activating transcription factor. 
1.2.2 Canonical HH signaling in cancer 
The first link between HH signaling and cancer was the discovery of PTCH mutations in 
patients with Gorlin syndrome. Gorlin patients develop basal cell carcinoma at high incidence 
and are prone to medulloblastoma, RMS and meningioma56-58. Nowadays it is clear that the 
HH signaling pathway is also active in the majority of sporadic basal cell carcinoma and a 
subset of sporadic medulloblastoma. In many of these tumors, HH pathway activation is due 
to inactivating mutations in PTCH or SUFU or activating mutations in SMO44,53,59.  
In addition, HH signaling is activated in several cancers that are not associated with Gorlin 
syndrome. In glioblastoma, HH signaling plays an important role in cancer stem cell 
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maintenance and tumorigenesis60-62. In breast cancer HH signaling activity caused by HH 
ligand overexpression is associated with an unfavorable outcome63,64. Similarly, 
overexpression of the HH ligands plays a role in formation of pancreatic cancer65-67. In this 
tumor entity, ligand expression by the tumor cells has a paracrine function as it activates HH 
signaling in the tumor stroma, which can promote invasion and metastasis68,69. In prostate 
cancer, paracrine as well as autocrine pathway activation seems to be important and HH 
target gene expression is associated with loss of the negative regulator SUFU or HH ligand 
overexpression70-75. In melanoma, HH signaling is also active and exome sequencing 
detected mutations in PTCH, SUFU, SMO, GLI1, GLI2 or GLI376,77. 
1.2.3 Non-canonical HH signaling 
Besides the canonical HH/PTCH/SMO/GLI axis, several non-canonical regulation 
mechanisms of the pathway have been described in cancer. In many types of cancer that 
show an expression of components of classical HH signaling, non-canonical interactions play 
an additional role in tumorigenesis, maintenance or metastasis. First, HH, PTCH or SMO can 
regulate processes independently of the GLI transcription factors. Second, the GLI 
transcription factors can be activated in a HH/PTCH/SMO independent way. This section will 
focus on a few examples for both regulation mechanisms and their implications in cancer. 
1.2.3.1 GLI-independent effects of HH, PTCH and SMO 
The HH ligand sensor PTCH is a dependence receptor, meaning that it evokes pro-apoptotic 
effects when expressed in the absence of its ligands78,79. Thus, PTCH recruits a multiprotein 
complex including caspase 9 to its C-terminal intracellular region where the protein is 
cleaved and where further apoptotic events are initiated, e.g. caspase 3 cleavage. These 
effects are not impaired by SMO overexpression or treatment with SMO agonist (SAG), 
indicating that it is a SMO-independent process. 
Additionally, it is known that SHH decreases intracellular cAMP levels in a PTCH/SMO-
dependent manner through the activation of G proteins associated with SMO80,81. Activation 
of G proteins induces a calcium spike activity within the cell, which is necessary for several 
neuro-developmental processes82. Regulation of intracellular calcium signaling evokes 
different downstream effects, e.g. expression of neurotransmitters. It is however also part of 
a negative regulatory loop to the GLI transcription factors, as cAMP-dependent calcium 
spikes can trigger the activity of PKA, leading to the formation of GLI3 repressor forms and 
degradation of GLI283. Another effect of the calcium increase is a change in cellular 
metabolism84. These increased calcium levels go along with activation of AMP-activated 
protein kinase (AMPK) and trigger a rapid uptake of glucose especially in brown fat and 
muscle tissue. The SMO/calcium/AMPK axis has also an effect on neuronal precursor cells 
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because AMPK activation via SMO leads to an enhanced amount of polyamine resulting in 
cellular proliferation85. 
Finally, SMO activation can recruit PI3K, initiating the activation of the small GTPases RhoA 
and Rac1. This provokes remodeling of the actin cytoskeleton86. The activation of PI3K, 
RhoA and Rac1 occurs in the cytoplasm, independent of the cilial translocation of SMO. 
1.2.3.2 Non-canonical regulation of GLI 
GLI proteins can also be activated in a non-canonical way. This is especially important in the 
context of cancer where GLI protein interaction partners can either fully activate HH signaling 
autonomously or potentiate pathway activation59,87. 
For example, transforming growth factor-β (TGFβ) signaling can control GLI activity on 
transcriptional level as the GLI2 promoter contains a TGFβ-responsive element. Activation of 
TGFβ leads to binding of mothers against decapentaplegic homolog 3 (SMAD3) and β-
catenin to the GLI2 promoter, which results in GLI2 transcription88,89. In addition, treatment of 
pancreatic cancer cell lines with TGFβ induces GLI1 and GLI3 expression90. 
Furthermore, the tumor suppressor p53 can inhibit GLI activity by inducing its ubiquitination 
and proteasomal degradation91. Hence, p53-deficiency results in GLI1 activation in neural 
stem cells, medulloblastoma and glioblastoma. Furthermore, in cerebella lacking mouse 
double minute 2 homolog (MDM2), a negative regulator of p53, the GLI2 protein level is 
reduced92. This p53-GLI interaction is part of an inhibitory loop, as GLI1 activity itself triggers 
the ubiquitination and proteasomal degradation of p53 during tumorigenesis by activation of 
MDM293,94.  
In addition, members of the dual-specificity tyrosine-phosphorylation-regulated kinase 
(DYRK) family can regulate GLI activity. Whereas DYRK2 can trigger the proteasomal 
degradation of GLI295, DYRK1A can induce GLI1 activity by phosphorylation at the N-
terminal part, inducing its nuclear localization96. In a more complex interaction network, 
DYRK1B was shown to evoke oppositional effects on GLI activity97,98. In medulloblastoma 
and basal cell carcinoma DYRK1B enhances the GLI transcriptional activity99. In contrast, 
DYRK1B negatively modulates GLI activity in pancreatic cancer cells in a non-canonical 
manner97. In contrast another study showed that DYRK1B can inhibit canonical GLI 
activation in fibroblasts but can simultaneously enhance GLI activation in a non-canonical 
(SMO-independent) way. Therefore the authors stated that the role of DYRK1B in regulation 
of HH signaling is strongly dependent on the DYRK1B expression level, the mode of HH 
pathway activation (canonical or non-canonical), the time point of analysis and on the 
investigated model98.  
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Mitogen-activated protein (MAP) kinases are another group of kinases that regulate GLI 
protein activity by post-translational modifications. Extracellular signal-regulated kinases 
(ERKs) as well as c-Jun N-terminal kinases (JNKs) can directly phosphorylate GLI 
transcription factors at the N-terminus100. This is seen in fibroblasts and pancreatic cancer, 
where activation of the RAS/RAF/MEK/ERK pathway stimulates GLI transcriptional 
activity101,102. In pancreatic cancer, basal cell carcinoma and gastric cancer the cross-reaction 
between RAS/RAF/MEK/ERK and HH signaling pathways is essential for tumor growth103-105. 
It was shown that the interaction between the two pathways cooperatively induces the 
expression of growth-related factors like SOX2 and SOX9104.  
Finally, PI3K/AKT/mTOR signaling can act as a post-translational regulator of GLI proteins. 
Activation of this pathway antagonizes the HH signaling suppressors PKA and GSK3β, which 
normally reduce the transcriptional activity of GLI2 by phosphorylation at different sites. As a 
consequence, activation of PI3K/AKT/mTOR induces HH signaling activity in SHH primed 
cells106. AKT additionally enhances the nuclear localization and transcriptional activity of 
GLI1 in melanoma76 and also stabilizes and thus activates GLI2 during osteoblast 
differentiation107. In esophageal adenocarcinoma, the downstream effector of active 
PI3K/AKT/mTOR signaling S6K1 phosphorylates GLI1 resulting in its release from SUFU 
and its transcriptional activity108. In contrast, PI3K/AKT2 signaling can also negatively 
regulate GLI1 transcriptional activity in neuroblastoma cells, in which GLI1 has a tumor-
suppressive role109.  
1.2.4 HH signaling in RMS 
As already mentioned, PTCH germline mutations in patients with Gorlin syndrome result in 
an enhanced susceptibility to RMS. Similarly, Ptch+/- mice develop RMS, which resemble the 
human embryonal phenotype34,110. This is indicated by strong expression of terminal 
myogenic differentiation markers and of the two HH target genes Gli1 and Igf2. Indeed, Igf2 
expression was shown to be indispensable for the formation of Ptch+/- RMS110,111. Similarly, 
human ERMS are associated with overexpression of IGF212,112. In addition, constitutive 
activation of Smo can drive RMS tumorigenesis in the mouse3.  
However, the importance of genetic mutations in HH signaling components in patients with 
sporadic RMS is still controversial. Whole-genome and RNA sequencing of 32 RMS did not 
find any mutations in genes associated with HH signaling13 and also sequencing of PTCH 
and SMO in 6 RMS with active HH signaling (high GLI1 and PTCH expression levels) did not 
reveal any mutations113. Similarly, another study on 147 RMS samples did not detect any 
tumors with mutations in the HH signaling pathway114. In contrast, PTCH and SUFU 
missense mutations were found in 4 out of 22 highly differentiated, fusion gene-negative 
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cases of RMS115. Furthermore, fluorescence in situ hybridization and comparative genomic 
hybridization of 12 ERMS samples revealed chromosomal loss of 9q22, which includes the 
PTCH locus, in 4 cases116. Additionally, another study described LOH in PTCH or SUFU in 4 
of 9 RMS cases22. Finally, another study showed LOH in 1 tumor out of 14 RMS samples117. 
Together, the aforementioned studies indicate that HH pathway mutations can occur, but are 
rare in sporadic cases of RMS. 
Although data on HH pathway mutations in RMS are controversial, several studies have 
provided strong and clear evidence of HH signaling activation in RMS, indicated by HH target 
gene overexpression. For example, in situ hybridization of formalin-fixed tumors showed 
strong expression of PTCH and GLI1 in almost all of the 43 analyzed RMS22. Similar results 
were obtained in a microarray analysis performed by our working group showing that ERMS 
express high levels of GLI1/3 and PTCH. Moreover, expression of HH target genes was 
significantly elevated in ERMS and fusion gene-negative ARMS compared to fusion gene-
positive ARMS and high expression of PTCH was associated with a poor overall survival21. In 
line with these results, immunohistochemical staining of GLI1 in 91 ERMS samples showed 
that increased GLI1 protein levels predict poor outcome118. The higher abundance of HH 
signaling in the ERMS subtype was also shown by quantification of GLI1 and PTCH1 
expression, which is found in 15 out of 70 ERMS but in none out of 20 ARMS113. In addition, 
comparative RNA sequencing analysis of ARMS and ERMS showed higher expression 
levels of GLI2/3 and SMO in the latter subtype13. Together, all study data agree with an 
upregulation of HH signaling activity in RMS and with higher expression levels of HH target 
genes in the embryonal subtype.  
Because mutations in HH signaling components were only rarely found in RMS patients (see 
above), several studies investigated whether HH ligands may activate HH signaling in RMS. 
A japanese study used immunohistochemical staining to show that 14 out of 18 RMS 
samples express SHH119. In addition, it has been shown that RMS cell lines and tissue 
samples express HH ligands. But in contrast to the aforementioned results, the two ligands 
IHH and DHH were predominantly expressed, indicated by Western Blot analysis, qRT PCR 
and immunohistochemical staining120. The same study also revealed that HH ligand 
expression correlates with GLI1 expression in patient samples and that depletion of either 
SHH, IHH or DHH significantly decreases tumor growth in a xenograft RMS model. Another 
recent study showed that patient-derived xenograft tumors intrinsically express IHH and 
DHH, whereas only a minority expresses SHH118. 
Due to the importance of HH signaling in RMS, our group recently analyzed the effects of HH 
antagonists on the growth of RMS cell lines. The data showed that SMO inhibitors evoke a 
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very heterogeneous response in these cells. Thus, the drugs sonidegib and HhAntag can 
reduce GLI1 expression in the ERMS cell lines RD and RUCH-2, which is however 
concentration-dependent. Vismodegib only reduces the GLI1 level in RD cells, whereas 
cyclopamine does induce the expression of GLI1. In addition, sonidegib and HhAntag can 
evoke strong anti-cancer effects on ERMS cell lines, but these effects are not always 
accompanied by a downregulation of HH signaling activity121. 
Together, these data show that HH signaling is active in RMS. The way of pathway activation 
in these tumors is not fully understood. However, the better understanding of pathway 
activation is of uppermost interest for further preclinical and clinical investigations with HH 
antagonists, e.g. SMO inhibitors.   
1.3 Smoothened (SMO) inhibitors 
Since the discovery of cyclopamine (see above), HH signaling inhibitors are under 
investigation for targeted therapy of HH-associated cancers. These drugs are especially 
small molecule inhibitors targeting SMO or GLI. The GLI1/2 inhibitor GANT-61 is effective in 
preclinical models for RMS, osteosarcoma, neuroblastoma and ovarian cancer122-126 and has 
the potential to inhibit both canonical and non-canonical HH signaling activity. However, this 
drug is not used in clinical trials, because it is not stable127. In contrast, vismodegib and 
sonidegib that target the HH pathway at the level of SMO and thus inhibit canonical HH 
signaling, have been approved by the FDA for treatment of basal cell carcinoma (reviewed 
in128). Since these tumors harbor mutations in PTCH in the vast majority of cases129, SMO 
inhibitors are especially effective. Vismodegib and sonidegib and also other available SMO 
inhibitors are currently under clinical investigation ranging from phase I to IV for several other 
cancers, which are listed in the ClinicalTrials.gov database. For the treatment of RMS, we 
here used the SMO inhibitors cyclopamine, vismodegib, sonidegib and HhAntag.  
1.3.1 Cyclopamine, vismodegib, sonidegib and HhAntag 
Cyclopamine was the first discovered natural SMO inhibitor with the potential to block HH 
signaling (reviewed in130). In a preclinical mouse model for pancreatic cancer, which shows 
HH signaling activation in nearly all cases, cyclopamine inhibits the HH pathway very 
efficiently and prolongs the median survival of the animals131. Nevertheless, cyclopamine 
was never used in clinical trials because of its poor aqueous solubility, suboptimal 
pharmacokinetic properties and acid lability. Instead, several derivatives of cyclopamine were 
developed. One example is saridegib (also known as IPI-926), which shows a similar 
effectiveness but better pharmacokinetics than cyclopamine. Saridegib was also a very 
promising agent in a preclinical model for pancreatic cancer132. Because of its success a few 
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clinical trials with saridegib were initiated. However, in phase II studies for chondrosarcoma 
and myelofibrosis it was ineffective133,134 and studies with this drug were discontinued.  
The pyridine derivative vismodegib (also known as GDC-0449, Genentech) is a SMO 
inhibitor with remarkable effectiveness. It also has better pharmacokinetic properties 
compared to cyclopamine. Preclinical and clinical trials on basal cell carcinoma and 
medulloblastoma, which both show active HH signaling due to PTCH mutations, proved 
safety and efficiency of vismodegib135-138. Therefore the compound was approved by the FDA 
and EMA (European Medicines Agency) for treatment of locally advanced and metastatic 
basal cell carcinoma. In a study assessing long-term effects of vismodegib, approximately 70 
% of patients suffering from advanced basal cell carcinoma responded to this drug139. 
Additionally, vismodegib is under investigation for therapy of other cancer entities, including 
ovarian cancer, B-cell lymphoma, chronic lymphocytic leukemia and medulloblastoma. 
However, in a small study enrolling prostate cancer patients, vismodegib efficiently reduced 
HH signaling activity but did not reduce tumor size140. Similarly, patients with metastatic 
colorectal cancer did not benefit from vismodegib compared to standard therapy141. The drug 
was also not effective in maintenance treatment of patients with ovarian cancer in 
remission142. 
Besides cyclopamine, saridegib and vismodegib several other small molecule inhibitors 
targeting SMO were developed, among them sonidegib (also called LDE225, Novartis). 
Sonidegib shows preclinical and clinical effectiveness in the treatment of basal cell 
carcinoma and medulloblastoma143-146. Hence, it is the second SMO inhibitor, which was 
approved by the FDA for treatment of locally advanced basal cell carcinoma with response 
rates of up to 58 %147,148. Currently, sonidegib is in a clinical phase Ib trial in combination with 
a cyclin-dependent kinase 4/6 inhibitor for PTCH mutant medulloblastoma in children 
(NCT03434262). Additionally sonidegib is in clinical trials for several types of other solid 
cancers and is efficient in preclinical models for HH-associated glioblastoma and 
melanoma149,150. Finally, sonidegib is efficient in a preclinical model for chronic myeloid 
leukemia when combined with the tyrosine kinase inhibitor nilotinib151. 
Another drug screening discovered HhAntag, which is a benzimidazol derivative. This drug 
binds to and inhibits SMO in a way different from vismodegib or sonidegib. In addition this 
compound is effective in SMO mutant cells that developed resistance against vismodegib or 
sonidegib152. In a mouse model for medulloblastoma, HhAntag reduced tumor growth, which 
was associated with anti-proliferative and pro-apoptotic effects and a massive infiltration of 
host immune cells, especially macrophages153. Despite its high effectiveness in preclinical 
cancer models, HhAntag is not investigated in clinical trials due to its poor pharmacokinetics.  
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1.3.2 Adverse effects 
In general, SMO inhibitors are well tolerated. Nevertheless, clinical trials and every day 
clinical practice reported that up to 36 % of vismodegib-receiving patients discontinue 
treatment due to high grade adverse effects139,154,155. The most common adverse effects are 
muscle spasms, alopecia, fatigue, nausea and weight loss138,156,157.  
The observed muscle spasms are thought to be caused by non-canonical effects of HH 
signaling on cellular calcium influx triggered by SMO in a GLI-independent manner (see 
above). As a consequence the effects of calcium channel blockers were investigated in a 
small group of basal cell carcinoma patients. Even though the addition of calcium channel 
blockers during therapy resulted in a significant reduction in muscle cramps, further trials with 
larger patient cohorts are required84,158. 
1.3.3 Resistance mechanisms 
Besides interruption of therapy due to severe adverse effects, another drawback of SMO 
inhibitors in the clinics is development of resistance. In a patient with metastatic 
medulloblastoma, vismodegib therapy showed a remarkable first response, but after 3 month 
of treatment the patient relapsed and died approximately 2 month later159. Sequencing of a 
metastatic biopsy found a D473H mutation in SMO, which was not present in the primary 
tumor or in the metastasis before treatment. This amino acid substitution is located within 
one of the transmembrane sites of SMO. The corresponding murine residue 477 was also 
mutated in a vismodegib-resistant allograft model for medulloblastoma and the mutation was 
suggested to impair vismodegib-binding to Smo160. More recently, another case report of a 
medulloblastoma patient with an initial PTCH mutation first showed a substantial response to 
vismodegib treatment161. However, also this patient developed metastases carrying the SMO 
mutations G477L or L412P. Acquired SMO mutations also occur in basal cell carcinoma after 
treatment with SMO inhibitors. Besides mutations that prevent the binding of the drugs to 
SMO, other mutations induce a conformational shift of SMO towards a constitutive active 
form162-164.  
As SMO inhibitors interact with different sites of the SMO binding pocket, resistance towards 
one drug may be overcome by subsequent treatment with another SMO inhibitor. For 
example, it was shown that HhAntag treatment of a vismodegib-resistant (D477G amino acid 
substitution) allograft model for medulloblastoma effectively reduced tumor growth and Gli1 
expression within the tumor tissue152. 
With help of the Ptch+/- p53-/- mouse model for medulloblastoma, additional resistance 
mechanisms towards SMO inhibitors were identified152,165. Treatment of medulloblastoma-
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bearing mice with sonidegib leads to resistance development in nearly all animals, but only a 
small number of resistant tumors show point mutations within Smo. However, 50 % of them 
show chromosomal amplification of Gli2. The degree of gene amplification correlates with 
Gli2 expression levels, indicating an activation of Hh signaling downstream of Smo. 
Interestingly, the sonidegib-resistant tumors that neither have a point mutation in Smo nor an 
amplification of Gli2 show activation of the Pi3k/Akt/mTor pathway. As a consequence a 
combined treatment with sonidegib and PI3K/AKT/mTOR inhibitors delayed resistance 
acquisition and in a few cases indeed completely prevented resistance165.  
In summary, SMO inhibitor resistance is a common phenomenon occurring during treatment 
of cancer cells with vismodegib or sonidegib. To antagonize resistance, secondary treatment 
options are crucial. In case of an acquired SMO mutation, the use of alternative SMO 
antagonists seems to be an option. In contrast, downstream pathway activation by GLI2 
amplification or non-canonical HH signaling activation cannot be antagonized with SMO 
inhibitors. In these cases, the usage of GLI inhibitors or the combination of SMO inhibitors 
with inhibitors targeting the effectors of non-canonical pathway activation might be an option.  
1.3.1 SMO inhibitors in RMS 
As mentioned above, RMS show aberrant activation of the HH signaling cascade. However, 
so far only a few clinical trials with SMO inhibitors are listed in the ClinicalTrials.gov 
database. In 2012 a clinical phase I trial for the SMO inhibitor LY2940680 as single agent 
therapy in pediatric RMS or medulloblastoma was set up. Unfortunately, this trial was 
resigned as not enough patients could be recruited. Another phase I study, which was 
completed in 2014, investigated dose finding and safety of sonidegib in children with RMS 
(NCT01125800) and other tumor entities. 50 % of participants were suffering from serious 
adverse effects like vomiting, headache, general physical health deterioration, convulsion, 
decreased appetite, nausea and fatigue. A follow-up trial to assess the effectiveness of 
sonidegib in RMS was not conducted. Furthermore, in 2016 a phase I/II trial for combination 
treatment of RMS with vismodegib and a Notch signaling inhibitor was completed 
(NCT01154452). Unfortunately, no clinical activity was observed even though HH and Notch 
signaling were efficiently inhibited within the tumors.  
In addition, the effectiveness of SMO inhibitors is also investigated in different preclinical 
RMS models. Treatment of RMS cell lines with cyclopamine decreased cell growth in a 
concentration-dependent manner166. In contrast, cyclopamine treatment did not reduce tumor 
growth of full-blown RMS in vivo even though Hh signaling activity was efficiently blocked in 
this model167. A more recent analysis of our group with the SMO inhibitors cyclopamine, 
vismodegib, sonidegib and HhAntag revealed that the drugs can induce anticancer effects in 
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human RMS cell lines. However, these effects are not necessarily associated with inhibition 
of HH signaling121. Among the investigated compounds, sonidegib and HhAntag are more 
effective than the others. Surprisingly, cyclopamine and vismodegib even enhance cell 
growth of certain RMS cell lines. The lack of association between GLI1 levels and cellular 
proliferation might point to a non-canonical regulation of GLI in some RMS and shows that 
the anticancer effects caused by SMO inhibitors are most likely off-target effects. This 
hypothesis is strengthened by another group showing that cyclopamine is less effective than 
the GLI1/2 inhibitor GANT-61 in blocking HH signaling activity and proliferation of several 
ERMS cell lines168. In contrast, a more recent study investigating the impact of vismodegib, 
sonidegib and GANT-61 on spheroid cultures of ERMS cell lines resulted in potent 
anticancer effects of all three drugs118. These results suggest that canonical HH signaling 
regulates ERMS self-renewal and thus tumor initiation. Because modulation of HH signaling 
did not result in changes in cell cycle, cell viability or proliferation, the authors hypothesized 
that tumor regression may not be an appropriate endpoint to estimate treatment 
effectiveness.  
Together, the effects of SMO inhibitors on RMS cell lines remain uncertain. 
1.4 PI3K/AKT/mTOR signaling 
The PI3K/AKT/mTOR signaling pathway is a major regulator of cell growth and survival 
under physiological and pathological conditions. Its aberrant activation is a hallmark of many 
different cancers. The pathway senses activation of receptor tyrosine kinases (RTKs) and 
translates the information into a cellular response like proliferation, differentiation, apoptosis 
or regulation of cell metabolism169. In the context of cancer, PI3K/AKT/mTOR signaling is 
often aberrantly activated by mutations in RTKs, e.g. EGFR, in the negative regulator 
phosphatase and tensin homolog (PTEN), in PI3K or in AKT170. Additionally, aberrant growth 
factor expression or interaction with other oncogenic pathways like RAS/RAF/MEK/ERK 
signaling can activate PI3K/AKT/mTOR signaling in cancer. A simplified scheme of the 
pathway is depicted in Fig. 2. 
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Figure 2: The PI3K/AKT/mTOR signaling pathway. RTKs induce autophosphorylation of the 
intracellular domain. PI3K binds to the phosphorylated RTK and triggers the formation of PIP3. This 
reaction can be reversed by the tumor suppressor PTEN. PIP3 further recruits AKT to the cell 
membrane where it gets phosphorylated. Fully activated AKT induces several downstream reactions 
resulting in the activation of mTORC1. As a consequence mTORC1 phosphorylates S6K1, which in 
turn phosphorylates ribosomal protein S6. This induces protein synthesis, cell growth and survival. A 
more detailed description of the PI3K/AKT/mTOR signaling pathway can be found in the main text. 
Activation of RTKs by e.g. IGF1, IGF2 or EGF results in RTK autophosphorylation. This 
recruits the regulatory subunit of PI3K to the intracellular domain of the activated RTK. In 
turn, the catalytic subunit of PI3K phosphorylates the inositol ring structure of 
phosphatidylinositol-4,5-bisphosphate (PIP2), which is anchored in the cell membrane by its 
lipid chains. This results in the formation of phosphatidylinositol-3,4,5-trisphosphate (PIP3). 
Subsequently, this enzymatic reaction can be reversed by the tumor suppressor PTEN that 
thus blocks signal transduction. PIP3 recruits proteins with a pleckstrin homology (PH) 
domain to the cell membrane, e.g. AKT and 3-phosphoinositide-dependent protein kinase-1 
(PDK1). PDK1 then phosphorylates Thr308 of AKT. Full activation of AKT is accomplished 
by the mTOR complex 2 (mTORC2), which phosphorylates AKT at Ser473 in the C-terminal 
region. AKT itself is a Ser/Thr protein kinase and serves as a central cell fate regulator. This 
kinase phosphorylates many different proteins, mostly resulting in their inactivation. AKT can 
for example inactivate the complex of tuberous sclerosis protein 1 (TSC1) and 2 (TSC2), 
which is a negative regulator of mTORC1171. In addition, AKT can inactivate another 
mTORC1 suppressor called proline-rich AKT substrate of 40 kDa (PRAS40), which results in 
activation of mTORC1172,173. This in turn results in phosphorylation of ribosomal protein S6 
kinase 1 (S6K1) at Thr389. Full activation of S6K1 is then accomplished by phosphorylation 
at Thr229 by PDK1. S6K1 further phosphorylates ribosomal protein S6, potentiating 
ribosome function, protein synthesis and cell growth. Simultaneous phosphorylation of AKT, 
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S6K1 and/or S6K can be detected with phospho-specific antibodies and serves as readout 
for activation of the PI3K/AKT/mTOR signaling pathway.  
The pathway contains several negative feedback loops. For example, S6K1 and mTORC1 
phosphorylate and negatively regulate insulin receptor substrate 1 (IRS1), which normally 
mediates signal activation from RTKs to PI3K174-176. In addition, S6K1 inhibits mTORC2 and 
thus AKT signaling, which links mTORC1 and mTORC2 together177. 
As already mentioned, AKT represents a central regulatory factor of the PI3K/AKT/mTOR 
pathway, which - besides mTORC1 activation - can trigger many cellular responses178. 
Amongst others, AKT mediates cell survival by direct phosphorylation and inactivation of 
BAD, inhibiting its pro-apoptotic effects on proteins of the Bcl-2 family179,180. In addition, AKT 
phosphorylates and inactivates the kinase GSK3β and the transcription factor FOXO, 
resulting in a decreased expression of pro-apoptotic genes. On the other hand it activates 
MDM2, which is a negative regulator of the tumor suppressor p53181-183. 
As mentioned above, several interactions between PI3K/AKT/mTOR and HH signaling have 
been described. For example a positive interaction between AKT and HH signaling exists in 
esophageal and breast cancer184,185. As a consequence the effectiveness of combination 
treatments with inhibitors of HH and PI3K/AKT/mTOR signaling is investigated in several 
preclinical models. In cell culture and mouse models for glioblastoma and pancreatic cancer 
the combination of sonidegib with PI3K inhibitors induces synergistic anticancer effects149,186. 
Furthermore, the combination of sonidegib with the dual PI3K and mTOR inhibitor BEZ235 
synergistically inhibits the self-renewal capacity of pancreatic cancer cells in vitro and in 
vivo186. In a clinical study on advanced solid tumors, the combination therapy of sonidegib 
and the PI3K inhibitor buparlisib is generally tolerable187. 
1.4.1 Inhibitors of PI3K/AKT/mTOR pathway 
Several drugs targeting the PI3K/AKT/mTOR pathway have been developed for cancer 
therapy169,188,189. Within this work the two mTOR inhibitors everolimus and rapamycin, the 
dual PI3K and mTOR inhibitor PI-103, the class I PI3K inhibitor pictilisib and the AKT inhibitor 
MK-2206 were used. 
The naturally occurring mTOR inhibitor rapamycin was first isolated back in 1975 from an 
Easter Island soil sample190. A few years later it was shown to evoke anticancer effects191 
and as a consequence this drug, which was originally used as an immunosuppressant agent 
in organ transplantation, has entered clinical phase III trials for a range of different cancer 
types. These include bladder cancer, lymphoma, leukemia, renal cell carcinoma and breast 
cancer. Several structurally very similar derivatives were developed and the first inhibitor of 
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mTOR that was approved in 2007 by the FDA was temsirolimus for renal cell carcinoma192. 
Only a few years later, a second mTOR inhibitor, everolimus, was approved for the treatment 
of advanced renal cell carcinoma and for subependymal giant-cell astrocytoma in patients 
with Tuberous Sclerosis. Tuberous Sclerosis is a hereditary disease, which is characterized 
by mutations in TSC1/2 resulting in constitutive activation of mTOR. Patients suffering from 
this disease develop nonmalignant tumors in different organs, e.g. the brain, skin or 
kidneys193. In addition, temsirolimus and everolimus have entered phase III clinical trials for 
mantle cell lymphoma, neuroendocrine tumors, breast cancer and large B-cell lymphoma. 
The latter phase III trial on 742 patients with relapsed large B-cell lymphoma showed that 
everolimus does not improve disease-free survival compared to placebo194. In contrast, 
everolimus improves the progression-free survival of patients with advanced, progressive 
neuroendocrine tumors195. 
In addition to mTOR inhibitors, several drugs targeting PI3K or AKT have been developed 
and have entered phase II clinical trials. The PI3K inhibitor buparlisib was supposed to enter 
a phase III clinical trials for breast cancer but due to a lack of efficiency, the trial was 
stopped196. In addition, buparlisib also did not improve the progression-free survival of 
patients with non-small cell lung cancer, hence the authors suggested using the drug in 
combination treatments rather than as monotherapy197. Clinical phase II trials with buparlisib 
are also ongoing for the treatment of prostate cancer, thyroid cancer, breast cancer, 
glioblastoma, melanoma and leukemia. 
The dual PI3K and mTOR inhibitor PI-103 did not reach any clinical trial due to its 
unfavorable pharmacokinetics198. However, it was further developed to a drug called pictilisib, 
which is in clinical phase II trials for lung cancer, breast cancer and glioblastoma. The results 
of a phase I clinical trial with 60 patients suffering from advanced solid tumors were 
published in 2015. The trial showed that pictilisib administration is safe and has favorable 
pharmacokinetic and pharmacodynamic properties199. Additionally, the results of three 
clinical phase II trials with breast cancer patients were reported in 2016. Two of them did not 
show any benefits of pictilisib addition to standard therapy200,201. In the third one, however, 
addition of pictilisib resulted in a significant reduction of proliferative cells within the tumor 
even though no clinical outcome was reported202. 
In addition, the AKT inhibitor MK-2206 has entered several phase II clinical trials. In 
colorectal cancer patients the effectiveness of MK-2206 was investigated in combination with 
a MEK inhibitor. However, the combination did not reach the expectations of target 
inhibition203. This was the same in trials for lung cancer and renal cell carcinoma204,205. 
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Nevertheless, clinical phase II trials on colon cancer, hepatocellular carcinoma, lymphoma, 
breast cancer, melanoma and lung cancer are ongoing. 
1.4.2 PI3K/AKT/mTOR signaling in RMS 
The activation of PI3K/AKT/mTOR signaling is a hallmark of many different cancer entities. 
This is also the case for primary RMS samples, which show phosphorylation of AKT and thus 
pathway activation in 82.5 % of cases206-208. In addition, phosphorylation of AKT, S6K1 and 
S6 is associated with a poor overall survival of RMS patients209. However, mutations in 
components of the core pathway are relatively rare. Thus, PIK3CA, which encodes the 
catalytic subunit of PI3K, is mutated in 7.4 % and FGFR4, encoding the fibroblast growth 
factor receptor 4, is mutated in 9.6 % of fusion gene-negative RMS114. Therefore, activation 
of PI3K/AKT/mTOR signaling is rather based on other mechanisms. Indeed, 91 % of ERMS 
show hypermethylation of PTEN. In addition, activation of the FGFR/RAS/AKT axis has been 
observed in 40 % of cases114,210.  
Therefore, several preclinical and clinical trials with PI3K/AKT/mTOR inhibitors in patients 
with RMS have been launched. The data show that treatment of RMS cell lines with the PI3K 
inhibitor LY294002 induces apoptosis under hypoxic conditions211. Furthermore, the mTOR 
inhibitor temsirolimus effectively reduces tumor growth in xenograft models of RMS209. 
However, when applied as monotherapy, temsirolimus did not meet the expectations in a 
clinical phase II trial for RMS212. In addition, chemotherapy in combination with either 
rapamycin or everolimus entered clinical phase II trials and the combination temsirolimus 
with chemotherapy entered a clinical phase III trial, which is currently recruiting. 
PI3K/AKT/mTOR inhibitors are also combined with RAS/RAF/MEK/ERK inhibitors in 
preclinical RMS studies and the results are promising. Thus, the combination of the mTOR 
inhibitor AZD8055 with the MEK inhibitor AZD6244 induces synergistic anticancer effects in 
human RMS cell lines and in RMS xenografts206. Furthermore, combination of the dual PI3K 
and mTOR inhibitor PI-103 with the MEK inhibitor UO126 cooperatively induces apoptosis213. 
Surprisingly, targeting one pathway separately activates the other pathway, e.g. PI-103 
induces phosphorylation of ERK and UO126 enhances phosphorylation of AKT, indicating 
cross-reactivity in RMS.  
The HH signaling pathway is another interaction partner of PI3K/AKT/mTOR signaling, as 
described above. Hence, the effectiveness of temsirolimus or rapamycin plus GANT-61 
(GLI1/2 inhibitor) in RMS cells was investigated and indeed, the combinations efficiently 
enhanced anticancer effects125.   
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In summary, the PI3K/AKT/mTOR signaling pathway seems to be a promising target for 
RMS therapy. In addition, the current research shows that the combination of 
PI3K/AKT/mTOR inhibitors with drugs targeting its interaction partners such as the HH 
signaling pathway efficiently enhances anticancer effects. Nevertheless, no clinical trials for 
these combinations have been launched. 
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2 Aim of the study 
RMS is the most common soft tissue sarcoma in children and it is currently treated with a 
combination of surgery or radiotherapy and multi-agent chemotherapy. However, because 
advanced RMS have a very poor prognosis, new therapeutic options for the disease are 
required.  
It has been shown that RMS, especially ERMS, show strong HH signaling activity. Therefore 
we tested the effectiveness of SMO inhibitors in preclinical ERMS models. So far, data of our 
group showed that some SMO inhibitors induce anticancer effects in ERMS cell lines. 
However, these effects are drug- and cell line-dependent and are not generally accompanied 
by downregulation of HH signaling activity. In addition, our group found evidence for an 
interaction between HH and PI3K/AKT/mTOR signaling in RMS. 
The aim of this thesis was to analyze whether SMO inhibitors can produce off-target effects 
in ERMS. Secondly, it was analyzed whether SMO inhibitors only exert reliable anticancer 
effects in those ERMS, which harbor mutations upstream of SMO in e.g. PTCH. Finally, the 
relevance of PI3K/AKT/mTOR signaling in regulation of HH signaling activity in ERMS was 
investigated. To achieve these aims, the effectiveness of SMO inhibitors and/or 
PI3K/AKT/mTOR inhibitors was investigated in ERMS tumor cells with and without PTCH 
mutations. 
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3 Material 
3.1 Technical equipment  
Table 1: Utilized technical equipment 
Technical Equipment Supplier 
-20 °C Freezer Liebherr GmbH, Bulle, Switzerland 
-80 °C Freezer Sanyo Electric Co., Ltd., Osaka, Japan 
4 °C Fridge Robert Bosch GmbH, Stuttgart 
Agarose gel electrophoresis chambers 
(PerfectBlue
TM 
Gel Systems) 
VWR International, Radnor, USA 
Autoclave (Sanoclave) Sanoclav, Bad Überkingen 
Autoclave (Systec DX-150) Systec GmbH, Linden 
Biological safety cabinet (Clean Air Euroflow 
Class II, Type A2) 
Telstar, Terrassa, Spain 
Centrifuges (Heraeus Biofuge pico, fresco, 
primo, Multifuge 3LR) 
Thermo Fisher Scientific Inc., Waltham, USA 
CO2 Incubator (6000, BBD 6220) Thermo Fisher Scientific Inc., Waltham, USA 
CO2 Incubator (CB220-230V-G) Binder GmbH, Tuttlingen 
Cooling Plate (EG 1150 C) Leica Microsystems GmbH, Wetzlar 
Digital monochrome printer (P91D) Mitsubishi Electric Corp., Chiyoda, Japan 
Dispersing tool for homogenizer (DS-8/P) MICCRA GmbH, Heitersheim 
Dissecting tools Karl Hammacher GmbH, Solingen 
Electronic pipette (Accu-jet) Brand GmbH & Co.KG, Wertheim 
Electrophoresis System (XCell4 SureLock
TM
 
Midi-Cell) 
Thermo Fisher Scientific Inc., Waltham, USA 
FACSCalibur
TM
 BD Biosciences Corp., Franklin Lakes, USA 
Freezing Container (Mr. Frosty
TM
) Thermo Fisher Scientific Inc., Waltham, USA 
Gas burner (Campingaz) Newell Brands, Hoboken, USA 
Heating shaker (Thermomixer®) Eppendorf AG, Hamburg 
Heating stirrer (MR 3000/3001) 
Heidolph Instruments GmbH & Co.KG, 
Schwabach 
Homogenizer (Miccra D-1) MICCRA GmbH, Heitersheim 
Hybridization oven (HB-1000 Hybridizer) VWR International, Radnor, USA 
Inverted microscope (Axiovert 25) Carl Zeiss AG, Oberkochen 
Liquid nitrogen tank Air Liquide S.A., Paris, France 
Micro-computed tomography (µCT) scanner 
(Quantum FX) 
PerkinElmer Health Sciences, Hopkinton, USA 
Microplate reader (SynergyMx) BioTek Instruments, Inc., Winooski, USA 
Microscope (Olympus BX 60) Olympus Corp., Shinjuku, Japan 
Microtome (HN 40) Leica Microsystems GmbH, Wetzlar 
Microwave Oven (Dimension 4) Panasonic Corp., Kadoma, Japan 
Mini centrifuge (Rotilabo®) Carl Roth GmbH & Co.KG, Karlsruhe 
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Mixer (Vortex-Genie® 2) Scientific Industries, Inc., Bohemia, USA 
Neon Transfection System Thermo Fisher Scientific Inc., Waltham, USA 
Paraffin dispenser (Dispenser PAG 12) Medite GmbH, Burgdorf 
Paraffin tissue floating bath (Round model) Medax GmbH & Co.KG, Neumünster 
PCR cycler (Mastercycler®, Mastercycler® 
Gradient S) 
Eppendorf AG, Hamburg 
pH meter (inoLab pH Level 1) Xylem Inc., Rye Brook 
Pipettes (Multipette, one-channel) Eppendorf AG, Hamburg 
Platform shaker (Unimax 1010) 
Heidolph Instruments GmbH & Co.KG, 
Schwabach 
Power supply for electrophoresis (E835) Consort, Turnhout, Belgium 
Power supply for Western Blot analysis (CS-
300V) 
Cleaver Scientific Ltd., Rugby, UK 
Precision scales (Sartorius Basic
plus
) Sartorius AG, Göttingen 
qRT PCR system (ABI Prism 7900HT) Thermo Fisher Scientific Inc., Waltham, USA 
Tissue processor (TP 1020) Leica Microsystems GmbH, Wetzlar 
UV-VIS spectrophotometer (NanoDrop
TM
 8000) Thermo Fisher Scientific Inc., Waltham, USA 
UV transilluminator Intas Science Imaging GmbH, Göttingen 
Vacuum pump system (EcoVac) Schuett-Biotec GmbH, Göttingen 
Water purification system (Arium® 611 VF) Sartorius AG, Göttingen 
Western Blot imaging system (FluorChem
TM
 Q) Bio-Techne Corp., Minneapolis, USA 
Western Blot transfer system (Trans-Blot® SD 
Semi-Dry Transfer Cell) 
Bio-Rad Laboratories, Inc., Hercules, USA 
 
3.2 Consumables  
Table 2: Utilized consumables 
Consumables Supplier 
1.5 mL reaction tubes Ochs GmbH, Bovenden/Lenglern 
1.5 mL safeseal microtubes Sarstedt AG & Co., Nürnberg 
2.0 mL reaction tubes Sarstedt AG & Co., Nürnberg 
15 mL Greiner centrifuge tubes Merck KGaA, Darmstadt 
12-well tissue culture plates Sarstedt AG & Co., Nürnberg 
24-well tissue culture plates Sarstedt AG & Co., Nürnberg 
384-well PCR plates (Framestar) 4titude Ltd., Berlin 
50 mL Greiner centrifuge tubes Merck KGaA, Darmstadt 
6-well tissue culture plates Sarstedt AG & Co., Nürnberg 
96-well assay plates (transparent) Corning, Inc., Corning, USA 
96-well reaction plates (black) Thermo Fisher Scientific Inc., Waltham, USA 
BD Discardit
TM
 II (2, 10, 20 mL), disposable 
syringes 
BD Biosciences GmbH, Franklin Lakes, USA 
BD Microfine + Demi Pen Needles BD Biosciences GmbH, Franklin Lakes, USA 
BD Plastipak
TM
 (100 mL), disposable syringe BD Biosciences GmbH, Franklin Lakes, USA 
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Blotting paper (GB 33 B003) Heinemann Labortechnik GmbH, Duderstadt 
Cell scrapers Sarstedt AG & Co., Nürnberg 
Cell strainers (40 µm) BD Biosciences GmbH, Franklin Lakes, USA 
Coverslips Menzel GmbH & Co.KG, Braunschweig 
CryoPure tubes Sarstedt AG & Co., Nürnberg 
Disposable needles (Sterican Ø 0,45 x 12 mm) B. Braun Medical AG, Emmenbrücke 
Eppendorf® Combitips advanced® pipette tips 
(0.2, 0.5, 2.5, 5, 10, 25, 50 mL) 
Merck KGaA, Darmstadt 
Feeding tubes (1.0 x 60 mm) Unimed SA, Lausanne, Schweiz 
Filter tips (10, 100, 200, 1000 µL) Kisker Biotech GmbH & Co. KG, Steinfurt 
Flow cytometry tubes Sarstedt AG & Co., Nürnberg 
Fluted filters Sartorius AG, Göttingen 
Glass slides Thermo Fisher Scientific Inc., Waltham, USA 
Glassware Schott AG, Mainz 
Neubauer counting chamber Brand GmbH & Co KG, Wertheim 
Nitrocellulose (NC) membrane (Hybond ECL), 
0.2 µm pore size 
GE Healthcare Europe GmbH, Freiburg 
Nunc
TM
 cell culture dishes (Ø 10 cm) Thermo Fisher Scientific Inc., Waltham, USA 
Nunc
TM
 cell culture dishes (Ø 6 cm) Thermo Fisher Scientific Inc., Waltham, USA 
NuPAGE Novex 4 – 12 % Bis-Tris Midi Gels Thermo Fisher Scientific Inc., Waltham, USA 
Pasteur pipettes Brand GmbH & Co.KG, Wertheim 
Petri dishes Ochs GmbH, Bovenden/Lenglern 
Pipette tips (10, 20, 100, 200, 1000 µL) Sarstedt AG & Co., Nürnberg 
Polyvinylidene difluoride (PVDF) membrane 
(Immobilon®-P), 0.45 µm pore size 
Merck KGaA, Darmstadt 
QPCR adhesive clear seals 4titude Ltd., Berlin 
Scalpel blades (10, 24) Aesculap AG & Co.KG, Tuttlingen 
Serological pipettes (2, 5, 10, 25, 50 mL) Sarstedt AG & Co., Nürnberg 
Sterile filters Omnilab-Krannich, Göttingen 
Superfrost glass slides (SuperFrost Plus
TM
) Thermo Fisher Scientific Inc., Waltham, USA 
Syringe 1, 30, 50 mL Terumo Medical Corp., Elkton, MD, USA 
 
3.3 Reagents and chemicals 
All chemicals, which are not listed in Table 3 were purchased from Merck KGaA, Darmstadt.  
Table 3: Utilized reagents and chemicals 
Reagents and chemicals Supplier 
50 bp, 100 bp plus, 1 kb DNA ladder Thermo Fisher Scientific Inc., Waltham, USA 
Acetic acid Carl Roth GmbH & Co.KG, Karlsruhe 
Agarose Bio-Budget Technologies GmbH, Krefeld 
Ampicillin Carl Roth GmbH & Co. KG, Karlsruhe 
BD Bacto
TM
 Tryptone BD Biosciences GmbH, Franklin Lakes, USA 
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Boric acid Carl Roth GmbH & Co.KG, Karlsruhe 
Bovine serum albumin (BSA) Carl Roth GmbH & Co.KG, Karlsruhe 
Chloroform Carl Roth GmbH & Co.KG, Karlsruhe 
Citric acid Carl Roth GmbH & Co.KG, Karlsruhe 
Collagen from rat tail Merck KGaA, Darmstadt 
Collagenase H Roche Diagnostic GmbH, Basel, Switzerland 
Contrast agent Imeron 300 Bracco Imaging Deutschland GmbH, Konstanz 
Cresol Red Merck KGaA, Darmstadt 
Deoxyribonucleotide triphosphates (dNTPs) Roche Diagnostic GmbH, Basel, Switzerland 
Dimethyl sulfoxide (DMSO) Thermo Fisher Scientific Inc., Waltham, USA 
Dithiothreitol (DTT) Thermo Fisher Scientific Inc., Waltham, USA 
DNA Gel Loading Dye (6X) Thermo Fisher Scientific Inc., Waltham, USA 
DNase/RNase-free H2O Thermo Fisher Scientific Inc., Waltham, USA 
Eosin Y Merck KGaA, Darmstadt 
Ethanol (EtOH), 99 % Fisher Scientific, Schwerte 
Ethidium bromide (0.07 %) 
Inno-train Diagnostik GmbH, Kronberg im 
Taunus 
Ethylendiaminetetraacetic acid (EDTA) MP Biomedicals, Santa Ana, USA 
EtOH, 99 %, denatured 
CVH Chemie-Vertrieb GmbH & Co. Hannover 
KG, Hannover 
Glycergel mounting medium Agilent Technologies Inc., Santa Clara, USA 
Haematoxylin, Mayer’s Merck KGaA, Darmstadt 
Hydrogen peroxide (H2O2, 35 %) Carl Roth GmbH & Co. KG, Karlsruhe 
Isoflurane (FORENE®) Abbott Laboratories, North Chicago, USA 
Isopropyl alcohol Carl Roth GmbH & Co. KG, Karlsruhe 
Kanamycin Carl Roth GmbH & Co. KG, Karlsruhe 
Liquid Barrier Marker Carl Roth GmbH & Co. KG, Karlsruhe 
Methanol Carl Roth GmbH & Co. KG, Karlsruhe 
NuPAGE MES SDS Running Buffer (20X) Thermo Fisher Scientific Inc., Waltham, USA 
Paraformaldehyde Carl Roth GmbH & Co. KG, Karlsruhe 
Pertex mounting medium Medite GmbH, Orlando 
Phosphatase inhibitor cocktail tablets 
(PhosSTOP
TM
) 
Roche Diagnostic GmbH, Basel, Switzerland 
Phosphate buffered saline (PBS) tablets Thermo Fisher Scientific Inc., Waltham, USA 
Potassium aluminum sulfate Merck KGaA, Darmstadt 
Powdered milk  Carl Roth GmbH & Co. KG, Karlsruhe 
Propidium Iodide (PI)  Miltenyi Biotec GmbH, Bergisch Gladbach  
Protease inhibitor cocktail tablets (cOmplete
TM
, 
mini)  
Roche Diagnostic GmbH, Basel, Switzerland 
Random hexamers  Thermo Fisher Scientific Inc., Waltham, USA 
S.O.C Medium Thermo Fisher Scientific Inc., Waltham, USA 
SeeBlue® Plus2 Pre-Stained Protein Standard  Thermo Fisher Scientific Inc., Waltham, USA 
Sodiumdodecylsulfate (SDS)  Carl Roth GmbH & Co. KG, Karlsruhe 
Trichloro acetaldehyde hydrate  Merck KGaA, Darmstadt  
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Triton
TM
 X-100 Merck KGaA, Darmstadt  
Trypan blue Merck KGaA, Darmstadt  
Tween® 20 Scharlau Chemie S.A., Barcelona, Spain 
Tween® 80 Merck KGaA, Darmstadt  
Xylene  Fisher Scientific, Schwerte 
Yeast extract Merck KGaA, Darmstadt  
 
3.3.1 Signaling pathway inhibitors 
Table 4: Utilized small molecule inhibitors for in vitro experiments  
Inhibitor Solvent  
Incubation 
concentration 
Supplier 
Cyclopamine EtOH 1 – 10 µM 
Sigma-Aldrich Inc., St. Louis, USA (now Merck 
KGaA, Darmstadt) 
Everolimus EtOH 50 nM 
Sigma-Aldrich Inc., St. Louis, USA (now Merck 
KGaA, Darmstadt) 
HhAntag DMSO 3.1 - 50 µM Genentech, San Francisco, USA 
MK-2206 DMSO 5 µM Selleckchem, Houston, USA 
Pictilisib DMSO 0.6 - 10 µM 
Selleckchem, Houston, USA and Genentech, San 
Francisco, USA 
PI-103 DMSO 3 µM Alexis Biochemicals, San Diego, USA 
Rapamycin DMSO 100 nM Merck KGaA, Darmstadt  
Smoothened 
agonist 
(SAG) 
DMSO 100 nM Cayman Chemical Company, Ann Arbor, USA 
Sonidegib DMSO 3.1 - 50 µM 
Active Biochem LTD, Kowloon, Hong Kong and 
Novartis AG, Basel, Switzerland 
UO126 DMSO 2 – 25 µM Cell Signaling Technology, Danvers, USA  
Vismodegib DMSO 3.1 - 50 µM 
Selleckchem, Houston, USA and Genentech, San 
Francisco, USA 
  
Table 5: Utilized small molecule inhibitors for in vivo experiments 
Inhibitor 
Daily dose [µg/g 
body weight] 
Stock concentration 
[mg/mL] * 
Supplier 
HhAntag 100 10 Genentech, San Francisco, USA 
Pictilisib 75 37.5 Genentech, San Francisco, USA 
Sonidegib 80 10 Novartis AG, Basel, Switzerland 
Vismodegib 100 10 Genentech, San Francisco, USA 
*All drugs for in vivo experiments were resuspended in vehicle as described in section 4.4.5. 
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3.3.2 Enzymes 
Table 6: Utilized enzymes  
Enzymes Supplier 
BamHI Thermo Fisher Scientific Inc., Waltham, USA 
Collagenase H Roche Diagnostic GmbH, Basel, Switzerland 
EcoRI Thermo Fisher Scientific Inc., Waltham, USA 
Hind III Thermo Fisher Scientific Inc., Waltham, USA 
HpaI Thermo Fisher Scientific Inc., Waltham, USA 
KpnI Thermo Fisher Scientific Inc., Waltham, USA 
NheI Thermo Fisher Scientific Inc., Waltham, USA 
NotI Thermo Fisher Scientific Inc., Waltham, USA 
Proteinase K  Carl Roth GmbH & Co. KG, Karlsruhe 
RNase A Carl Roth GmbH & Co.KG, Karlsruhe 
SuperScript
TM
 II Reverse Transcriptase Thermo Fisher Scientific Inc., Waltham, USA 
Taq Polymerase (MolTaq basis) Molzym GmbH & Co. KG, Bremen 
 
3.3.3 Kits and ready-to-use reagents  
Unless stated otherwise all kits and ready-to-use reagents listed in Table 7 were used 
according to the manufacturer’s instructions. 
Table 7: Utilized kits and ready-to-use reagents 
Reaction system Supplier 
FITC Annexin V Apoptosis Detection Kit I BD Biosciences Corp., Franklin Lakes, USA 
Cell Proliferation ELISA, BrdU 
(chemiluminescent) 
Roche Diagnostic GmbH, Basel, Switzerland 
Dako REAL
TM
 EnVision
TM
 Detection System Agilent Technologies Inc., Santa Clara, USA 
Dual-Luciferase® Reporter Assay System Promega Inc., Fitchburg, USA  
Neon
TM
 Transfection System Kit Thermo Fisher Scientific Inc., Waltham, USA 
Pierce BCA Protein Assay Kit Thermo Fisher Scientific Inc., Waltham, USA 
Pierce ECL Plus Western Blot substrate Thermo Fisher Scientific Inc., Waltham, USA 
Platinum SYBR Green qPCR Super Mix Thermo Fisher Scientific Inc., Waltham, USA 
PureLink® HiPure Plasmid Midiprep kit Thermo Fisher Scientific Inc., Waltham, USA 
QuantiTect SYBR Green PCR kit Qiagen, Venlo, Netherlands 
TRIzol
TM
 Reagent  Thermo Fisher Scientific Inc., Waltham, USA 
Water soluble tetrazolium salt 1 (WST-1) reagent  Roche Diagnostic GmbH, Basel, Switzerland 
 
3.4 Buffers and solutions 
If not stated otherwise all buffers and solutions listed in Table 8 were made with ultrapure 
H2O. 
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Table 8: Utilized buffers and solutions 
Buffer or solution Composition 
10X PBS, pH 7.4 
1.4 M  NaCl 
65 mM  Na2HPO4 
27 mM KCl 
15 mM KH2PO4 
10X Tris-boric acid-EDTA (TBE), pH 
8.0 
890 mM Tris/HCl 
730 mM Boric acid 
12.5 mM  EDTA 
10X Tris-buffered saline (TBS), pH 
7.4 
1.5 M NaCl 
0.5 M Tris/HCl 
6X SDS loading buffer 
35 % (v/v) Glycerol 
9 % (w/v) SDS 
8.5 % (w/v) DTT 
0.1 % (w/v) Bromophenolblue 
Dissolved in upper gel buffer 
Blotting buffer 
20 % (v/v) Methanol 
6 % (w/v) Tris 
3 % (w/v) Glycine 
0.0375 % (v/v)  SDS 
BSA-azide 
0.02 % (v/v) Sodium azide 
2 % (w/v) BSA 
Dissolved in PBST 
Casein 
0.2 % (w/v) Casein 
Dissolved in TBS 
Collagen solution 
0.1 M Acetic acid 
1 mg/mL Collagen from rat tail 
Cresol 
0.1 % (w/v) Cresol Red 
In saturated sucrose solution (100 % (w/v) sucrose in H2O) 
dNTPs 
10 mM dATP 
10 mM dCTP 
10 mM dGTP 
10 mM dTTP 
Eosin solution 
80 % (v/v) EtOH 
1 % (w/v) Eosin Y (water soluble) 
Haematoxylin solution 
5 % (w/v)  Potassium aluminum sulfate 
5 % (w/v)  Trichloro acetaldehyde hydrate 
1 % (w/v)  Citric acid 
0.1 % (w/v) Haematoxylin 
0.015 % (w/v) Sodium iodate 
Lysis buffer (RIPA) 
50 nM Tris/HCl, pH 7.4 
1 % (v/v)  NP-40 
0.25 % (v)v Sodium deoxycholat 
150 mM NaCl 
1 mM EDTA 
1 tablet/10 mL Phosphatase inhibitor PhosSTOP
TM
 
1 tablet/ 10mL Protease inhibitor cocktail cOmplete
TM
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Lysogeny broth (LB) medium 
1 % (w/v) BD Bacto
TM
 tryptone 
0.5 % (w/v) Yeast extract 
1 % (w/v)  NaCl, pH 7.0 
LB agar 
1.5 % (w/v) Agar 
Dissolved in LB medium 
Methylcellulose tween 
0.5 % (w/v) Methylcellulose 
0.2 % (w/v) Tween® 80 
Paraformaldehyde (PFA) 
4 % (w/v) PFA 
Dissolved in PBS 
PBS-Tween (PBST) 
0.1 % (v/v) Tween® 20 
Dissolved in PBS 
PI staining solution 
10 µg/mL PI 
100 µg/mL RNase A 
Dissolved in PBS 
Proteinase K, pH 8.0 
50 mM Tris/HCl 
5 mM EDTA 
10 mg/mL Proteinase K 
STE buffer, pH 8.0 
100 mM  NaCl 
50 mM   Tris/HCl  
1 mM  EDTA 
1 % (w/v)  SDS 
Stripping buffer 
62.5 mM Tris, pH 6.7 
2 % (w/v) SDS 
100 mM β-mercaptoethanol 
10X TBS buffer, pH 7.4 
10 mM Tris 
100 mM NaCl 
TBS-Triton (TBST) 
0.1 % (v/v) Triton X-100 
Dissolved in TBS 
Trypan blue solution 
0.4 % (w/v) Trypan blue 
Dissolved in PBS 
Upper gel buffer, pH 6.8 
6 % (w/v) Tris 
0.4 % (v/v) SDS 
 
3.5 Media  
3.5.1 Media for prokaryotic cell cultivation 
The cultivation of bacterial cells was done in LB medium or on LB agar plates. The 
compositions of LB medium and LB agar are listed in Table 8. Medium was autoclaved 
before use. After cooling down of the medium, the antibiotic ampicillin (100 µg/mL) or 
kanamycin (50 µg/mL) was added. LB agar plates were poured into petri dishes afterwards 
and allowed to harden completely. LB medium and LB agar plates were stored at 4 °C. 
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3.5.2 Media and reagents for eukaryotic cell cultivation 
Table 9: Utilized media and reagents for eukaryotic cell cultivation 
Medium or reagent Supplier 
Accutase GE Healthcare, Little Chalfont, UK 
Dulbecco’s Modified Eagle Medium (DMEM) Thermo Fisher Scientific Inc., Waltham, USA 
Fetal calf serum (FCS) Thermo Fisher Scientific Inc., Waltham, USA 
G418 disulfate salt solution (50 mg/mL) Merck KGaA, Darmstadt  
PBS (cell culture)* Thermo Fisher Scientific Inc., Waltham, USA 
Penicillin, 10000 U/mL, and Streptomycin, 10 
mg/mL (P/S) 
Pan - Biotech GmbH, Aidenbach 
Puromycin dihydrochloride (10 mg/mL) Merck KGaA, Darmstadt  
TrypLE Express Thermo Fisher Scientific Inc., Waltham, USA 
* 1 PBS tablet was dissolved in 500 mL ultrapure H2O, autoclaved before use and stored at 4 °C. 
3.6 Biological material 
3.6.1 Bacterial strains 
Plasmids were amplified by transformation and growth of chemical competent DH5α 
Escherichia coli (E. coli) cells obtained from Thermo Fisher Scientific Inc., Waltham, USA. 
3.6.2 Eukaryotic cell lines and primary cells 
Table 10: Utilized eukaryotic cell lines and primary cells 
Cell line / 
Cells 
Specification 
Medium and 
supplements 
Source or Reference 
B9 
Murine adult fibroblasts, 
Shh-responsive 
DMEM, 10 % 
FCS, 1 % P/S 
214
, referred to as 
Ptch
flox/flox
ERT2
+/-
 
HEK293 
Human embryonic kidney 
cells, untransfected (control 
cells for HEK293 Shh-N) 
DMEM, 10 % 
FCS, 1 % P/S 
ATCC*, Manassas, USA 
HEK293 
Shh-N 
Human embryonic kidney 
cells, stably transfected 
with Shh-N expression 
plasmid 
DMEM, 10 % 
FCS, 1 % P/S, 
0.4 mg/mL G418 
215
 
RD Human ERMS 
DMEM, 10 % 
FCS, 1 % P/S 
ATCC, Manassas, USA 
RD 
SMOlow 
Human ERMS, stably 
transfected with shSMO 
DMEM, 10 % 
FCS, 1 % P/S, 
1µg/mL 
puromycin  
118
, cells were kindly provided by 
Prof. B. Schäfer (University 
Children’s Hospital of Zurich, 
Switzerland) 
RD 
SMOhigh 
Human ERMS, stably 
transfected with pLKO.1 
(control cells for RD 
SMOlow) 
DMEM, 10 % 
FCS, 1 % P/S, 
1µg/mL 
puromycin 
118
, cells were kindly provided by 
Prof. B. Schäfer (University 
Children’s Hospital of Zurich, 
Switzerland) 
RUCH-2 Human ERMS 
DMEM, 10 % 
FCS, 1 % P/S 
ATCC, Manassas, USA 
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Primary 
Ptch
+/-
 cells 
Murine ERMS-like 
DMEM, 10 % 
FCS, 1 % P/S 
RMS-bearing Ptch
+/-
 mice 
* ATCC: American Type Culture Collection 
3.7 Synthetic DNA oligonucleotides 
All DNA oligonucleotides listed in Table 11 and Table 12 were obtained from Eurofins 
Scientific SE, Luxemburg, Luxemburg. 
Table 11: Utilized synthetic DNA oligonucleotides for genotyping PCR of Ptch
+/-
 mice 
Primer Name Primer Sequence (5’ – 3’ orientation) 
Amplification 
product 
Reference 
Exon 7-F AGGAAGTATATGCATTGGCAGGAG  950 bp (mutant Ptch 
allele) 
216
 
Neo-R GCATCAGAGCAGCCGATTGTCTG 
mPTCNx_f  GGGAGGGGATTTCAGCAGAATGTT  445 bp (wild type 
Ptch allele) mPTCwt_r TCAAGGAGCAGAGGCCCAA 
 
Table 12: Utilized synthetic DNA oligonucleotides for qRT PCR 
Primer name Primer sequence (5’ – 3’ orientation) Location Transcript 
18S-fwd  CGCAAATTACCCACTCCCG exon 1 
18S rRNA  
18S-rev2 TTCCAATTACAGGGCCTCGAA exon 1 
hHPRT1_F1 TGGCGTCGTGATTAGTGATG exon 1+2 
HPRT  
hHPRT1_R1 CGAGCAAGACGTTCAGTCCT exon 2+3 
HsaGli 1 tq F AGCTACATCAACTCCGGCCA exon 11 
GLI1  
HsaGli1 tq R GCTGCGGCGTTCAAGAGA exon 12 
HSA_Hhip_tq_FW1 ATGGTGGGTTGTGCTTTCCA exon 3 
Hhip  
HSA_Hhip_tq_RV1 CAGAAGCAGTTGTGTTTGTGCT exon 4 
mGli1-tq-f TACATGCTGGTGGTGCACATG exon 9 
Gli1  
mGli1-tq-r ACCGAAGGTGCGTCTTGAGG exon 10 
mGli2F.1 GCAAGGTCAAGACTGAGGCTGA exon 8 
Gli2  
mGli2R.1 GCTGCTCCTGTGTGTCATACTCCTT exon 9 
mHhipF.1 GGAGCCTTACTTGGACATTCACAA exon 4 
Hhip  
mHhipR.2 ACCGTTCCTGGTTGGTGGTATAA exon 5 
mTBP-Q-Fwd CACCAATGACTCCTATGACCCCTA exon 3 
Tbp  
mTBP-Q-Rev CAGTTGTCCGTGGCTCTCTTATTC exon 5 
hsPTC1F.2 GAGGTTGGTCATGGTTACATGGA exon 6 PTCH 
hsPTC1R.2 TGCTGTTCTTGACTGTGCCACC exon 7  
hSMO-F1 CAAGAACTACCGATACCGTGC exon 6 SMO 
hSMO-R1 AGCATGGTCTCGTTGATCTTGC exon 7  
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3.8 Plasmids  
Table 13: Utilized plasmids and amount for transfection of RMS cells 
Plasmid Application 
DNA amount for 
transfection 
Reference or supplier 
pCR3.1 Gli reporter assay 0.5 µg 
Thermo Fisher Scientific Inc., 
Waltham, USA 
pCR3.1 mGli1 Gli reporter assay 0.5 µg 
217
 
pGL-9xGli BS Gli reporter assay 5.5 µg 
218
 
pHA-Akt-DN 
Overexpression of 
dominant negative Akt 
6 µg 
219
 
pmaxGFP
TM
 Transfection control 6 µg 
Lonza Group AG, Basel, 
Switzerland 
pMyrAkt∆4-129 
Overexpression of 
constitutive active Akt 
6 µg 
220,221
  
Addgene, Cambridge, USA 
pRL-CMV   Gli reporter assay 0.5 µg Promega Inc., Fitchburg, USA  
 
3.9 Antibodies  
For immunohistochemical staining of tissue paraffin sections the HRP-conjugated secondary 
antibody from the Dako REALTM EnVisionTM Detection System was used. 
Table 14: Utilized antibodies for Western Blot analysis and immunohistochemistry 
Primary antibodies 
Antibody Dilution Supplier 
mAb mouse anti-AKT (Clone 
55/PKBa/Akt) 
1:1000 
BD Biosciences Corp., 
Franklin Lakes, USA 
mAb mouse anti-HSC70 (B-6) 1:10000 
Santa Cruz Biotechnology, 
Santa Cruz, USA 
mAb mouse anti-Ki67 1:50 
BD Biosciences Corp., 
Franklin Lakes, USA 
mAb mouse anti-S6 (54D2) 1:1000 
Cell Signaling Technology, 
Danvers, USA  
mAb rabbit anti-β-Actin (13E5) 1:1000 
Cell Signaling Technology, 
Danvers, USA  
mAb rabbit anti-pAKT (Ser473) 
(193H12) 
1:1000 
Cell Signaling Technology, 
Danvers, USA  
pAb rabbit anti-Caspase 3 
1:500 (Caspase 3 pro form) and 
1:250 (Caspase 3 cleaved) 
Cell Signaling Technology, 
Danvers, USA  
pAb rabbit anti-ERK 1:1000 Merck KGaA, Darmstadt  
pAb rabbit anti-pERK 
(Thr202/Tyr204) 
1:1000 
Cell Signaling Technology, 
Danvers, USA  
pAb rabbit anti-pS6 (Ser240/244) 1:2000 
Cell Signaling Technology, 
Danvers, USA  
pAb rabbit anti-SMO 1:1000 Abcam, Cambridge, UK 
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Secondary antibodies 
Antibody Dilution Supplier 
pAb goat anti-rabbit IgG 1:5000 Dianova, Hamburg 
pAb rabbit anti-mouse IgG 1:5000 Dianova, Hamburg 
mAb/pAb: monoclonal/polyclonal antibody, HSC70: heat-shock protein 70, IgG: immunoglobulin G 
3.10 Software 
Table 15: Utilized software 
Software Developer 
Adobe Photoshop CS5 Adobe Systems Inc., San José, USA 
AlphaView Q SA 3.2.2 Cell Bioscience, California, USA 
CellSens Dimension Olympus GmbH, Hamburg 
CompuSyn ComboSyn, Inc., Paramus, USA 
Flowing Software 2 
Perttu Terho, Cell Imaging Core, Turku Centre 
for Biotechnology, Finland 
FlowJo Tree Star Inc, Oregon, USA 
Gen5  BioTek Instriuments Inc., Bad Friedrichshall 
GraphPad Prism 6 GraphPad Software Inc, La Jolla, USA 
Microsoft Office Microsoft Co., Redmont, USA 
Quantum FX µCT (SimpleViewer) PerkinElmer Health Sciences, Hopkinton, USA 
Scry v6.0 Kuchel & Sautter UG, Bad Teinach-Zavelstein 
SDS 2.2 Applied Biosystems, Darmstadt 
 
3.11 Databases 
Table 16: Utilized databases 
Database Source 
Basic Local Alignment Search Tool (BLAST) https://blast.ncbi.nlm.nih.gov/Blast.cgi 
Catalogue Of Somatic Mutations In Cancer 
(COSMIC) 
https://cancer.sanger.ac.uk/cell_lines 
ClinicalTrials.gov https://clinicaltrials.gov 
Ensembl genome browser http://www.ensembl.org/index.html 
Genomics of Drug Sensitivity in Cancer Project https://www.cancerrxgene.org/ 
Mouse Genome Informatics (MGI) http://www.informatics.jax.org/ 
National Center for Biotechnology Information 
(NCBI) 
http://www.ncbi.nlm.nih.gov/ 
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4 Methods 
4.1 Cell biology 
4.1.1 Cultivation of adherent cells  
Table 10 contains a list of the used eukaryotic cell lines and their specific growth conditions. 
Cells were cultivated in Ø 10 cm cell culture dishes in an atmosphere of 37 °C, 5 % CO2 and 
95 % humidity. Cell culture medium was renewed every fourth day and cultures were split 
when they reached > 90 % confluence. To passage cells, medium was removed, cells were 
washed with PBS and 2 mL of TrypLE Express was added. When all cells were detached, 
they were resuspended in 8 mL of cell culture medium and split 1:10 – 1:30 into fresh cell 
culture dishes. For inhibitor treatment, cell numbers were counted as described in section 
4.1.5 and cells were seeded at the densities listed in Table 17. 
Table 17: Seeding densities for eukaryotic cells 
Experimental endpoint Cultivation format Seeding density 
Cell cycle analysis Ø 6 cm cell culture dishes 1 x 10
5
 cells/dish 
Proliferation (BrdU assay), 
Viability (WST-1 assay) 
96-well plates 
4 x 10
3
 cells/well 
1 x 10
4
 cells/well (RD SMOlow) 
Proliferation (cell counting) 24-well plates 
5 x 10
4
 cells/well (RD SMOlow)  
1 x 10
5
 cells/well (RD SMOhigh) 
qRT PCR, Apoptosis 6-well plates 1 x 10
5
 cells/well 
Western Blot analysis Ø 10 cm cell culture dishes 1 x 10
6
 cells/dish 
 
4.1.2 Cryopreservation and thawing of eukaryotic cells 
Cells that were > 90 % confluent were washed with PBS and detached as described in 
section 4.1.1. The cell suspension was transferred into a 15 mL reaction tube and 
centrifuged at 300 x g and 4°C for 5 min. The supernatant was removed and cells were 
resuspended in 10 mL cell culture medium containing 5 % DMSO. The cell suspension was 
distributed in ten CryoPure tubes, which were immediately placed in the freezing device Mr. 
FrostyTM. After 12 h aliquots were transferred into liquid nitrogen. 
Aliquots with frozen cells were thawed by pipetting 1 mL of cell culture medium onto the 
frozen cells and gently resuspending them until they were completely thawed. Subsequently, 
cells were transferred into a Ø 10 cm cell culture plate and resuspended in 20 mL fresh cell 
culture medium. The cells were allowed to attach for 24 h and afterwards cell culture medium 
was renewed. 
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4.1.3 Generation of SHH conditioned medium (SHH-CM) 
Stably transfected HEK293 Shh-N cells and untransfected HEK293 cells (for preparation of 
control conditioned medium, control-CM) were cultured until they reached 70 % confluence. 
Then the cell culture medium was replaced by low-serum cell culture medium (DMEM with 2 
% FCS and 1 % P/S). After 24 h the medium was transferred into a 50 mL reaction tube and 
filtered through a 0.2 µm pore filter to remove cells and cell debris. SHH-CM and control-CM 
were stored at 4 °C for up to one month. 
4.1.4 Isolation and cultivation of primary murine RMS cells 
For the cultivation of primary RMS cells, 12-well tissue culture plates were coated with 
collagen solution. Afterwards plates were allowed to dry under the sterile bench and either 
stored at 4 °C for up to one week or used immediately. Directly before use, plates were 
sterilized by UV exposure for 1 h.  
For the isolation of primary cells, RMS-bearing Ptch+/- mice were euthanized, tumors were 
excised and washed in PBS. A small piece was fixed in 4 % PFA for HE staining to confirm 
RMS histology. The rest of the tumor was chopped into very small pieces with a scalpel, 
transferred into 2 mL reaction tubes with pre-warmed DMEM containing 3 mg/mL 
collagenase H and incubated at 37 °C and 1000 rpm for 50 min to allow for collagen 
cleavage. Afterwards the tissue was resuspended and transferred onto a cell strainer, which 
was placed onto a 50 mL reaction tube. By gentle rubbing with a pipette tip and washing with 
PBS, cells were separated through the strainer. Cell suspension was centrifuged at 300 x g 
and 4 °C for 10 min. Supernatant was discarded, cells were resuspended in cell culture 
medium and transferred into the collagen-coated 12-well plates. Primary cells were cultivated 
in an atmosphere of 37 °C, 5 % CO2 and 95 % humidity. After 24 h of cultivation, cell cultures 
were washed several times with PBS to remove all floating cells and cell debris. The 
remaining adherent cells were incubated with fresh culture medium. 
When cells were approximately 80 – 90 % confluent, but latest 4 days after isolation, the 
medium was replaced with medium containing the respective drugs.  
4.1.5 Counting of living eukaryotic cells 
To count the number of living cells, adherent cell cultures were detached with TrypLE 
Express as explained in section 4.1.1. 10 µL of cell suspension was mixed with 1 µL of 
trypan blue solution, which only stains dead cells, and the number of living cells was counted 
in a Neubauer counting chamber. 
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4.1.6 Proliferation assay  
To assess the number of proliferating cells, DNA incorporation of the thymidine analog 5-
bromo-2’-deoxyuridine (BrdU) was measured using the Cell Proliferation ELISA. The 
procedure was performed according to the manufacturer’s instructions. In brief, cells were 
seeded in a 96-well plate as described in section 4.1.1 and incubated with drugs for 24 - 48 
h. For the last 24 h, cells were co-incubated with drugs and 10 µM BrdU. At the end of 
treatment, medium was removed and cells were fixed with Fix-Denat solution for 30 min. 
Peroxidase-conjugated BrdU antibody was diluted 1:100 in antibody dilution solution, 
distributed onto the 96-well plate and the plate was incubated for 1 h. Antibody solution was 
discarded and wells were washed three times for 5 min with washing buffer. In the 
meanwhile, peroxidase substrate was prepared. After the last washing step, substrate 
solution was added and the luminescence of all wells was measured in the SynergyMx 
microplate photometer with Gen5 software. 
All experiments were performed in triplicates for human ERMS cell lines and in 
quadruplicates for primary RMS cells. Cells lacking either BrdU, BrdU antibody or peroxidase 
substrate were included as negative assay controls. 
4.1.7 Cell viability assay 
To assess cell viability, WST-1 was used, which is cleaved by viable cells into a formazan 
dye. Cells were seeded in a 96-well plate as described in section 4.1.1 and incubated with 
drugs for 24 h. 4 h before the end of treatment 10 µL/well WST-1 was added. At the end of 
treatment, the absorbance at a wavelength of 450 nm was measured in the SynergyMx 
microplate photometer with Gen5 software. 
4.1.8 Apoptosis assay 
The amount of apoptotic cells was quantified by Annexin V staining and flow cytometry. 
During apoptosis phosphatidylserine is translocated from the cytosolic side of the cell 
membrane to the cell surface. Annexin V can bind phosphatidylserine and mark apoptotic 
cells. The conjugation with a fluorescent dye like fluorescein isothiocyanate (FITC) allows for 
flow cytometric analysis. Thus, Annexin V+ cells are supposed to be apoptotic cells. 
For apoptosis assay, cells were seeded in 6-well plates as described in section 4.1.1 and 
incubated with respective drugs for 48 h. Afterwards, cells were washed with ice cold PBS 
and detached for 3 min with 1 mL/well accutase. To stop the reaction, 1 mL/well ice cold PBS 
was added and the cell suspension was transferred into a 15 mL reaction tube, which was 
pre-cooled on ice. The cell suspension was centrifuged at 300 x g and 4 °C for 5 min and the 
supernatant was discarded. Cells were washed once with ice cold PBS following a second 
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centrifugation and discarding of the supernatant. Cells were stained with FITC-Annexin V 
from the FITC Annexin V Apoptosis Detection Kit I according to the manufacturer’s 
instructions. In brief, binding buffer (10X) was diluted with ultrapure H2O and mixed 1:50 with 
FITC-Annexin V solution. Cells were resuspended in 100 µL of this staining solution, 
transferred to a 1.5 mL reaction tube and incubated for 10 min at room temperature in the 
dark. Another 200 µL of 1X binding buffer were added to dilute the staining solution and flow 
cytometry was performed on a FACSCaliburTM device. The fluorescence of FITC-Annexin V 
was measured in channel FL-1 (FITC has an emission maximum at a wavelength of 519 
nm). Data acquisition was performed with FlowJo and GraphPad Prism 6 softwares.  
4.1.9 Cell cycle analysis 
To measure the cell cycle distribution, fixed cells were stained with the intercalating DNA dye 
PI and analyzed by flow cytometry. Fig. 3 shows an example of PI cell cycle analysis in RMS 
cells. 
 
Figure 3: Cell cycle analysis of PI-stained RMS cells. Fixed RMS cells were stained with PI as 
described in the text. PI signal strength was measured by flow cytometry in the FL-3 channel of a 
FACSCalibur
TM
. Data analysis was performed with Flowing Software 2. Gating was performed as 
depicted. H-1, H-2, H3, H-4 and H-5 represent cells in the sub-G0, G0/G1, S, G2/M and super-G2/M 
phase of the cell cycle, respectively. 
Cells were seeded in Ø 6 cm cell culture dishes as described in section 4.1.1 and incubated 
with respective drugs for 24 h (RD cells) or 72 h (RUCH-2 cells). At the end of treatment, cell 
culture medium was removed and cells were washed with PBS. To detach the cells, 2 
mL/plate accutase were added and the plates were incubated at 37 °C for 2 min. 3 mL of cell 
culture medium were added to stop the accutase reaction. The cell suspension was 
transferred into a 15 mL reaction tube and centrifuged at 300 x g and 4 °C for 5 min. The 
supernatant was discarded and cells were resuspended in 1 mL ice cold PBS. For fixation, 
10 mL EtOH were pre-cooled at -80 °C in a 15 mL reaction tube. While vortexing the EtOH-
containing reaction tube at medium speed, the cell suspension was injected into the alcohol 
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and the tube was subsequently put back on dry ice. To fix the cells, they were incubated at -
20 °C for at least 3 h. 
The fixed cells were centrifuged at 600 x g and 4 °C for 5 min. The supernatant was 
discarded, cells were resuspended in 2 mL PBS and centrifuged again at 600 x g and 4 °C 
for 5 min. The supernatant was again discarded and cells were resuspended in 450 µL PI 
staining solution containing 10 µg/mL PI and 100 µg/mL RNase A in PBS. The cell 
suspension was incubated at 37 °C for 30 min and afterwards PI staining intensity was 
measured by flow cytometry on a FACSCaliburTM (channel FL-3 because PI has an emission 
maximum at a wavelength of 617 nm). A minimum of 3 x 104 cells/sample were counted and 
data analysis was performed with Flowing Software 2.  
4.1.10 Transfection of RMS cell lines 
The ERMS cell line RD was transfected with the Neon Transfection System according to the 
manufacturer’s instructions. In brief, RMS cells were washed with PBS and detached. After 
centrifugation at 300 x g and 4 °C for 5 min the cells were resuspended in Resuspension 
Buffer R to a density of 4 x 106 cells/mL. For transfection, 4 x 105 cells were mixed with 6 µg 
plasmid DNA (pDNA) in a final volume of 100 µL. The respective amounts of the used 
plasmids are listed in Table 13. To track transfection efficiency, control cells were transfected 
with an enhanced green fluorescent protein (EGFP) expression plasmid. Electroporation of 
the cells was performed with 1000 V in 2 pulses each lasting for 30 msec. Afterwards the 
cells were seeded in 6-well plates containing DMEM with 10 % FCS. After 24 h of cultivation, 
cells were checked under a microscope for viability and EGFP expression. Protein or RNA 
isolation was performed 48 h after transfection. 
4.1.11 Transfection of RD cells with a Gli reporter system  
The transcriptional activity of Gli proteins in RMS cells was measured with a luciferase-based 
Gli reporter system. For this purpose cells were transfected with 2 µg of the firefly luciferase 
reporter plasmid pGL-9xGli BS containing nine Gli protein binding sites. For normalization 
cells were co-transfected with 0.12 µg of the Renilla luciferase reporter plasmid pRL-CMV. 
As positive assay control, cells were additionally co-transfected with 2 µg of the Gli1 
overexpression plasmid pCR3.1 mGli1. In all other settings pDNA amount was filled up to 
4.12 µg with 2 µg of the respective empty pCR3.1 plasmid. As negative control cells were 
transfected with 4 µg pCR3.1 and 0.12 µg pRL-CMV. The respective plasmids are listed in 
Table 13.  
Transfection was performed as described in section 4.1.10 and cells were seeded in 6-well 
plates. After 48 h cells were detached and reseeded in a transparent 96-well plate at a 
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density of 5 x 103 cells/well. Incubation with respective drugs was performed for 48 h and 
afterwards the dual-luciferase assay was performed as described below in section 4.1.12.  
4.1.12 Dual-luciferase assay 
The Dual-Luciferase® reporter assay system was used according to the manufacturer’s 
instructions. In brief, transfected cells were washed. For cell lysis 20 µL/well passive lysis 
buffer were added. Cell lysis was performed at room temperature while shaking at 250 rpm 
for 15 min. The plates were frozen at -80 °C for a minimum of 15 min. LAR II and Stop’n’Glo 
solutions were prepared following the manufacturer’s instructions and pre-warmed to room 
temperature before use. The firefly and Renilla luciferase activity was measured in a 
SynergyMx microplate photometer by serial injection of the two substrates and subsequent 
luminescence measurement with Gen5 software. The firefly luciferase activity was 
normalized to Renilla luciferase activity using GraphPad Prism 6 software.  
4.1.13 E.coli transformation 
To avoid contamination with undesired microorganisms, the glassware required for bacterial 
transformation was autoclaved in advance and all open bottles with the required solutions 
were sterilized with a gas flame.  
The chemical competent DH5α E. coli strain was used for transformation and amplification of 
pDNA. The bacteria (stored in 50 µL aliquots at -80 °C) were thawed on ice and 100 ng of 
pDNA was added. After incubation on ice for 20 min, a heat shock at 42 °C for 30 sec was 
performed. The transformation mix was again cooled down on ice for 1 min and mixed with 
450 µL S.O.C. medium. Bacteria were incubated at 37 °C while shaking at 400 rpm for 50 
min. 150 µL of the mixture were plated on LB agar with ampicillin (100 µg/mL) or kanamycin 
(50 µg/mL) to select for transformed bacteria. The plate was incubated at 37 °C overnight in 
upside down position. The next day, single colonies were picked for plasmid amplification.  
4.1 Protein chemistry  
4.1.1 Protein isolation from cultured cells 
All steps were performed on ice and all required buffers were pre-cooled to 4 °C. 
Cell culture medium was removed and cells were washed with PBS. Cells were covered with 
2 mL PBS and scratched off with a cell scraper. Remaining cells were gently washed off with 
PBS and transferred to a 50 mL reaction tube. Cells were centrifuged at 1800 rpm and 4 °C 
for 5 min. Supernatant was discarded, cells were resuspended in 800 µL PBS and 
transferred into a 1.5 mL reaction tube. Cells were again centrifuged at 1800 rpm and 4 °C 
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for 5 min. The supernatant was discarded and the cells were shock-frozen in liquid nitrogen 
for mechanical cell lysis. Afterwards samples were thawed on ice for 20 min and suspended 
in 60 – 100 µL lysis buffer. Samples were incubated on ice for 30 min. Lysates were 
centrifuged at 13000 rpm and 4 °C for 30 min and the supernatant, which now contained all 
soluble cell proteins, was transferred into a fresh 1.5 mL reaction tube. Lysates were stored 
at -80 °C.  
4.1.2 Protein isolation from RMS tissue 
For protein isolation, a piece of approximately 30 mg RMS tissue was cut into small pieces 
while keeping it on ice. The tissue was transferred into a 2 mL reaction tube with 300 µL lysis 
buffer. Tissue was homogenized at 20000 rpm for 1 min while keeping the tube constantly on 
ice. Afterwards, samples were shock-frozen in liquid nitrogen for mechanical cell lysis. 
Lysates were thawed on ice for 20 min and centrifuged at 10000 rpm and 4 °C for 10 min. 
The supernatant containing proteins was transferred into a 1.5 mL reaction tube and stored 
at -80 °C. 
To prevent sample contamination, the homogenizer was washed with 70 % EtOH and 
ultrapure H2O. Afterwards it was dried in a 55 °C oven before the next sample was 
homogenized.  
4.1.3 Bicinchoninic acid (BCA) assay 
The BCA assay for protein quantification is based on two reactions. In alkaline solutions, 
peptide bonds reduce cupric ions (Cu2+) resulting in the formation of Cu+ ions. These in turn 
form a colored, water-soluble complex with BCA, which has an absorption maximum at a 
wavelength of 562 nm. Absorbance shows linear correlation with the protein concentration 
222. 
The Pierce BCA Protein Assay Kit was used to measure protein concentrations according to 
the manufacturer’s instructions. In brief, triplicates of 1 µL/well protein solution were 
transferred into a transparent 96-well assay plate and mixed with 200 µL/well of substrate 
solution. A BSA dilution series was used as standard. The plate was incubated at 37 °C for 
15 – 30 min. Subsequently, the absorbance at 540 nm was measured in a SynergyMx 
microplate photometer. Based on linear regression of the absorbance measured in the BSA 
dilution series, the concentration of protein samples was calculated with Gen5 software. 
4.1.4 Western Blot 
Protein lysates containing 20 – 35 µg of protein were mixed with 2.5 µL of SDS loading buffer 
(6X) and ultrapure H2O to a total volume of 15 µL. Proteins were denatured at 96 °C for 5 
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min while shaking at 450 rpm. Then the tubes were centrifuged at low speed to collect all 
liquids and protein samples were loaded onto a NuPAGETM 4 – 12 % Bis-Tris Protein Gel. 
The protein ladder SeeBlue® Plus2 Pre-Stained was used to determine protein sizes.  
Electrophoresis was performed at 160 mA, 100 V and 100 W for 20 min in NuPAGETM MES 
SDS running buffer. Afterwards voltage was raised to 160 V and electrophoresis ran for 
another 1.5 h until the protein ladder was separated. To avoid heat, the electrophoresis 
chamber was put on ice during the run. 
After proteins were separated, they were blotted to a NC or PVDF membrane by the Semi-
dry blotting method. Blotting was performed in a Trans-Blot® SD Semi-Dry Transfer Cell at 
120 mA, 20 V and 100 W for 1 h 20 min223-225. 
Afterwards, the membrane was blocked with 5 % (w/v) milk in PBST buffer for 1 h and 
washed three times for 10 min with PBST buffer while shaking at room temperature. Primary 
antibodies were diluted in BSA-azide as described in Table 14. 3 mL of primary antibody 
dilution were transferred into a 50 mL reaction tube together with the membrane with proteins 
facing the interior. Incubation was done on a roller shaker at 4 °C overnight. Then the 
membrane was washed three times in PBST buffer for 10 min while shaking. Horse radish 
peroxidase (HRP)-conjugated secondary antibodies were prepared in 5 % (w/v) milk in PBST 
buffer as described in Table 14 and the membrane was incubated in the solution for 1 h at 
room temperature while gently shaking. Remaining antibodies were removed by washing the 
membrane in PBST buffer three times for 10 min. The Pierce ECL Plus Western Blot 
substrate was prepared by mixing solution A with solution B in a ratio of 1:1. Membrane was 
put on a straight surface and the substrate was distributed on the membrane. After an 
incubation for 90 sec, the remaining substrate was removed and HRP signals were detected 
using a FluorChem Q system. Picture acquisition and processing was done with AlphaView 
Q SA and Adobe Photoshop CS5 softwares. 
If necessary, bound proteins were stripped off the membrane by incubation in stripping buffer 
at 55 °C for 30 min while slowly rotating. Afterwards the membrane was washed thoroughly 
three times for 10 min with PBST buffer and blocked with 5 % (w/v) milk in PBST buffer for 1 
h while gently shaking at room temperature. 
4.2 Molecular biology  
4.2.1 Genomic DNA (gDNA) isolation from mouse tail biopsies 
For PCR-based genotyping, gDNA was isolated from mouse tail biopsies. To digest the 
tissues, tail biopsies were incubated in 500 µL STE buffer with 0.5 mg/mL Proteinase K 
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overnight at 55 °C. Samples were centrifuged at 13000 rpm for 10 min to remove tissue 
debris. The supernatant was transferred into a new reaction tube. 1 mL of 99 % ice cold 
EtOH was added and mixture was shaken thoroughly to precipitate gDNA. After 
centrifugation at 13000 rpm for 25 min the supernatant was discarded, gDNA was washed 
with 500 µL of 70 % EtOH and centrifuged again at 13000 for 10 min. The supernatant was 
discarded and gDNA was dried at 55 °C for 10 min. Afterwards 125 µL RNase/DNase-free 
H2O were added and gDNA was dissolved while shaking at 1400 rpm and 42 °C for 10 min. 
Solutions were stored at -20 °C. 
4.2.2 Total RNA isolation from cell culture 
For total RNA isolation from cultured cells, the TRIzolTM reagent was used according to the 
manufacturer’s instructions. This process is based on phenol-chloroform extraction226. To 
prevent RNA degradation, the whole isolation process was performed on ice if not stated 
otherwise. 
Cells were washed once with ice cold PBS and subsequently 1 mL/well (6-well plates) or 0.5 
mL/well (12-well-plates, 2 wells were pooled afterwards) of cold TRIzolTM reagent were 
added. Cells were resuspended thoroughly and transferred into a sterile 2 mL reaction tube. 
The cell suspension was vortexed at maximum speed for 2 min and incubated another 5 min 
at room temperature. Per 1 mL TRIzolTM reagent 200 µL chloroform were added and the mix 
was again vortexed at maximum speed for 15 sec. Afterwards, phases were allowed to 
separate for 3 min at room temperature and by centrifugation at 4 °C and 12000 rpm for 10 
min. The lighter aqueous phase that contained the RNA was transferred into a new 1.5 mL 
reaction tube with 700 µL of ice cold isopropanol and the mix was inverted several times. The 
remaining lower organic phase and the interphase, containing proteins and DNA, were 
discarded. For full RNA precipitation, samples were incubated at -20 °C overnight or at -80 
°C for 15 min. Afterwards they were centrifuged at 12000 rpm and 4 °C for 30 min. 
Supernatant was discarded and RNA was washed twice with 500 mL of ice cold 70 % EtOH 
by centrifugation at 12000 rpm and 4 °C for 10 min. After the second washing step, the 
alcohol was discarded and the RNA was allowed to air dry. Afterwards the RNA was 
dissolved in 10 – 20 µL of RNase/DNase-free H2O while shaking at 900 rpm and 56 °C for 5 - 
10 min. The exact volume was adjusted to the size of the visible RNA pellet. RNA samples 
were stored at -80 °C. 
4.2.3 Total RNA isolation from RMS tissue 
A piece of approximately 20 mg frozen RMS tissue was transferred into 1 mL of ice cold 
TRIzolTM reagent. Tissue was homogenized for 2 min at 20000 rpm on ice until all visible 
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tissue chunks were chopped. To avoid sample contamination, the homogenizer was carefully 
cleaned with forceps, washed in RNase/DNase-free H2O and dried before isolating RNA from 
the next sample. The homogenates were incubated at room temperature for 5 min and 200 
µL of chloroform were added. All following steps were performed according to the description 
in section 4.2.2. RNA from RMS tissue was dissolved in 25 µL of RNase/DNase-free H2O 
and stored at -80 °C.  
4.2.4 Photometric quantification of nucleic acids 
For quantification of nucleic acids, the NanoDrop 8000 spectrophotometer was used. The 
sample absorbance at a wavelength of 260 nm (A260) was measured and the following 
equation, which is based on the Beer-Lambert’s law, was used for quantification.  
c   
A    
b
   A   f 
c: nucleic acid concentration in ng/µL,  
A: absorbance in arbitrary units 
 : wavelength-dependent extinction coefficient in ng x cm/µL  
b: pathlength in cm 
f: factor for   and b combined, 50 ng/µL for double-stranded DNA and 40 ng/µL for RNA 
To detect sample contamination with proteins, A280 was measured and the ratio A260/A280 was 
calculated. In general, ratios of 1.8 for DNA samples and 2.0 for RNA samples are 
considered as pure. 
4.2.5 Genotyping polymerase chain reaction (PCR) 
PCR for genotyping was performed in a total volume of 10 µL. 1 µL of gDNA (corresponds to 
approximately 100 ng) was mixed with 1 µL PCR buffer (10X, provided with MolTaq), 0.5 µL 
forward primer (10 µM), 0.5 µL reverse primer (10 µM), 0.2 µL dNTPs (10 mM each), 1 µL 
cresol, 5.7 µL ddH2O and 0.1 µL MolTaq.  
PCR for the mutant Ptch alleles was performed in the following steps: 
 95 °C   5 min 
 95 °C  1 min 
 62 °C  1 min  35 cycles 
 72 °C  3 min 
 72 °C  5 min 
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PCR for the wildtype Ptch alleles was performed in the following steps: 
 95 °C   5 min 
 95 °C  20 sec 
 60 °C  20 sec  35 cycles 
 72 °C  45 sec 
 72 °C  5 min 
PCR products were analyzed by agarose gel electrophoresis and afterwards stored at 4 °C 
(short-term) or -20 °C (long-term). When the PCR efficiency was low, the amount of MgCl2 in 
the reaction was increased (100 mM MgCl2 solution was provided with MolTaq). 
4.2.6 Agarose gel electrophoresis 
Agarose gel electrophoresis was used for separation and visualization of DNA fragments, 
e.g. products of genotyping PCR. 1 % (w/v) agarose was dissolved in TBE buffer by boiling 
for approximately 5 min in a microwave oven at 1000 W. While stirring at room temperature 
for 10 – 15 min, the solution was allowed to cool down to about 50 °C and 5 drops of 
ethidium bromide (0.07 %) were added per 100 mL gel volume. The agarose solution was 
poured into an electrophoresis gel tray and the comb was put in place. The gel was allowed 
to solidify at room temperature for approximately 30 – 45 min. Afterwards it was transferred 
into the electrophoresis chamber filled with TBE buffer. DNA samples and a size ladder were 
loaded onto the gel and electrophoresis was run at 100 V. DNA was visualized in an UV 
transilluminator. 
4.2.7 Quantitative Real-Time PCR (qRT PCR) 
4.2.7.1 Reverse transcription  
The first step of qRT PCR is to reverse transcribe the mRNA in total RNA samples into 
cDNA. Reverse transcription was performed in a total volume of 20 µL with the SuperScriptTM 
II reverse transcriptase. 2 µg of total RNA were diluted in 7 µL of RNase/DNase-free H2O, 
mixed with 5 µL of 50 ng/µL random hexamer oligonucleotides and incubated at 70 °C for 10 
min. Next, 2 µL of 0.1 M DTT and 1 µL of dNTPs (10 mM each) were mixed with 4 µL of 1st 
strand buffer (5X). The mixture was added to the RNA sample and incubated at room 
temperature for 10 min. After preheating at 42 °C for 2 min, 100 U of SuperScriptTM II reverse 
transcriptase were added and reverse transcription was performed at 42 °C for 1 h. To stop 
the reaction, the mixture was incubated at 70 °C for 10 min. The yield of cDNA was 
estimated to be 50 ng/µL (a 50 % reaction efficiency was assumed) and samples were stored 
at -20 °C.  
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4.2.7.2 qRT PCR 
Gene expression levels were quantified with SYBR green-based qRT PCR. The primer pairs 
used for qRT PCR are listed in Table 12. For qRT PCR using samples from human cell 
culture experiments the Platinum SYBR Green qPCR Super Mix was employed and for 
samples of murine origin the QuantiTect SYBR Green PCR kit was used. 
For qRT PCR with the Platinum SYBR Green qPCR Super Mix, 2 µL of diluted template 
cDNA were mixed with 0.4 µL forward primer (10 µM), 0.4 µL reverse primer (10 µM), 4 µL 
SYBR green mix (5X) and 3.2 µL RNase-/DNase-free H2O. PCR was performed in the 
following steps:  
95 °C   2 min 
 95 °C  15 sec 
 60 °C  1 min   
For qRT PCR with the QuantiTect SYBR Green PCR kit, 2 µL of diluted template cDNA were 
mixed with 0.4 µL forward primer (10 µM), 0.4 µL reverse primer (10 µM), 5 µL SYBR green 
mix (4X) and 2.2 µL RNase-/DNase-free H2O. PCR was performed in the following steps:  
 50 °C   2 min 
 95 °C  15 min 
 95 °C  15 sec 
 60 °C  30 sec  40 cycles 
 72 °C  30 sec 
When either qRT PCR was finished, a melting curve analysis was recorded to assess 
whether single, specific products had been produced. 
For quantification of the gene expression level of a specific gene the standard curve method 
was applied. For this purpose a 5-fold dilution series starting with 10 ng/µL cDNA (gene of 
interest) or with 25 pg/µL cDNA (18S rRNA) was generated. For each gene one standard 
curve with cDNA from a source that is known to express the gene of interest was generated. 
The Ct values were plotted against the cDNA concentration and by nonlinear regression a 
standard curve was generated. With the help of the regression analysis the concentration of 
gene-specific cDNA in the samples of interest was calculated. These values were normalized 
to the corresponding values of the housekeeper gene (18S rRNA, HPRT or Tbp). The results 
were normalized to control samples, e.g. solvent treated cells. Measurements were 
performed in triplicates on an ABI Prism 7900HT device with the help of SDS software 
40 cycles 
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(version 2.2.1). Standard curve generation with the semilog line equation as well as 
normalization was done with GraphPad Prism 6 software.  
4.2.8 Plasmid DNA amplification, isolation and purification 
Single colonies of transformed DH5α E. coli (transformation is described in section 4.1.13) 
were transferred into 100 mL of LB medium containing ampicillin (100 µg/mL) or kanamycin 
(50 µg/mL) and grown overnight at 37 °C while shaking at 155 rpm. 
Isolation of pDNA was performed with the PureLink® HiPure Plasmid Midiprep kit, which is 
based on anion-exchange chromatography in columns. Cells are lysed and lysates are 
loaded onto the column. Positively charged residues within the column material interact with 
the negative charges of DNA’s phosphate groups. Unbound cell debris, proteins and RNA 
can be washed away with Wash buffer. Afterwards, salt concentrations within the column are 
raised with Elution buffer, DNA binding to the column material is released and the DNA is 
eluted.  
The isolation process was performed according to the manufacturer’s instruction. In brief, the 
bacteria suspension was transferred into 50 mL reaction tubes and centrifuged at 10000 rpm 
and 4 °C for 10 min. Supernatant was discarded and the cells were resuspended in 4 mL 
Resuspension Buffer. For lysis of the bacteria, 4 mL of Lysis Buffer were added, the mixture 
was inverted gently, incubated at room temperature for 5 min and 4 mL of Precipitation buffer 
were added. Afterwards, the mixture was centrifuged at 10000 rpm and 4 °C for 10 min. In 
the meanwhile, columns were equilibrated with 10 mL Equilibration buffer. When 
centrifugation was finished, the supernatant was transferred onto the columns and allowed to 
drain by gravity flow. Then the columns were washed twice with 10 mL of Wash buffer. 
Afterwards the bound pDNA was eluted with 5 mL Elution buffer and the flow-through was 
collected in a 15 mL reaction tube. The eluate was transferred in 1 mL aliquots to five 2 mL 
reaction tubes. 1 mL of pure isopropanol was added and the mixture was incubated at -20 °C 
overnight or at -80 °C for 20 min. Afterwards the precipitated pDNA was centrifuged at 13000 
rpm and 4 °C for 30 min. Supernatant was discarded and to wash the pDNA 200 µL of 70 % 
EtOH were added and the mixture was centrifuged at 13000 rpm and 4 °C for 10 min. Then 
supernatant was discarded and the pDNA was dried upside down at 55 °C for 5 min. The 
pDNA was resuspended in 20 µL of RNase/DNase-free H2O while shaking at 1400 rpm and 
42 °C for 10 min. All suspensions of one plasmid were pooled and stored at -20 °C. 
4.2.9 Restriction enzyme hydrolysis 
Test-restriction analysis of the amplified pDNA was performed using two adequate restriction 
endonucleases. For this purpose 1 µg of pDNA was mixed with 3 units of the respective 
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restriction enzymes in 1X hydrolysis buffer in a total volume of 10 µL. Hydrolysis was 
performed at 37 °C for 2 h. Afterwards the reaction was stopped by incubation at 70 °C for 10 
min. The used restriction enzymes and suppliers are listed in Table 6.  
To analyze hydrolysis products, 2 µL of 6X DNA Loading dye were added and the pDNA was 
separated by agarose gel electrophoresis. Depending on the expected product sizes, 
agarose concentrations were 0.5 - 2 % (w/v). 
4.3 Histology and immunohistochemistry 
4.3.1 Haematoxylin and eosin (HE) staining 
For HE staining, RMS tissue fixed in 4 % PFA was embedded in paraffin and cut into 4 - 5 
µm sections. Sections were mounted onto glass slides and deparaffinized in xylene for 10 
min and another 10 min in fresh xylene. Afterwards the tissue was hydrated in a descending 
EtOH series (100 %, 96 %, 70 % EtOH for 1 min each while shaking). After a thorough 
washing step with ultrapure H2O, the slides were incubated in haematoxylin for 15 min and 
rinsed with warm tap water until the draining water got clear. The tap water induces formation 
of haemalaun, which stains all basophile structures (e.g. DNA, ribosomes) blue. In the 
meanwhile a few drops of acetic acid were added to eosin solution, which helps to intensify 
the staining of the acid dye eosin. Slides were incubated for 20 sec in eosin solution and 
shortly rinsed with ultrapure H2O. Subsequently tissue slides were dehydrated in an 
ascending EtOH/xylene series (70 %, 96 % and 100 % EtOH, two times xylene). Slides were 
mounted with pertex and dried at 55 °C for at least 20 min.  
4.3.2 Ki67 staining 
For Ki67 staining, paraffin embedded RMS tissue was cut into 4 – 5 µm sections and 
mounted onto superfrost glass slides. Tissue was deparaffinized in xylene for 10 min and 
another 10 min in fresh xylene. Afterwards the tissue was hydrated in a descending EtOH 
series (2x 100 %, 95 %, 80 %, 70 % EtOH for 2 min each). Slides were rinsed with ultrapure 
H2O and antigen-retrieval was performed by cooking the slides in citric acid buffer (pH 6) 
once for 4 min and three times for 3 min at 600 W in a microwave oven. Slides were cooled 
down to room temperature and rinsed two times in TBS buffer for 2 min. Endogenous 
peroxidases were blocked by incubating the slides for 20 min in 3 % H2O2 in TBS buffer while 
shaking. Afterwards slides were washed for 5 min in ultrapure H2O and rinsed in TBS buffer. 
Slides were placed in a moist chamber, the remaining liquid was removed and the tissue was 
blocked with 0.2 % casein in TBS buffer for 20 min to prevent unspecific antibody binding. 
Primary antibody against Ki67 was diluted 1:50 in TBS buffer and distributed onto the tissue 
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slides. Incubation was performed overnight at 4 °C. The remaining antibody dilution was 
removed by washing the slides with TBST buffer for three times. HRP-conjugated secondary 
antibody and HRP substrate were used from the Dako REALTM EnVisionTM Detection 
System. Slides were incubated with the ready-to-use secondary antibody for 30 min and 
washed twice with TBS buffer. Diaminobenzidine (DAB) chromogen was diluted in substrate 
buffer 1:50 and transferred to the slides for 10 min. To stop staining, slides were rinsed with 
TBST and washed with ultrapure H2O for 5 min. Afterwards the slides were counterstained 
with haematoxylin for 5 sec, washed in warm tap water for 5 min and mounted with glycergel. 
To count the number of Ki67+ nuclei, staining was analyzed on a microscope with a camera. 
From each tumor 5 pictures of randomly chosen regions within the tissue were taken at 200 x 
magnification with CellSens Dimension software. The number of Ki67+ and the total number 
of nuclei were counted manually using AlphaView Q SA software. For small RMS a minimum 
of 6 x 103 nuclei were counted. The percentage of Ki67+ nuclei was calculated with 
GraphPad Prism 6 software.  
4.4 Animal experiments  
Experiments using animals were performed in compliance with all relevant legal and ethical 
requirements and have been approved by the Lower Saxony State Office for Consumer 
Protection and Food Safety experiments (file number 33.14-42502-04-13/1084). Research 
staff working with animals was trained according to the recommendations of Federation of 
European Laboratory Animal Science Associations (FELASA - Category B). 
4.4.1 Mouse lines 
Wildtype mice of the inbred strains C57BL/6N (B6) and BALB/c (Balb) were either bred 
in-house or purchased from Jackson Laboratories (Bar Harbor, USA) or Charles River 
Laboratories (Wilmington, USA). Balb-Ptchdel/+ mice harbor a heterozygous deletion of exon 8 
and 9 within the Ptch gene216. For in vivo studies and for isolation of primary RMS cells these 
mice were bred to B6 mice. The resulting BalbxB6-Ptchdel/+ mice show a high susceptibility to 
RMS216 and were named Ptch+/- mice. 
The in vivo study with HhAntag/pictilisib was performed with B6xBalb-Ptchneo67/+ mice227 that 
harbor a heterozygous deletion of exon 6 and 7 within the Ptch gene and were generated by 
breeding of B6-Ptchneo67/+ mice with Balb mice (for further description and PCR-based 
genotyping see228).  
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4.4.2 Breeding of mice  
Breeding and housing of mice was done in the animal facility at the Institute of Human 
Genetics, University Medical Center Göttingen. Mice were housed in air-flow racks in 
Makrolon type 2 cages with a 12 h light-dark cycle at 22 °C +/- 2 °C and 55 % +/- 10 % 
relative humidity. Tap water and food pellets were sterilized for 20 min at 110 °C and 
provided ad libitum. All work performed with animals was done under a laminar flow system. 
For breeding, healthy animals with the desired genotype were used at an age of 10 – 35 
weeks.  
4.4.3 Tail biopsy and genotyping 
At the age of 4 weeks, mice underwent ear marking for numeration of each animal. In 
addition, a tail biopsy of approximately 0.2 cm length was taken from the tip of the tail and 
was used for gDNA isolation and PCR-based genotyping as described in sections 4.2.1 and 
4.2.5. The DNA oligonucleotides that were used for genotyping of Ptch+/- animals are listed in 
Table 11.  
4.4.4 Tumor monitoring and study design  
Once a week all Ptch+/- mice were monitored for the occurrence of RMS. Prevalent sites for 
RMS were the extremities and the lower back region. In RMS-bearing animals the size of the 
tumor was estimated manually by palpation and careful visual observation. When a tumor 
reached a diameter of approximately 0.5 cm, the animal was considered for in vivo drug 
treatment.  
RMS-bearing animals were weighted before therapy onset and twice a week during the 
treatment period. The animals were monitored for tumor growth and their general health 
status twice daily. Animals were euthanized by cervical dislocation following CO2 anesthesia 
when the loss of body weight was > 20 %, when RMS reached a diameter > 1 cm, when the 
animals showed bad health conditions (apathy, paralysis, ruffled fur) or if typical signs for 
tumors of the cerebellum (e.g. tumbling motion) occurred (please note that Ptch+/- animals 
can develop medulloblastoma216,227).  
At the end of the study, all animals were euthanized and RMS tissue was taken for RNA or 
protein isolation and immunohistochemistry as described in sections 4.2.3, 4.1.2 and 4.3.2, 
respectively. The identity of tumors as RMS was confirmed by HE staining according to 
section 4.3.1. 
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4.4.5 Drug formulation for in vivo treatment 
Drugs for in vivo studies were provided as powder by the manufacturers and are listed in 
Table 5. All drugs were applied systemically by oral gavage as described in section 4.4.6. 
For this purpose they were resuspended in methylcellulose tween (MCT). The dosage of 
each drug and concentrations of the prepared suspensions are listed in Table 5.  
To prepare 100 mL of vehicle, 0.5 mg methylcellulose were transferred into a sterile glass 
flask. While stirring at high speed, approximately 40 mL of 80 °C – 90 °C ultrapure H2O were 
added. When the mixture was dispersed, it was slowly filled up to 100 mL with cold ultrapure 
H2O. Storage at 4 °C overnight or for several hours resulted in a clear solution. The solution 
was equilibrated to room temperature and 200 µL of tween 80 were added while stirring. The 
MCT solution was filtered through a 0.4 µm pore filter and could be stored at 4 °C for up to 
one month.  
Drug suspensions were prepared according to manufacturer’s recommendations. In brief, 
drug powder was weighed out on precision scales and transferred into a 2 mL reaction tube 
where it was mixed with the respective amount of vehicle to reach the concentrations listed in 
in Table 5. For preparation of the vismodegib, sonidegib or pictilisib suspensions, the vehicle 
was slowly added the day before use and tubes were kept at 4 °C without mixing. The next 
day, tubes were shaken at 1400 rpm and 37 °C for 3 - 5 min. Powder clumps were triturated 
with a pipette tip in serial steps with short centrifugation at medium speed in between to 
collect all clumps at the bottom of the tube. For preparation of the HhAntag solution, the drug 
powder was triturated directly after addition of vehicle. Prepared mixtures were stored for a 
maximum of 48 h at 4 °C. 
4.4.6 Oral gavage of SMO inhibitors and/or pictilisib 
RMS-bearing, but otherwise healthy Ptch+/- mice with a tumor size of approximately 0.5 cm 
were used for the in vivo treatment studies. To avoid cross-contamination of the cohorts, all 
animals receiving the same treatment were kept in separate housing cages. Animals were 
treated twice daily with vehicle/vehicle, single drug/vehicle or drug/drug combinations by oral 
gavage. In between a time span of 5 h was left to prevent potential drug-drug interactions 
and complexations, which could have lowered the intestinal resorption and hence the 
therapeutic effectiveness of the combination treatment. 
Drug suspension or vehicle was mixed thoroughly and pre-warmed to 37 °C directly before 
oral treatment. The respective amount of drug suspension was aspirated with a sterile 
syringe. The feeding tube was attached and pre-filled with drug suspension/vehicle. Animals 
were restrained in the back, neck and tail region in an upright position so that the head and 
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neck were fixed. The feeding tube was internalized into the esophagus of the mouse and the 
drug suspension/vehicle was released. Feeding tubes were wiped and rinsed once with 70 % 
EtOH and several times with ultrapure H2O and allowed to dry before storing. In addition, 
feeding tubes were autoclaved monthly.  
4.4.7 Tumor size assessment by in vivo micro computed tomography (µCT) 
The tumor growth was analyzed using a low dose in vivo µCT (QuantumFX, Perkin Elmer) at 
90 kVp tube voltage, 200 µA tube current and a 2 min total acquisition time. Mice were 
anesthetized with 1 - 2 % isoflurane in 1:1 air, oxygen mix before and during the scan. In 
order to visualize the tumors 5 ml/kg of Imeron 300 contrast agent were injected into the tail 
vein approximately 30 sec prior imaging. Data sets were reconstructed with a voxel size of 
80 µm and analyzed using Scry v6.0 software. An example picture is shown in Fig. 4. 
The contrast agent Imeron 300 contains a nonionic iodine compound called iomeprol. Iodine 
compounds can enhance the absorption of X-rays in vessels and tissues when injected 
intravenously. Delivered through the tumor vasculature, the contrast agent accumulates 
within the RMS and allows for proper monitoring of cancer structures, as shown in Fig. 4.  
To calculate tumor volume the following equation was used, which assumes that the volume 
resembles an ellipsoid structure229. Tumor growth was calculated by scanning ERMS-bearing 
animals before therapy onset and at the end of treatment. For the animals in the study with 
HhAntag/pictilisib treatment a third scan at day 21 of treatment was performed.  
    
a   b   c
2
   
V: tumor volume  
a: width 
b: height  
c: length 
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Figure 4: Low dose in vivo µCT of RMS. Picture shows one example of a Ptch
+/-
 mouse that has 
developed a RMS located at the inner knee. Tumor was visualized as described in the text and data 
acquisition was done with Scry software. 
For data analysis the Response Evaluation Criteria in Solid Tumors (RECIST) were 
used230,231. In short, the sum of tumor volumes of all ERMS lesions that were observed in one 
mouse was calculated. For each animal, the sum of tumor volumes at the end of study was 
normalized to the sum of tumor volumes at therapy onset. An increase in tumor volume of > 
20 % was defined as progressive disease (PD), a reduction in tumor volume of > 30 % was 
defined as partial response (PR) and changes in tumor volume in-between PD and PR were 
defined as stable disease (SD).   
4.5 Statistics 
Statistical analysis was done with GraphPad Prism 6 software. Data were considered 
significant if p values were < 0.05. For statistical comparisons between two groups, a 
Student’s t-test was performed. In order to compare more than two groups of data originating 
from in vitro experiments (considered following a Gaussian distribution), a one-way analysis 
of variance (ANOVA) was performed. For multiple testing between different treatments and 
control, Dunnett’s test was performed. When different treatments groups were compared with 
each other, Tukey’s test was done. In order to compare more than two groups of data 
originating from in vivo experiments (considered not following a Gaussian distribution), a 
one-way ANO A with Dunn’s test for multiple comparisons was performed. 
Estimation of tumor growth in vivo and statistical analysis of group differences was 
performed with the help of Albert Rosenberger (Genetic Epidemiology, University Medical 
Center, Göttingen). Differences in tumor growth were analyzed using a mixed random effects 
Methods 54 
 
 
 
model with repeated measures. Multiple testing was corrected by the method of Dunnett 
Hsu. All calculations were performed with SAS 9.4 software.  
Correlation analysis between Gli1 expression levels and relative tumor size at the end of 
treatment was performed using GraphPad Prism 6 software. As tumor samples were not 
expected to follow a Gaussian distribution, a non-parametric Spearman test was applied.  
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5 Results  
5.1 Targeting HH and PI3K/AKT/mTOR signaling pathways in human 
ERMS cell lines 
Previous studies have shown that SMO inhibitors can evoke anticancer effects in human 
ERMS cell lines121. These effects are highly concentration and cell line dependent. 
Surprisingly, the anticancer effects are not necessarily associated with a downregulation of 
HH signaling activity. For example the SMO inhibitor sonidegib significantly reduces 
proliferation of RD cells at a concentration of 30 µM but at the same concentration does not 
affect expression of the HH signaling target gene GLI1. Additionally the SMO inhibitor 
vismodegib rather induces than reduces the proliferation of ERMS cell lines.  
Here we tried to unravel if the anticancer effects of SMO inhibitors that were not associated 
with a downregulation of HH signaling activity were off-target effects. In addition, the impact 
of SMO inhibitors on cell cycle distribution and GLI transcriptional activity was investigated. 
Finally, and as the most important section of this part of the thesis, the importance of 
PI3K/AKT/mTOR signaling in regulation of GLI transcriptional activity was elucidated and the 
effects of a combination treatment with SMO plus PI3K/AKT/mTOR inhibitors were analyzed. 
5.1.1 Cyclopamine, sonidegib or HhAntag, but not vismodegib, enhance anti-
proliferative effects of cells with a low SMO expression level 
To investigate whether SMO inhibitors might evoke off-target effects in ERMS cell lines, their 
impact on RD cells with a stable SMO knockdown was analyzed. If the antitumoral effects of 
SMO inhibitors were indeed dependent on SMO, we expected that a SMO knockdown 
should prevent these effects. 
The SMO knockdown cells were a gift from Prof. Dr. Beat Schaefer (University Children's 
Hospital of Zurich, Department of Oncology, Zurich, Switzerland) and were generated by 
expression of an exogenous small hairpin RNA targeting the SMO transcript (shSMO). 
Control cells were transfected with the respective empty vector118. To confirm the SMO 
knockdown, the expression level of SMO was investigated. RD cells transfected with shSMO 
showed a clear but incomplete downregulation of SMO on protein level (Fig. 5A) and on 
mRNA level (Fig. 5B). Hence, in our lab these cells were called RD SMOlow and control cells 
were called RD SMOhigh. Functionally the SMO knockdown reduced HH signaling activity as 
indicated by a downregulation of GLI1 and PTCH1 expression levels (Figs. 5C and 5D, 
respectively). 
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Figure 5: RD SMOlow cells show a clear but incomplete downregulation of SMO. SMO 
knockdown was confirmed by (A) Western Bot analysis with specific antibodies for SMO and the 
housekeeper protein ß-actin and (B) qRT PCR. (C, D) Gene expression levels of the HH target genes 
GLI1 and PTCH1, which were normalized to 18S rRNA and HPRT and are shown as fold expression 
to RD SMOhigh cells that were set to 1. Bars represent the mean +standard error of the mean (SEM) 
of two independent experiments performed in duplicates. For statistical analysis a student’s t test was 
performed. *P<0.05, **P<0.01, ***P<0.001 compared to expression levels of RD SMOhigh cells. 
Upon knockdown confirmation, growth of RD SMOlow and RD SMOhigh cells was monitored 
by counting the number of living cells from treatment onset until 120 h. As seen in Fig. 6A, 
cyclopamine, sonidegib and HhAntag reduced growth of RD SMOhigh in a concentration 
dependent manner. 30 µM HhAntag nearly stopped growth and 30 µM sonidegib even 
reduced cell numbers during treatment. In contrast, vismodegib did not affect cell growth of 
RD SMOhigh cells. Surprisingly, when RD SMOlow cells were incubated with 5 µM 
cyclopamine cell growth was arrested and 10 µM cyclopamine even induced cell death, 
indicated by a decreasing number of living cells. Similarly, 10 µM sonidegib efficiently 
stopped cell growth and 30 µM induced cell death. The same was true for HhAntag 
treatment, even though the decrease in cell number after treatment with 30 µM was not as 
strong as it was seen for sonidegib treatment at the same concentration. In contrast and as 
also seen in RD SMOhigh cells, vismodegib did not affect growth of RD SMOlow cells. 
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Additionally, the proliferative capacity and cellular viability of the cells was investigated by 
BrdU incorporation assay and by WST-1 assay, respectively, after treatment with SMO 
inhibitors for 24 h.  
When RD SMOhigh cells were treated with cyclopamine or vismodegib the cellular 
proliferation or viability was not affected (Fig. 6B). In contrast sonidegib enhanced cellular 
proliferation at a concentration of 10 µM and reduced cellular proliferation and viability at a 
concentration of 30 µM. HhAntag enhanced cellular proliferation at a concentration of 10 µM 
and reduced cellular viability at a concentration of 30 µM. Likewise in RD SMOlow cells, 
cyclopamine, vismodegib and 10 µM sonidegib did not affect cellular proliferation and 
viability. In contrast 30 µM sonidegib reduced both parameters to a similar extent as it was 
seen for RD SMOhigh cells. HhAntag indeed reduced proliferation and viability of RD 
SMOlow cells at both applied concentrations and at 30 µM the reduction of cellular viability 
was stronger than it was seen for control cells. These results are in line with the observations 
made by counting the number of living cells after 24 h of treatment with SMO inhibitors (see 
Fig. 6A). 
To sum up, RD cells with a stable but incomplete SMO knockdown are more sensitive 
towards the SMO inhibitors cyclopamine, sonidegib and HhAntag. These results might 
indicate that growth of ERMS cells is dependent on SMO activity. Hence, dual blockade of 
SMO activity by genetic downregulation of the basal expression level and pharmacologic 
inhibition of the remaining protein activity seems to be very efficient. As a consequence 
cyclopamine, sonidegib or HhAntag treatment induces stronger anti-proliferative effects in 
RD SMOlow compared to RD SMOhigh cells. However the lack of any effect of vismodegib is 
hard to explain. One possible explanation might be an acquired SMO mutation inducing 
selective resistance of RD cells against vismodegib. In literature, e.g. a D477G mutation in 
SMO has been described to cause resistance towards vismodegib while only mildly affecting 
the effectiveness of cyclopamine, sonidegib or HhAntag232,233. However, this is rather 
unlikely, since the parental RD cells do not harbor this mutation (personal communication of 
Heidi Hahn with Javed Khan, Genetic Branch, NIH). Finally, the different cellular response to 
one out of four investigated SMO inhibitors might indicate that the drugs indeed exert off-
target effects. Thus, if SMO would be the only target of all four drugs, one would expect 
similar cellular responses to either drug. 
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Figure 6: RD SMOlow cells are sensitiver towards cyclopamine, sonidegib or HhAntag 
compared to RD SMOhigh cells. (A) RD SMOlow and RD SMOhigh cells were treated with the 
indicated SMO inhibitors for up to 120 h. Every 24 h cells were harvested, stained with toluidine blue 
and the number of living cells was counted. Data represent the mean +SEM of three independent 
experiments performed in duplicates. (B) RD SMOlow and RD SMOhigh cells were treated with the 
indicated SMO inhibitors for 24 h. For BrdU incorporation assay, BrdU was added for 24 h. Cell 
viability was analyzed with the help of WST-1 assay. Data are normalized to data from solvent treated 
cells that were set to 100 % and bars represent the mean +SEM of two (cell viability) and three (BrdU 
incorporation assay) independent experiments performed in triplicates. Statistical analysis was 
performed according to one-way ANO A and Dunnett’s test for multiple comparisons. *P<0.05, 
**P<0.01, ***P<0.001 compared to solvent treated cells. 
5.1.2 HhAntag, but not cyclopamine, vismodegib or sonidegib, induces a 
moderate G2/M arrest although it does not affect HH signaling activity  
As already mentioned above, the effects of the used SMO inhibitors on proliferation, 
measured with the help of BrdU incorporation assay, and on apoptosis, measured with the 
help of Annexin V / PI staining have been already published121. The data showed that the 
anticancer effects were not as strong as expected and were in parts not accompanied by a 
downregulation of HH target gene expression. Additionally, proliferation of ERMS cell lines 
was sometimes even enhanced by the drugs (e.g. by vismodegib). 
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To complete these studies, changes in cell cycle distribution of RD and RUCH-2 cells treated 
with cyclopamine, vismodegib, sonidegib or HhAntag were investigated. In addition a GLI 
reporter assay system was utilized to test if SMO inhibitor treatment affects the activity of GLI 
transcription factors.  
5.1.2.1 Moderate G2/M arrest of RD cells upon incubation with HhAntag 
For cell cycle distribution analysis, RD and RUCH-2 cells were treated with the four SMO 
inhibitors for 24 h and 72 h, respectively. Then the cells were fixed, stained with PI and 
analyzed by flow cytometry (Fig. 7).  
In this setting, approximately 26 % of RD cells were in G1/G0 phase (Fig. 7A), 9 % in S 
phase (Fig. 7B) and around 33 % of cells resided in G2/M phase (Fig. 7C). In case of RUCH-
2 cells approximately 19 % of cells were in G1/G0 phase (Fig. 7A), 2-3 % in S phase (Fig. 
7B) and 48 % in G2/M phase (Fig. 7C). Neither cyclopamine, nor vismodegib, nor sonidegib 
affected cell cycle distribution of the investigated cell lines. In contrast, 30 µM HhAntag 
induced a significant G2/M arrest of RD cells. This was indicated by a significantly enhanced 
number of cells in G2/M phase (raise from 33 % of solvent treated cells to 42 % of cells 
treated with 30 µM HhAntag) and a decrease in cell numbers in G1/G0 and S phase (not 
significant). Treatment of RUCH-2 cells with 30 µM HhAntag likewise reduced the number of 
cells that reside in G1/G0 and S phase, but at the same time the number of cells in G2/M 
phase was unaffected. This might indicate an induction of apoptosis, which would lead to an 
increasing number of cells residing as Sub-G1/G0 cells. Indeed, the numbers of RUCH-2 
cells in Sub-G1/G0 were moderately, but not significantly, enhanced after treatment with 30 
µM HhAntag (data not shown).  
The data showing that cyclopamine, vismodegib and sonidegib do not affect cell cycle 
distribution of RD and RUCH-2 cells conflicts with previously published data showing that a 
24 h treatment with 30 µM sonidegib can reduce, and that a 24 h treatment with 5 µM 
cyclopamine or 10 µM vismodegib can even induce the proliferation rate of RD and RUCH-2 
cells as analyzed by BrdU incorporation assay121. However, and in accordance with the 
proliferation assay121, 24 h treatment with 30 µM HhAntag can induce a significant cell cycle 
arrest of RD cells. 
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Figure 7: HhAntag induces a G2/M arrest of RD cells. Cells were treated for 24 h (RD cells) or 72 h 
(RUCH-2 cells) with SMO inhibitors as indicated. Fixed cells were stained with PI, cell cycle 
distribution was analyzed by FACS and the relative amount of cells that resided in (A) G1/G0 phase, 
(B) S phase and (C) G2/M phase was calculated. Bars represent the mean +SEM of four (RD cells) or 
five (RUCH-2 cells) independent single experiments. Statistical analysis was performed according to 
one-way ANO A and Dunnett’s test for multiple comparisons. *P<0.05, **P<0.01, ***P<0.001 
compared to solvent treated cells. 
5.1.2.2 SMO inhibitors do not affect GLI transcriptional activity 
To investigate whether SMO inhibitors indeed block the activation status of HH signaling, a 
GLI reporter assay was performed (Fig. 8). For this purpose RD cells were transfected with a 
firefly luciferase whose expression is regulated by a GLI responsive promoter. For 
normalization of transfection efficiency, cells were co-transfected with a constitutively 
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expressed Renilla luciferase. Transfected cells were treated with the four SMO inhibitors 
cyclopamine, vismodegib, sonidegib and HhAntag and with SMO agonist (SAG) that is 
expected to increase the HH signaling activity within the cells. As another positive control 
cells were also co-transfected with a Gli1 overexpression plasmid. As negative control cells 
were not transfected with the firefly luciferase plasmid but with an empty analogue plasmid. 
 
Figure 8: SMO inhibitors do not alter GLI reporter activity in RD cells. RD cells were transfected 
with a GLI-responsive firefly luciferase and treated with 1 µM cyclopamine, 10 µM vismodegib, 10 µM 
sonidegib, 10 µM HhAntag or 100 nM SAG for 48 h. (A) Firefly luciferase activity normalized to the 
activity of a Renilla luciferase. (B) Raw data for firefly or Renilla luciferase activity. Bars represent the 
mean +SEM of three (vismodegib, HhAntag treatment), two (cyclopamine, sonidegib treatment) or one 
(SAG treatment) independent experiments performed in triplicates. 
As seen in Fig. 8A neither cyclopamine, nor vismodegib, nor sonidegib, nor SAG were able 
to efficiently alter GLI reporter activity in RD cells. Surprisingly, HhAntag slightly enhanced 
the normalized GLI reporter activity. However, this effect was not based on a real 
upregulation of the firefly luciferase activity but rather on a lower Renilla luciferase activity 
upon treatment with HhAntag (Fig. 8B). 
In summary, the data show that HH signaling activity is apparently not modulated by any of 
the four investigated SMO inhibitors or SAG when performing a luciferase-based GLI 
reporter assay. These data are in contrast with the downregulation of GLI1 expression level 
in RD cells treated with 10 µM vismodegib, sonidegib or HhAntag and in contrast with the 
upregulation of GLI1 expression level in RD cells treated with 1 µM cyclopamine121.  
Together neither cyclopamine, nor vismodegib, nor sonidegib, nor HhAntag affect the GLI 
transcriptional activity in RD cells and, except HhAntag, also do not affect the cell cycle 
distribution of RD or RUCH-2 cells. This experiment again indicates that the antitumoral 
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effects of the SMO inhibitors (see121) may not result from SMO inhibition, but are rather off-
target effects of the drugs. 
5.1.3 Non-canonical regulation of HH signaling in ERMS cell lines 
5.1.3.1 Marginal activation of HH signaling by SHH 
As described above, the SMO inhibitors did not show the expected inhibitory effects on HH 
signaling activity (see section 5.1.2.2). In order to see whether HH signaling activity can be 
modulated in ERMS cells at all, the cells were next incubated with SHH. For this purpose 
SHH conditioned medium from HEK293 cells that stably overexpress and secrete SHH was 
used. As control, ERMS cells were incubated with medium obtained from untransfected 
HEK293 cells. Murine B9 cells (also called Ptchflox/flox ERT2+/- cells214) that are responsive to 
HH signaling modulation served as control cells. 
SHH containing medium did not regulate the expression of GLI1 and PTCH in RD cells, 
whereas HHIP expression seemed to be upregulated in dependency of the housekeeper 
gene (Fig. 9A). This was similar in RUCH-2 cells, in which normalization to HPRT resulted in 
upregulation of GLI1 but in downregulation of HHIP. Normalization to 18S rRNA resulted in 
upregulation of PTCH. The functionality of the SHH conditioned medium was proven by a 
strong upregulation of Gli1 in B9 cells (Fig. 9B). Since changes of the GLI1, PTCH and HHIP 
expression levels in ERMS cells were extremely moderate and were also dependent on the 
housekeeper gene used for normalization, it was concluded that SHH does only marginally 
induce the HH signaling activity, if at all. 
Together with the results described in section 5.1.2.2 these results show that canonical HH 
signaling activity is, if at all, only marginally adjustable in ERMS cells. 
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Figure 9: SHH may, if at all, only moderately regulate HH signaling in ERMS cell lines. (A) RD 
and RUCH-2 cells were incubated for 24 h with medium obtained from HEK293 cells stably 
overexpressing SHH. Cells that were incubated with medium obtained from untransfected HEK293 
cells were considered as baseline (cntl). Data show qRT PCR analysis of the HH target genes GLI1, 
HHIP and PTCH. 18S rRNA and HPRT were used for normalization. The expression levels are shown 
as fold expression to cntl that were set to 1. Bars represent the mean +SEM of two independent 
experiments performed in duplicates. Statistical analysis was done according to student’s t test. 
*P<0.05, **P<0.01, ***P<0.001 compared to cntl treated cells. (B) Murine B9 cells served as positive 
control. Gli1 expression levels were normalized to either 18S rRNA or Tbp. 
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5.1.3.2 Potential non-canonical regulation of HH signaling by the PI3K/AKT/mTOR 
axis 
Next, it was investigated whether HH signaling activity can be regulated in a non-canonical 
way. From literature several oncogenic pathways are known to interact with HH signaling 
downstream of SMO. Thus, many tumors or tumor cell lines including RMS show 
convergence of PI3K/AKT/mTOR and HH signaling108,121,185,234,235. In addition, 
PI3K/AKT/mTOR signaling plays an important role in HH signal potentiation for embryonic 
differentiation106. Furthermore, interactions between HH signaling and the RAS/MEK/ERK 
signaling pathway have been described in cancer. Examples are pancreatic cancer90,102,236 
and melanoma76. Therefore, it was analyzed whether HH signaling activity might be 
regulated by one of these pathways in ERMS cell lines. To inhibit PI3K/AKT/mTOR signaling 
activity, RD and RUCH-2 cells were treated with the pure PI3K inhibitor pictilisib, the dual 
PI3K/mTOR inhibitor PI-103, the pure AKT inhibitor MK-2206 and the mTOR inhibitors 
everolimus and rapamycin. In order to target the RAS/MEK/ERK signaling pathway, cells 
were treated with the MEK inhibitor UO126. Finally, AKT activity was modulated by 
overexpression of a constitutively active and a dominant negative AKT (AKT-CA and AKT-
DN, respectively). 
First, the functionality of the drugs was investigated. For this purpose the phosphorylation of 
AKT and S6 and that of ERK was analyzed upon application of PI3K/AKT/mTOR inhibitors 
and of UO126, respectively. 
As expected, UO126 efficiently downregulated phosphorylation of ERK (Fig. 10A). 
Additionally and as already known from literature213 UO126 enhanced the phosphorylation of 
AKT. 
PI-103, pictilisib or MK-2206 strongly reduced phosphorylation of AKT, whereas everolimus 
and rapamycin enhanced pAKT levels (Fig. 10B). This enhancement of pAKT levels by 
mTOR inhibitor treatment is an effect described as part of a mTOR feedback loop inhibition 
and occurs in different tumor cell lines237. PI-103, pictilisib, everolimus or rapamycin 
efficiently reduced phosphorylation of the mTOR target S6. In contrast, MK-2206 did not 
affect pS6. A lack of pS6 reduction upon MK-2206 treatment is described for several human 
cancer cell lines238-240. 
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Figure 10: Proof of functionality of PI3K/AKT/mTOR and RAS/MEK/ERK inhibitors. RD cells were 
treated with (A) the ERK inhibitor UO126 as indicated and (B) PI-103 (3 µM), pictilisib (10 µM), MK-
2206 (5 µM), everolimus (5 nM) and rapamycin (100 nM) for 48 h. Afterwards cell lysates were used 
for Western Blot analysis to detect the protein levels of pAKT/AKT, pERK/ERK and pS6/S6 with 
specific antibodies. HSC70 and ß-Actin served as loading controls. Protein sizes in kDa are displayed 
on the right side of the blot. Shown is a representative blot out of two independent experiments. 
Next, HH signaling activity was investigated. As shown in Fig. 11A, incubation of RD cells 
with UO126 upregulated GLI1 expression in a concentration dependent manner, whereas 
treatment with PI-103, pictilisib, MK-2206, everolimus or rapamycin efficiently downregulated 
GLI1 expression in these cells (Fig. 11B). 
Together, the results depicted in Figs. 10 and 11 show a positive correlation between 
PI3K/AKT/mTOR and HH signaling. In addition, the results indicate that AKT might be a 
central factor within non-canonical regulation of HH signaling activity in ERMS cells. Thus, 
whereas inhibition of AKT (i.e. by PI-103, pictilisib, MK-2206) decreases HH signaling 
activity, activation of AKT (i.e. by UO126) increases it. Unfortunately it is not clear whether 
the impact of UO126 on HH signaling activity originates from AKT modulation. This effect 
could also be an off-target effect of UO126 or could originate from an AKT-independent 
interaction between RAS/MEK/ERK and GLI. Nevertheless incubation with UO126 is able to 
activate AKT and HH signaling activity. 
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Figure 11: UO126 enhances and PI3K/AKT/mTOR inhibitors reduce HH activity. RD cells were 
treated with (A) the ERK inhibitor UO126 as indicated and (B) PI-103 (3 µM), pictilisib (10 µM), MK-
2206 (5 µM), everolimus (5 nM) and rapamycin (100 nM) for 24 h. Afterwards cells were harvested for 
RNA isolation and qRT PCR of the HH target gene GLI1. GLI1 expression was normalized to 18S 
rRNA and HPRT and is shown as fold expression to solvent treated cells that was set to 1. Bars 
represent the mean +SEM of three (UO126 treatment) and six (PI-103, pictilisib, MK-2206, everolimus, 
rapamycin treatment) independent experiments performed in duplicates. Statistical analysis was 
performed according to one-way ANOVA and Dunnett’s test for multiple comparisons. *P<0.05, 
**P<0.01, ***P<0.001 compared to solvent treated cells.  
5.1.3.2.1 Genetic modulation of AKT activity 
To test the hypothesis, whether AKT regulates HH signaling activity in ERMS, AKT activity 
was genetically modulated. For this purpose, RD cells were transfected with hemagglutinin 
(HA)-tagged AKT-CA and AKT-DN. The latter harbors a kinase inactivating K179M mutation 
within the catalytic domain). AKT-CA is characterized by a myristoylation signal targeting the 
protein to the cell membrane, which results in activation of downstream AKT/mTOR 
signaling221. Additionally, AKT-CA misses the pleckstrin homology domain, leading to a 
smaller protein size of approximately 50 kDa compared to endogenous AKT and AKT-DN, 
which both are approximately 60 kDA in size. Lysates of HEK293 cells transfected with AKT-
CA and AKT-DN were a gift from a former member of our group, J. Pyczek, and were used 
as control. The protein levels of AKT were analyzed with the help of specific antibodies 
against the HA-tag to see whether the exogenous proteins are expressed. In addition, 
antibodies against AKT and pAKT were used to see whether transfection has an influence on 
AKT activity. Additionally, since AKT can influence mTOR activity, phosphorylation of the 
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mTOR target S6 was analyzed. The data showing overexpression of AKT-CA and AKT-DN in 
HEK293 cells have been already described in another thesis241. 
In HEK293 cells, which show a very good transfectability, transfection with AKT-CA and 
AKT-DN resulted in a strong expression of the exogenous protein as shown with the help of 
antibodies detecting the HA tag or pAKT/AKT (Fig. 12). In addition, AKT-CA is highly 
phosphorylated, indicating its functionality. Transfection with the dominant negative form of 
AKT, AKT-DN, decreased the level of endogenous pAKT. However, no obvious difference in 
phosphorylation of S6 could be detected. These results show that the exogenous AKT 
proteins act, as expected, on phosphorylation of AKT, but apparently do not act on the AKT 
downstream effector mTOR in HEK293 cells. 
 
 
Figure 12: Overexpression of AKT variants in RD and HEK293 cells. RD and HEK293 cells were 
transfected with plasmids carrying either a HA-tagged constitutively active (AKT-CA) or dominant 
negative (AKT-DN) AKT. In parallel, cells were also transfected with EGFP to confirm transfectability 
(control). 12 h and 48 h after transfection cells were harvested and lysates from transfected and 
untransfected (untr) cells were analyzed by Western Blot with specific antibodies against HA, AKT, 
pAKT, S6 and pS6. HSC70 served as loading control. Estimated protein sizes in kDa are indicated on 
the right side of the blot. 
In RD cells, AKT-CA was expressed and phosphorylated, as indicated by a HA and pAKT 
signal at the expected size of 50 kDa (exogenous protein). Comparable to the observations 
that have been made in HEK293 cells, pS6 remained unaffected. The HA tag detection of 
AKT-DN was very weak and also the general AKT level was apparently not altered in cells 
transfected with AKT-DN, indicating a weak expression of the AKT-DN protein. In addition, 
phosphorylation of S6 remained unaffected by AKT-DN transfection as well. 
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To sum it up, it was possible to transfect RD cells with AKT-CA and AKT-DN. However, the 
expression of AKT-DN was very weak and both exogenous proteins did not affect 
phosphorylation of the AKT/mTOR downstream target S6. 
5.1.3.2.2 No impact of genetic AKT modulation on HH signaling activity 
Even though phosphorylation of S6 was not affected in RD cells and AKT-DN was merely 
expressed, it was investigated, whether the expression of AKT-CA or AKT-DN has an impact 
on HH signaling activity in RD cells (Fig. 13). 
 
Figure 13: Impact of AKT variants on HH signaling activity. RD cells were transfected with 
plasmids carrying constitutive active (AKT-CA) or dominant negative (AKT-DN) forms of AKT. 48 h 
after transfection cells were harvested for RNA isolation and subsequent qRT PCR analysis for the HH 
target genes GLI1 and PTCH1. 18S rRNA (left panel) and HPRT (right panel) were used for 
normalization. Expression levels are shown as fold expression of untransfected (untr) cells that were 
set to 1. Bars indicate the mean +SEM of one biological replicate performed in duplicates. Statistical 
analysis was performed according to one-way ANO A and Dunnett’s test for multiple comparisons. 
*P<0.05, **P<0.01, ***P<0.001 compared to untransfected cells. 
The expression level of GLI1 was not altered upon expression of AKT-CA or AKT-DN, 
whereas PTCH expression was reduced (Fig. 13). Although this experiment has been 
performed only once, it was not repeated. This was due to the fact, that according to the 
literature AKT-CA should have decreased pS6 levels in control cells or ERMS cells221, which 
however was not the case. Therefore it is not clear whether the missing GLI1 upregulation 
upon transfection with AKT-CA and the missing downregulation upon transfection with AKT-
DN are due to lack of activity of the plasmid-derived proteins.  
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5.1.4 SMO inhibitors can induce cooperative anticancer effects when combined 
with PI3K/AKT/mTOR inhibitors 
Because PI3K/AKT/mTOR inhibitors significantly reduced HH signaling activity in ERMS cells 
(see Fig. 11B) it next was investigated whether a combination of SMO and PI3K/AKT/mTOR 
inhibitors may enhance the anticancer effects of the SMO inhibitors. 
The experiments were performed with vismodegib, sonidegib and HhAntag and with the 
PI3K/AKT/mTOR inhibitors described in section 5.1.3.2.  
5.1.4.1 No cooperative inhibition of HH signaling activity upon combination of SMO 
and PI3K/AKT/mTOR inhibitors 
First it was tested if the combination of SMO inhibitors with PI3K/AKT/mTOR inhibitors 
cooperates in reduction of HH signaling activity in the ERMS cell lines RD and RUCH-2. For 
this purpose the expression level of the HH target gene GLI1 was quantified. (Parts of the 
results already have been shown in Fig. 11.) 
In the applied concentrations vismodegib (Fig. 14A), sonidegib (Fig. 14B) and HhAntag (Fig. 
14C) alone reduced the HH signaling activity in RD cells, even though the reduction was only 
moderate when vismodegib or sonidegib were applied. In RUCH-2 cells vismodegib and 
sonidegib did not affect HH signaling activity and HhAntag only moderately reduced it. All 
applied PI3K/AKT/mTOR inhibitors reduced the HH signaling activity in both cell lines. The 
reduction was most efficient upon treatment with PI-103 or pictilisib. 
However, when the SMO inhibitors were combined with PI3K/AKT/mTOR inhibitors, the 
effects on GLI1 suppression were not strengthened (Figs. 14A – 14C). 
Results 71 
 
 
 
 
Figure 14: Impact of SMO and PI3K/AKT/mTOR inhibitors on HH signaling activity. RD and 
RUCH-2 cells were treated for 24 h with the indicated drugs. Concentration of vismodegib, sonidegib 
or HhAntag was 10 µM, those of PI-103, pictilisib, MK-2206, everolimus and rapamycin were 3 µM, 10 
µM, 5 µM, 5 nM and 100 nM, respectively. Afterwards cells were harvested and qRT PCR for the HH 
target gene GLI1 was performed. GLI1 expression was normalized to 18S rRNA and is shown as fold 
expression to solvent treated cells that were set to 1. Bars represent the mean +SEM of at least two 
independent experiments performed in duplicates. Statistical analysis was performed according to 
one-way ANO A and Tukey’s test for multiple comparisons. *P<0.05, **P<0.01, ***P<0.001 compared 
to solvent treated cells. (A), (B) and (C) show the gene expression levels after treatment with 
vismodegib, sonidegib, HhAntag and/or PI3K/AKT/mTOR inhibitors, respectively. 
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5.1.4.2 Moderate cooperative effects on pAKT/AKT, pS6/S6 or caspase 3 cleavage 
upon combination of SMO and PI3K/AKT/mTOR inhibitors 
As a next step, the impact of SMO inhibitors alone and in combination with PI3K/AKT/mTOR 
inhibitors on pAKT/AKT and pS6/S6 levels as well as on cleaved caspase 3 as a marker for 
apoptosis was investigated. For this purpose cell lysates were subjected to Western Blot 
analysis and analyzed with specific antibodies. (Parts of the results already have been 
shown in Fig. 10). 
Vismodegib or sonidegib did not evoke any obvious effects on pAKT or pS6/S6 levels in RD 
and RUCH-2 cells, but seem to enhance the total level of AKT in RUCH-2 cells (Figs. 15A 
and 15B). As already published by our lab121 HhAntag reduced pAKT in RD and RUCH-2 
cells, but did not affect AKT or pS6/S6 levels (Fig. 15C). None of the SMO inhibitors affected 
caspase 3 cleavage. As already described (see Fig. 10B), PI-103, pictilisib and MK-2206 
efficiently reduced pAKT in RD and RUCH-2 cells. In contrast to MK-2206, PI-103 and 
pictilisib additionally reduced pS6. Everolimus and rapamycin reduced pS6 in both cell lines 
as expected, but enhanced pAKT, as already shown in Fig. 10B. Furthermore PI-103, 
pictilisib and MK-2206 induced cleavage of caspase 3 in RD cells. Similar results were 
obtained with RUCH-2 cells in two out of three blots. 
In RD cells, the combination of vismodegib, sonidegib and HhAntag with PI3K/AKT/mTOR 
inhibitors did not change the protein pattern. The only and obvious exception was the 
combination of HhAntag plus MK-2206, which induced cleavage of caspase 3. Similarly, in 
RUCH-2 cells many of the combinations did not enhance the effects that were observed 
upon treatment with either drug alone. However, exceptions were the combination of 
vismodegib plus MK-2206 that reduced the protein level of AKT while enhancing the level of 
cleaved caspase 3 and the combinations of HhAntag plus pictilisib and HhAntag plus MK-
2206 that reduced the level of pS6 more efficiently than either single drug alone. In addition 
the combination of HhAntag plus pictilisib more efficiently induced cleavage of caspase 3 
when compared to single drug treatment. 
 
Results 73 
 
 
 
 
Figure 15: Impact of SMO and PI3K/AKT/mTOR inhibitors on phosphorylation of AKT, S6 and 
the cleavage of caspase 3. RD and RUCH-2 cells were treated with the indicated drugs for 48 h. 
Concentration of vismodegib, sonidegib or HhAntag was 10 µM, those of PI-103, pictilisib, MK-2206, 
everolimus and rapamycin were 3 µM, 10 µM, 5 µM, 5 nM and 100 nM, respectively. Afterwards cells 
were harvested for Western Blot analysis to detect the levels of pAKT/AKT, pS6/S6 and caspase 3 
(Casp3) in its pro and cleaved (cl) form with the help of specific antibodies. HSC70 served as loading 
control and protein sizes in kDa are indicated on the right side. (A), (B) and (C) show Western Blots 
after treatment with vismodegib, sonidegib, HhAntag and/or PI3K/AKT/mTOR inhibitors, respectively. 
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5.1.4.3 Sonidegib and HhAntag, but not vismodegib, can evoke cooperative anti-
proliferative effects when combined with PI3K/AKT/mTOR inhibitors 
Even though no cooperative effects of combined treatment with SMO plus PI3K/AKT/mTOR 
inhibitors on HH signaling and only a few cooperative effects on pAKT/AKT, pS6/S6 or 
caspase 3 cleavage have been observed, the impact of SMO inhibitors alone and in 
combination with PI3K/AKT/mTOR inhibitors on cellular proliferation of RD and RUCH-2 cells 
was investigated. Proliferation of the cells was quantified by BrdU incorporation assay. 
Vismodegib (Fig. 16A) and sonidegib (Fig. 16B) did not show any effects on proliferation of 
RD and RUCH-2 cells, whereas HhAntag (Fig. 16C) reduced it. Similarly, PI-103 and pictilisib 
alone reduced cellular proliferation of both cell lines. MK-2206 did not affect proliferation of 
RD cells but reduced proliferation of RUCH-2 cells. Everolimus and rapamycin did not affect 
proliferation of either cell line. 
When vismodegib was combined with PI3K/AKT/mTOR inhibitors, no changes were 
generally observed compared to the single treatments. In contrast, the combination of 
sonidegib plus rapamycin induced a cooperative anti-proliferative effect in RUCH-2 cells. A 
cooperative effect was defined as a decrease in proliferation upon combination treatment 
that was significant compared to solvent treated cells and that was significantly lower than 
the decrease with either drug alone. Cooperative effects were also seen when HhAntag was 
combined with PI3K/AKT/mTOR inhibitors. Thus, the combination of HhAntag plus pictilisib 
induced cooperative anti-proliferative effects in RD cells. In RUCH-2 cells cooperative anti-
proliferative effects were also seen for HhAntag plus either PI-103, MK-2206 or rapamycin. 
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Figure 16: Impact of SMO and PI3K/AKT/mTOR inhibitors on proliferation. RD and RUCH-2 cells 
were treated for 24 h with drugs supplied in BrdU containing medium. Concentration of vismodegib, 
sonidegib and HhAntag was 10 µM and those of PI-103, pictilisib, MK-2206, everolimus and 
rapamycin were 3 µM, 10 µM, 5 µM, 50 nM and 100 nM, respectively. BrdU incorporation of solvent 
treated cells was set to 100 %. Bars represent the mean +SEM of three independent experiments 
performed in triplicates. For statistical analysis a one-way ANO A with Tukey’s test for multiple 
comparisons was performed. *P<0.05, **P<0.01, ***P<0.001 compared to solvent treated cells and 
#P<0.05 compared to solvent treated cells and to cells treated with either single drug. (A), (B) and (C) 
show BrdU incorporation after treatment with vismodegib, sonidegib, HhAntag and/or 
PI3K/AKT/mTOR inhibitors, respectively. 
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5.1.4.4 Combinations of SMO inhibitors with pictilisib can induce synergistic anti-
proliferative effects 
As some of the combinations were indeed able to intensify the anticancer effect of either 
single drug, it was investigated whether this intensification was synergistic or rather additive. 
For this purpose the PI3K inhibitor pictilisib was employed and combined with vismodegib, 
sonidegib or HhAntag. Pictilisib was chosen, because it targets the PI3K/AKT/mTOR 
pathway most upstream and is used in clinical studies. RD cells were incubated with five 
different concentrations of vismodegib, sonidegib, HhAntag and/or five different 
concentrations of pictilisib. BrdU incorporation during treatment was measured and the 
combination index (CI) was calculated with the help of CompuSyn software.  
As already described by our lab121 and as seen in Fig. 6B vismodegib alone rather induced 
the proliferation of RD cells (Fig. 17A). In contrast sonidegib, HhAntag as well as pictilisib 
treatment inhibited the proliferation of RD cells in a concentration dependent manner (Figs. 
17B and 17C). 
When vismodegib, sonidegib or HhAntag were combined with pictilisib, a moderate 
enhancement of the anti-proliferative effects of either single drug was seen at some 
concentrations. Thus, the combination of 50 µM vismodegib plus 10 µM pictilisib led to a 
stronger reduction in proliferation than either single drug. With a CI of 0.69 this effect was 
synergistic. Additionally, the combination of 25 µM and 50 µM sonidegib plus 5 µM and 10 
µM pictilisib, respectively, led to a stronger reduction in proliferation than either single drug. 
Out of these two combinations only the latter showed synergistic behavior with a CI of 0.61. 
When HhAntag was applied in concentrations above 12.5 µM (corresponding to pictilisib 
concentrations above 2.5 µM) a stronger anti-proliferative effect of the combined treatment 
was observed compared to the anti-proliferative affects after treatment with either drug alone. 
Of these treatments the combination of 12.5 µM HhAntag plus 2.5 µM showed a synergistic 
behavior with a CI of 0.74. 
Together the data show that vismodegib alone rather induces than reduces proliferation of 
ERMS cells, which is in accordance with published data121. In addition, the combination of 
SMO inhibitors > 12.5 µM plus pictilisib > 2.5 µM results in an enhancement of the anti-
proliferative effects that sometimes is synergistic. 
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Figure 17: Synergistic anti-proliferative effects of combined SMO and PI3K inhibition. RD cells 
were treated with the indicated drugs for 48 h. For the last 24 h BrdU was added and then BrdU 
incorporation (Inc.) was measured. Left: Bars represent the mean +SEM of three independent 
experiments performed in triplicates. Solvent treated cells were set to 100 %. Right: Combination 
Indices (CI) calculated with CompuSyn software. (A), (B) and (C) show BrdU incorporation and CI 
after treatment with vismodegib, sonidegib, HhAntag and/or pictilisib, respectively. 
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5.1.4.5 Sonidegib or HhAntag, but not vismodegib, can induce cooperative pro-
apoptotic effects when combined with PI3K/AKT/mTOR inhibitors 
Next apoptosis was investigated in RD cells that have been treated with SMO inhibitors 
alone or in combination with PI3K/AKT/mTOR inhibitors. For this purpose 10 µM and 30 µM 
of the SMO inhibitors vismodegib, sonidegib and HhAntag were applied alone or in 
combination with PI3K/AKT/mTOR inhibitors (the concentrations are indicated in the figure 
legend of Fig. 16). For quantification of apoptosis, Annexin V staining of living cells was 
performed and the number of apoptotic cells was measured with the help of flow cytometry.  
Vismodegib alone did not induce apoptosis (Fig. 18A). In contrast, sonidegib and HhAntag 
significantly induced apoptosis when applied at a concentration of 30 µM (Figs. 18B and 
18C). This is identical to data described in the thesis of R. Ridzewski228. Additionally, PI-103 
and pictilisib significantly induced apoptosis, whereas MK-2206, everolimus and rapamycin 
did not. 
Upon combination of SMO and PI3K/AKT/mTOR inhibitors, several combinations induced 
cooperative pro-apoptotic effects, meaning that the increase in apoptotic cells was significant 
compared to solvent treated cells and compared to the increase after treatment with either 
drug alone. The combinations of 30 µM sonidegib plus pictilisib, PI-103 or MK-2206 
cooperatively induced apoptosis. The same was true for the combinations of 10 or 30 µM 
HhAntag plus MK-2206. 
To sum up, sonidegib and HhAntag as well as PI-103 and pictilisib induce apoptosis in RD 
cells. In addition, the combinations of sonidegib plus PI-103, pictilisib or MK-2206 or the 
combination of HhAntag plus MK-2206 provoke cooperative pro-apoptotic effects. 
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Figure 18: Impact of SMO and PI3K/AKT/mTOR inhibitors on apoptosis. RD cells were treated for 
48 h with the indicated drugs. Concentrations of vismodegib, sonidegib or HhAntag were 10 µM or 30 
µM, those of PI-103, pictilisib, MK-2206, everolimus and rapamycin were 3 µM, 10 µM, 5 µM, 5 nM 
and 100 nM, respectively. Apoptotic cells were quantified by Annexin V staining and subsequent 
FACS analysis. Bars represent the mean percentage of apoptotic cells +SEM of two independent 
experiments performed in duplicates. For statistical analysis a one-way ANO A with Tukey’s test for 
multiple comparisons was performed. *P<0.05, **P<0.01, ***P<0.001 compared to solvent treated 
cells; #P<0.05 compared to solvent treated cells and to cells treated with either single drug. (A), (B) 
and (C) show percentage of Annexin V+ cells for vismodegib, sonidegib, HhAntag and/or 
PI3K/AKT/mTOR inhibitors, respectively. 
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5.1.5 Chapter summary 
In summary the results of this chapter show that ERMS cells are rather unresponsive to 
stimulation by the SHH ligand or SMO agonist and that SMO inhibitors do not inhibit HH/GLI 
activity in ERMS cells. In contrast, GLI activity is inhibited by the PI3K/AKT/mTOR inhibitors 
PI-103, pictilisib, MK-2206, everolimus and rapamycin. Although we were not able to track 
this interaction down to any component of the PI3K/AKT/mTOR pathway (e.g. AKT), these 
drugs were combined with SMO inhibitors and potential cooperative effects on HH signaling, 
cellular proliferation and apoptosis were investigated. Whereas HH signaling activity is not 
affected, some of the combinations induce cooperative anticancer effects. Thus, the 
combinations of HhAntag plus PI-103, pictilisib, MK-2206 or rapamycin can induce strong 
cooperative anti-proliferative effects and the combinations of sonidegib plus PI-103, pictilisib 
or MK-2206 as well as the combination of HhAntag plus MK-2206 induce strong cooperative 
pro-apoptotic effects. 
The fact that ERMS cell lines were only moderately responsive to SHH or SMO inhibitors 
was at the first glance very surprising. This is due to the fact that patient-derived ERMS 
express high levels of HH ligands and of the downstream targets GLI1 and PTCH21,120. This 
discrepancy thus could indicate that human ERMS cell lines simply do not reflect the in vivo 
situation or that canonical HH signaling does not play a crucial role in ERMS. In addition it is 
possible that SMO inhibitors are only useful in those ERMS that are caused by mutations 
upstream of SMO i.e. by mutations in PTCH that are found in rare cases of ERMS. To 
approach these hypotheses, we next employed ERMS that are caused by PTCH mutations. 
Due to the non-canonical activation of HH signaling in human ERMS cell lines and since a 
knock-down of PTCH in these cells would not have adequately reflected the patient’s 
situation, we used primary tumor cell cultures from Ptch mutant mice for the experiments. 
Like patients with heterozygous PTCH mutations these mice develop ERMS-like tumors that 
like human ERMS show active HH signaling and increased activity of AKT34,242. Due to the 
latter fact and due to the interaction between the PI3K/AKT/mTOR and the HH signaling 
pathway, we also combined SMO inhibitors with PI3K/AKT/mTOR inhibitors. 
5.2 Targeting Hh and Pi3k/Akt/mTor signaling pathways in murine 
Ptch+/- ERMS cells 
Due to a heterozygous deletion of Ptch exon 8 and 9, Ptch+/- mice on a BALB/c background 
develop ERMS-like tumors with highly active Hh signaling216,243. From these ERMS primary 
cultures were established and used to investigate the impact of the SMO inhibitors 
vismodegib, sonidegib and HhAntag alone or in combination with the PI3K inhibitor pictilisib 
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on Hh signaling activity, Pi3k/Akt/mTor signaling activity, apoptosis and proliferation. The 
experiments focused on pictilisib as this drug is the most upstream of the ones investigated 
in the previous chapters and because it efficiently downregulated pAKT/AKT as well as 
pS6/S6 and evoked anticancer effects in human ERMS cell lines (see above). 
5.2.1 SMO inhibitors as well as pictilisib efficiently inhibit Gli1 expression 
At first the impact of SMO inhibitors alone and in combination with pictilisib on Hh signaling 
activity was investigated in Ptch+/- ERMS cells by measurement of the expression level of the 
major Hh target gene Gli1 and two additional target genes Hhip and Gli2. 
As expected and in contrast to human ERMS cell lines, all three SMO inhibitors significantly 
reduced the expression level of Gli1 in murine Ptch+/- ERMS cells (Fig. 19). However, the 
drugs did not affect the expression level of Hhip or Gli2. As also seen in human ERMS cell 
lines, pictilisib reduced Gli1 expression. However, this drug concomitantly induced Hhip and 
Gli2 expression, which could be a sign for an Akt-dependent epigenetic silencing of Hhip in 
the Ptch+/- ERMS. This hypothesis is discussed in section 6.5.2.  
Upon combination of the SMO inhibitors with pictilisib the decrease in Gli1 expression levels 
was enhanced. When sonidegib or HhAntag were combined with pictilisib this effect was 
even cooperative upon normalization of the data to Tbp. With respect to the pictilisib-
mediated upregulation of Hhip and Gli2 it was interesting to see that some SMO inhibitors 
were able to rescue the pictilisib-induced expression levels. Whereas vismodegib did not 
affect Hhip and Gli2 expression (the only exception was a slight rescue of Hhip expression 
when normalized to Tbp), sonidegib rescued the expression level of Hhip back to basal 
levels and HhAntag rescued the pictilisib-induced Hhip expression level by 50 %. Sonidegib 
additionally rescued the expression level of Gli2 back to basal level (when normalized to 
Tbp).  
To sum up, SMO inhibitors as well as pictilisib reduce Gli1 expression levels and the 
combination of SMO inhibitors plus pictilisib can be more efficient than either drug alone. 
Surprisingly, pictilisib upregulates the expression levels of Hhip and Gli2. However, this 
upregulation is partly rescued when pictilisib is combined with SMO inhibitors. 
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Figure 19: SMO inhibitors reduce Gli1 and can rescue the upregulation of Hhip occurring upon 
pictilisib treatment.  Primary cultures from ERMS tissue of Ptch
+/-
 mice were treated with the 
indicated drugs for 48 h. Concentration of vismodegib, sonidegib and HhAntag was 10 µM and that of 
pictilisib was 5 µM. After treatment RNA was isolated and subjected to qRT PCR analysis for Gli1, 
Hhip and Gli2. Expression levels were normalized to 18S rRNA (left) and Tbp (right) and are shown as 
fold expression to solvent treated cells that was set to 1. Bars represent the mean +SEM of three 
independent experiments performed in duplicates. For statistical analysis a one-way ANOVA with 
Tukey’s test for multiple comparisons was performed. *P<0.05, **P<0.01, ***P<0.001 compared to 
solvent treated cells or as indicated; #P<0.05 compared to solvent treated cells and cells treated with 
either single drug. 
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5.2.2 Pictilisib inhibits Akt phosphorylation and induces cleavage of caspase 3 
In the next step, the impact of SMO inhibitors alone or in combination with pictilisib on 
Pi3k/Akt/mTor activity and apoptosis was investigated. For this purpose phosphorylation of 
Akt and caspase 3 cleavage were measured by Western Blot analysis and quantified. 
Whereas none of the SMO inhibitors showed any effect on Akt or pAkt levels, pictilisib 
treatment efficiently downregulated pAkt levels in a concentration dependent manner as 
expected (Fig. 20). 1 µM pictilisib additionally downregulated the total Akt level in Ptch+/- 
ERMS cells and these pictilisib-mediated changes in Akt/pAkt were not affected by SMO 
inhibitors. 
Likewise, none of the SMO inhibitors significantly enhanced cleavage of caspase 3 in Ptch+/- 
ERMS cells. In contrast, treatment with pictilisib led to a concentration dependent 
enhancement of caspase 3 cleavage (Fig. 20B). However, the combination of SMO inhibitors 
plus pictilisib did not further strengthen the induction of caspase 3 cleavage. Whereas 
pictilisib slightly reduced the level of caspase 3 in its pro form, none of the SMO inhibitors 
significantly affected it. 
In summary, SMO inhibitors do not affect phosphorylation of Akt and thus the activity of 
Pi3k/Akt/mTor signaling in Ptch+/- ERMS cells. They also do not alter pictilisib-induced 
inhibition of Akt phosphorylation. Pictilisib induces cleavage of caspase 3 in these cells, 
which, however, is also not strengthened when combined with SMO inhibitors.  
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Figure 20: Impact of Smo and Pi3k inhibition on Pi3k/Akt/mTor activity and caspase 3 cleavage 
in primary Ptch
+/-
 ERMS cells. Primary cells from ERMS of Ptch
+/-
 mice were treated with the 
indicated drugs for 12 h. Concentration of vismodegib, sonidegib or HhAntag was 5 µM. After 
treatment cells were harvested and cell lysates were used for Western Blot analysis to detect the level 
of pAkt, Akt, and caspase 3 (pro and cleaved (cl) form) with specific antibodies. Hsc70 served as 
loading control. (A) One representative blot out of three independent experiments is shown. Protein 
sizes in kDa are indicated on the right side. (B) Semi-quantitative densitometry. Bars represent the 
mean +SEM of three (pAkt/Akt) or two (caspase 3) independent experiments and protein levels of 
solvent treated cells were set to 1. For statistical analysis a one-way ANO A with Tukey’s test for 
multiple comparisons was performed. *P<0.05, **P<0.01, ***P<0.001 compared to solvent treated 
cells. 
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5.2.3 Synergistic anti-proliferative effects of SMO inhibitors in combination with 
pictilisib 
As a next step it was investigated whether SMO inhibitors alone and in combination with 
pictilisib were able to affect proliferation of Ptch+/- cells. ERMS cultures were incubated with 
five different concentrations of vismodegib, sonidegib, HhAntag and/or five different 
concentrations of pictilisib. BrdU incorporation during treatment was measured and the 
combination index (CI) was calculated with the help of CompuSyn software. 
Vismodegib (Fig. 21A), sonidegib (Fig. 21B) or HhAntag (Fig. 21C) reduced the proliferation 
of Ptch+/- ERMS cells in a concentration dependent manner. Sonidegib and HhAntag were 
more effective than vismodegib. Pictilisib treatment likewise reduced the proliferation in a 
concentration dependent manner. The combination of either SMO inhibitor plus pictilisib 
enhanced the anti-proliferative effects of the single drugs. By calculation of the CI, all 
combinations turned out to be synergistic. In case of vismodegib, the CI was between 0.3 
and 0.7 for all concentrations (synergism) with the exception of the lowest concentration that 
showed strong synergism (CI between 0.1 and 0.3). The combination of sonidegib plus 
pictilisib showed synergism at concentrations > 18 µM sonidegib and > 5 µM pictilisib. 
Concentrations beneath these showed moderate synergism (CI between 0.7 and 0.85). The 
combination of HhAntag plus pictilisib showed synergism at all concentrations. The exception 
was the highest concentration of 36 µM HhAntag and 8 µM pictilisib that showed moderate 
synergism. 
In summary, all SMO inhibitors synergistically cooperated with pictilisib to inhibit proliferation 
of Ptch+/- ERMS cells. 
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Figure 21: Synergistic anti-proliferative effects of SMO and PI3K inhibitors in Ptch
+/-
 ERMS 
cells. Primary cells from ERMS of Ptch
+/-
 mice were treated with the drugs as indicated for 48 h. For 
the last 24 h BrdU was added and BrdU incorporation (Inc.) was measured. Left: Bars represent the 
mean +SEM of three independent experiments performed in quadruplicates. Solvent treated cells 
were set to 100 %. Right: Combination indices (CI) calculated with CompuSyn software. (A - C) shows 
BrdU incorporation and CI for vismodegib, sonidegib, HhAntag and/or pictilisib.
 
5.2.4 Chapter summary 
To sum up the second chapter, Ptch+/- ERMS cells respond to SMO inhibitors alone and in 
combination with pictilisib. This response is more pronounced and much more solid than that 
of the cell lines derived from human sporadic ERMS. Thus, SMO inhibitors clearly reduce the 
Hh signaling activity of Ptch+/- cells and this reduction can be enhanced when combined with 
pictilisib, which itself also reduces Hh signaling activity. Although pictilisib-induced pro-
apoptotic effects are not enhanced by addition of either of the SMO inhibitors, all three 
investigated SMO inhibitors evoke synergistic anti-proliferative effects when they are 
combined with pictilisib. Together, the combination of SMO inhibitors plus pictilisib 
cooperatively induces anticancer effects that are associated with a strong inhibition of Hh 
signaling activity (Gli1 expression) in Ptch+/- ERMS cells. 
As all drugs alone or in combination were very effective in cultured Ptch+/- ERMS cells, they 
were also applied in vivo in the established Ptch+/- mouse model for ERMS. 
5.3 Targeting Hh and Pi3k/Akt/mTor signaling pathways in ERMS of 
Ptch+/- mice 
As mentioned above Ptch+/- mice develop tumors that resemble human ERMS. ERMS-
bearing animals were treated with the SMO inhibitors vismodegib, sonidegib or HhAntag 
alone or in combination with pictilisib. All animals were treated twice a day with 
vehicle/vehicle (controls), drug/vehicle or drug/drug combinations. Tumor growth was 
monitored with the help of in vivo µCT analysis. At the end of the study RMS were analyzed 
with respect to proliferation, apoptosis and Hh, Pi3k/Akt/mTor activation status. 
5.3.1 SMO inhibitors and pictilisib can reduce ERMS tumor growth and their 
combination can enhance the antitumoral effects 
ERMS-bearing Ptch+/- mice were treated daily with HhAntag and/or pictilisib for a period of 35 
days. Tumor size was monitored before therapy onset, at day 21 and at the end of treatment. 
As shown in Figs. 22C and 22F, the treatment with HhAntag plus pictilisib resulted in 
extremely small tumors at the end of treatment, which precluded protein and RNA isolation. 
Therefore the treatment period for vismodegib and sonidegib in combination with pictilisib 
was reduced to 21 days. The tumor size in these studies was monitored before therapy onset 
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and at the end of treatment. The amount of drugs used in the studies was based on 
recommendations given by the manufacturer and were 100 mg/kg vismodegib or HhAntag, 
80 mg/kg sonidegib and/or 75 mg/kg pictilisib. The analysis of HhAntag and/or pictilisib 
treated tumors is already described in the thesis of R. Ridzewski228. 
As shown in Figs. 22A - 22C and Table 18, treatment with vismodegib, HhAntag or pictilisib 
enhanced the number of mice that showed stable disease (SD) or partial response (PR) 
compared to vehicle treatment. Sonidegib alone or in combination with pictilisib and also 
vismodegib in combination with pictilisib resulted in PR in the majority of mice. According to 
RECIST analysis, HhAntag in combination with pictilisib was the most effective therapy, 
leading to PR in all mice. However, one must note that animals treated in context of the 
HhAntag/pictilisib study received the drugs for 35 days whereas animals of the 
vismodegib/pictilisib and sonidegib/pictilisib studies have been treated only for 21 days.  
The results are also summarized in the tumor growth curves (Figs. 22D – 22F) that show the 
expected tumor growth for each treatment group calculated with a “mixed random effects” 
model. Thus, treatment with vismodegib or HhAntag alone is expected to efficiently stop 
tumor growth, leading to an estimated relative tumor volume of approximately 1 at the end of 
therapy. Sonidegib and pictilisib are expected to induce tumor regression, resulting in a 
significantly reduced estimated tumor volume at the end of therapy compared to vehicle. 
When vismodegib or sonidegib are combined with pictilisib, tumor regression is expected to 
be similar as for pictilisib treatment alone, whereas the combination of HhAntag plus pictilisib 
is expected to result in tumor regression that is more efficient than the single treatments.  
To sum up, treatment with SMO inhibitors and/or pictilisib can induce efficient tumor 
regression in the Ptch+/- mouse model for ERMS, which was strongest for sonidegib 
monotherapy and the HhAntag plus pictilisib combination therapy.  
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Figure 22: Impact of SMO inhibitors and/or pictilisib on ERMS tumor growth. RMS-bearing 
Ptch
+/-
 mice received 100 mg/kg vismodegib, 80 mg/kg sonidegib or 100 mg/kg HhAntag alone or in 
combination with 75 mg/kg pictilisib daily for 21 (vismodegib/pictilisib or sonidegib/pictilisib) or 35 
(HhAntag/pictilisib) days. Drugs were supplied by oral gavage, suspended in methylcellulose tween 
vehicle. Tumor growth was monitored by low dose in vivo µCT. (A) – (C) Bars represent changes in 
tumor size normalized to starting point. PD: progressive disease, SD: stable disease, PR: partial 
response according to RECIST analysis. (D) – (F) Shown is the expected tumor growth for each 
treatment group calculated with a mixed random effects model. For statistical analysis multiple testing 
was performed by the method of Dunnett-Hsu. *P<0.05, **P<0.01, ***P<0.001 compared to vehicle. 
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Table 18: Analysis of data shown in Figs. 22A - 22C according to RECIST analysis. PD: 
progressive disease, SD: stable disease, PR: partial response. Values at therapy onset and end were 
evaluated. 
 
5.3.2 SMO inhibitors and/or pictilisib can reduce the number of Ki67+ tumor cells 
At the end of treatment, paraffin sections of tumor tissue were used to analyze the amount of 
Ki67+ nuclei by immunohistochemistry. The analysis of HhAntag and/or pictilisib treated 
tumors are already described in the thesis of R. Ridzewski228. 
In vehicle treated tumors the amount of Ki67+ nuclei ranged between 4 % and 8 % of all 
nuclei (Fig. 23). Treatment with either SMO inhibitor or with pictilisib seems to reduce the 
number of Ki67+ nuclei and in case of sonidegib the reduction was significant compared to 
vehicle. When the SMO inhibitors were combined with pictilisib the reduction of Ki67+ nuclei 
was enhanced and the reduction was significant compared to vehicle. 
 
PD SD PR
Vehicle 5 1 1
Pictilisib 2 2 3
Vismodegib 3 2 2
Vismodegib + Pictilisib 1 1 4
Total: 27
PD SD PR
Vehicle 5 1 1
Pictilisib 2 2 3
Sonidegib 0 1 6
Sonidegib + Pictilisib 0 2 4
Total: 27
PD SD PR
Vehicle 6 0 0
Pictilisib 1 3 1
HhAntag 3 1 1
HhAntag + Pictilisib 0 0 6
Total: 22
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Figure 23: Percentage of Ki67
+
 cells in Ptch
+/-
 ERMS treated with SMO inhibitors and/or 
pictilisib. ERMS from the study shown in Figs. 22A – 22C were stained with an antibody specific for 
the proliferation marker Ki67. 6000-10000 nuclei were counted within each tumor. Bars represent the 
mean +SEM of 6-11 tumors. For statistical analysis a one-way ANO A with Dunn’s test for multiple 
comparisons was performed. *P<0.05, **P<0.01 compared to vehicle. 
To sum up, all three investigated SMO inhibitors as well as pictilisib reduce proliferation of 
Ptch+/- ERMS. The combinations of vismodegib plus pictilisib and HhAntag plus pictilisib 
enhance the anti-proliferative effects of either single treatment whereas sonidegib alone is as 
efficient as the combination of sonidegib plus pictilisib. This is in line with the results shown in 
Figs. 22A - 22C and Table 18 demonstrating that vismodegib/pictilisib, sonidegib/pictilisib, 
HhAntag/pictilisib or sonidegib alone increase the number of mice showing PR and almost 
completely prevent PD. However, these results do not perfectly match with the estimated 
growth curves depicted in Figs. 22D - 22F as the latter model shows that pictilisib alone will 
reduce tumor growth in a similar manner as vismodegib/pictilisib and sonidegib/pictilisib. 
Differences between the growth estimation model and the data shown in Fig. 23 might be 
due to the small number of animals that were analyzed. Finally, the more pronounced 
decrease in Ki67+ cells in HhAntag/pictilisib treated tumors compared to either single 
treatment is in line with the estimated tumor growth reduction.    
5.3.3 SMO inhibitors, but not pictilisib, strongly reduce Gli1 expression 
Next, the expression level of the major Hh target Gli1 and of another target Hhip was 
analyzed in the tumor tissues (Fig. 24). Since ERMS that have been treated with HhAntag 
and/or pictilisib for 35 days were too small for protein or mRNA isolation (see section 5.3.1), 
a new cohort of mice was set up. ERMS-bearing mice were only treated for 14 days with 
HhAntag and/or pictilisib and then the tumors were isolated for molecular analysis (according 
to the tumor growth model shown in Fig. 22F, HhAntag and/or pictilisib already reduce tumor 
growth at around 14 days after therapy onset). 
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Figure 24: Effect of SMO and/or PI3K inhibitors on Hh signaling activity.  Ptch
+/-
 ERMS from 
studies shown in Figs. 22A and 22B and ERMS from Ptch
+/-
 mice treated with 100 mg/kg HhAntag 
and/or 75 mg/kg pictilisib for 14 days were used for RNA isolation and qRT PCR analysis to assess 
the expression levels of Gli1 and Hhip. Expression levels were normalized to 18S rRNA (left) or Tbp 
(right) and are shown as fold expression to vehicle treated cells that were set to 1. For statistical 
analysis a Kruskal-Wallis test with Dunn’s test for multiple comparisons was performed. *P<0.05, 
**P<0.01, ***P<0.001 compared to vehicle or as indicated. 
As shown in Fig. 24 vismodegib, sonidegib and HhAntag reduced the expression levels of 
Gli1 and Hhip. In contrast to the human ERMS cell lines and primary Ptch+/- ERMS cells, 
pictilisib did not significantly reduce or induce the expression of Gli1 or Hhip. Please also 
note the difference in gene expression when 18S rRNA or Tbp were used for normalization. 
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This difference could be due to intertumoral differences in housekeeper gene expression as 
RMS tissues are known to have a very heterogeneous cellular composition (experience of 
our group).  
The combination treatment with vismodegib or sonidegib plus pictilisib reduced Gli1 
expression to a similar extent as vismodegib or sonidegib alone. When sonidegib was 
combined with pictilisib the reduction of Hhip expression was pronounced and, in the case of 
sonidegib plus pictilisib, the reduction was significant compared to vehicle. Similarly, the 
reduction of Gli1 and Hhip expression was pronounced when HhAntag was combined with 
pictilisib and became significant compared to vehicle.  
Next, the Gli1 expression level of each tumor was correlated with the tumor growth pattern 
from the study shown in Figs. 22A and 22B to see if the relative tumor size at the end of 
treatment is associated with Hh signaling activity. Due to the fact that Gli1 expression data 
for the tumors of the combination study HhAntag and/or pictilisib shown in Fig. 22C were not 
available, the correlation analysis could not be performed for this cohort.  
The correlation analysis showed that the reduction of tumor size is associated with a 
downregulation of Hh signaling activity in the tumors that were treated with vismodegib or 
sonidegib alone or in combination with pictilisib (Fig. 25A). In contrast, in the cohorts that 
received vehicle or pictilisib, Gli1 expression levels were not positively correlated with tumor 
size (Fig. 25B), showing that tumor size in these cohorts is not associated with inhibition of 
Hh signaling activity. The latter is also true for the pictilisib cohort alone (Fig. 25C). 
In summary, all three SMO inhibitors reduce Hh signaling activity in Ptch+/- tumors, whereas 
pictilisib has no effect. In addition, pictilisib may enhance the inhibitory effect of HhAntag. 
Furthermore, the level of Hh signaling inhibition by vismodegib or sonidegib (alone and in 
combination with pictilisib; data for HhAntag are unfortunately not available, see above) 
correlates with reduction of tumor growth. 
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Figure 25: Vismodegib and sonidegib, but not pictilisib, reduce tumor growth in Ptch
+/-
 mice in 
dependency on Hh signaling activity. Shown is the correlation analysis of Gli1 expression levels 
shown in Fig. 24 and the corresponding relative (rel) tumor size. Spearman coefficient ρ is indicated 
for each pair of data. *P<0.05, **P<0.01, ***P<0.001. Analysis was performed for cohorts treated with 
(A) vismodegib, vismodegib/pictilisib, sonidegib and sonidegib/pictilisib, (B) vehicle and pictilisib or (C) 
pictilisib. 
  
rel tumor size day 21
re
l.
G
li
1
e
x
p
re
s
s
io
n
(r
a
ti
o
G
li
1
/1
8
S
 r
R
N
A
)
0.1 1 10
0.001
0.01
0.1
1
10 Vismodegib
Vismodegib
+ Pictilisib
Sonidegib
Sonidegib
+ Pictilisib
*
 = 0,448 rel tumor size day 21
re
l.
G
li
1
e
x
p
re
s
s
io
n
(r
a
ti
o
G
li
1
/T
b
p
)
0.1 1 10
0.001
0.01
0.1
1
10 Vismodegib
Vismodegib
+ Pictilisib
Sonidegib
Sonidegib
+ Pictilisib
***
 = 0,561
rel tumor size day 21
re
l.
G
li
1
e
x
p
re
s
s
io
n
(r
a
ti
o
G
li
1
/1
8
S
 r
R
N
A
)
0.01 0.1 1 10 100
0.1
1
10
 = -0,118
Pictilisib
Vehicle
rel tumor size day 21
re
l.
G
li
1
e
x
p
re
s
s
io
n
(r
a
ti
o
G
li
1
/T
b
p
)
0.01 0.1 1 10 100
0.1
1
10
 = -0,103
Pictilisib
Vehicle
rel tumor size day 21
re
l.
G
li
1
e
x
p
re
s
s
io
n
(r
a
ti
o
G
li
1
/1
8
S
 r
R
N
A
)
0.01 0.1 1 10
0.1
1
10
 = 0,079
Pictilisib
rel tumor size day 21
re
l.
G
li
1
e
x
p
re
s
s
io
n
(r
a
ti
o
G
li
1
/T
b
p
)
0.01 0.1 1 10
0.1
1
10
 = -0,454
Pictilisib
A
B
C
Results 95 
 
 
 
5.3.4 Effects of SMO inhibitors and pictilisib on Pi3k/Akt/mTor signaling and 
caspase 3 cleavage 
In addition, the influence of the drugs on Pi3k/Akt/mTor signaling activity and on caspase 3 
cleavage was investigated. For this purpose the phosphorylation level of Akt and the protein 
levels of caspase 3 in its pro and cleaved forms were analyzed in tumor tissue (Figs. 26A - 
26C show representative Western Blots; the results for the combination treatment with 
HhAntag plus pictilisib, shown in Fig. 26C, are also described in the thesis of R. 
Ridzewski228). Although the results were very heterogeneous, they were quantified by semi-
quantitative densitometric analysis (Fig. 27).  
As shown in Fig. 27, phosphorylation of Akt was only moderately reduced by the SMO 
inhibitors, whereas pictilisib significantly reduced pAkt/Akt levels as expected. Surprisingly, 
the combinations of either SMO inhibitor with pictilisib seem to rescue pAkt/Akt levels back to 
basal level or to the level, which was reached upon treatment with SMO inhibitors alone.  
Unfortunately, the results with respect to caspase 3 cleavage were very heterogeneous (see 
Figs. 26A – 26C) and therefore a distinct quantification did not make sense.  
In summary, all three SMO inhibitors moderately reduce phosphorylation of Akt in Ptch+/- 
ERMS tissue, whereas pictilisib has a strong and significant effect. However, the combination 
of either SMO inhibitor with pictilisib seem to rescue pAkt/Akt levels back to basal level or to 
the level upon treatment with SMO inhibitors alone. 
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Figure 26: Impact of vismodegib, sonidegib, HhAntag and/or pictilisib on Pi3k/Akt/mTor activity 
and caspase 3 cleavage in tumors of Ptch
+/-
 mice. Protein of ERMS from the study shown in Figs. 
22A and 22B and ERMS from Ptch
+/-
 mice treated with 100 mg/kg HhAntag and/or 75 mg/kg pictilisib 
for 14 days were used for Western Blot analysis. The protein levels of pAkt, Akt, Caspase 3 (Casp3 
pro and cleaved (cl) form) were detected with specific antibodies. Hsc70 served as loading control. 
The blots are representative for at least 2 independent blots and (A), (B) and (C) show the data for 
vismodegib, sonidegib, HhAntag and/or pictilisib, respectively. Protein sizes in kDa are indicated on 
the right side of the blots. 
A 
B 
C 
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Figure 27: Quantification of pAkt levels shown in Fig. 26. Densitometric analysis of data shown in 
Figs. 26A - 26C. Bars represent the mean +SEM protein levels of pAkt/Akt ratio, pAkt and Akt 
normalized to Hsc70. Protein levels of vehicle treated tumors were set to 1. For statistical analysis a 
Kruskal-Wallis test with Dunn’s test for multiple comparisons was performed. *P<0.05, **P<0.01, 
***P<0.001 compared to vehicle treated tumors.  
5.3.5 Chapter summary 
In the third chapter the anticancer effects of SMO inhibitors alone and in combination with 
pictilisib in the Ptch+/- mouse model for ERMS are described. In this model SMO inhibitors as 
well as pictilisib stop tumor growth. Sonidegib is the most efficient SMO inhibitor when used 
as a single agent and HhAntag plus pictilisib seem to be the most efficient combination. 
Additionally SMO inhibitors, especially sonidegib, as well as pictilisib reduce the proliferation 
rate of the tumors and this effect is strengthened in the combination treatments. Furthermore, 
as in cultured Ptch+/- ERMS cells, Hh signaling activity is significantly reduced by either SMO 
inhibitor. Moreover the downregulation of Hh signaling activity seen upon vismodegib and 
sonidegib treatment correlates with reduction of tumor size, indicating a direct dependency of 
tumor growth on Hh signaling in this model. But in contrast to cultured Ptch+/- ERMS cells and 
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human ERMS cell lines, pictilisib does not affect Hh signaling activity when applied alone or 
in combination with SMO inhibitors. Additionally the functionality of pictilisib was proven by a 
downregulation of pAkt within the tumor tissue.  
Together, these data show that RMS growth in the Ptch+/- mouse model is dependent on 
active canonical Hh signaling. Hence, the effective downregulation of Hh signaling by SMO 
inhibitors goes along with strong anticancer effects. The most effective drug was sonidegib. 
Pictilisib treatment also reduced tumor growth, but in an Hh-independent manner. In addition, 
the effectiveness of a combination treatment with SMO inhibitors and pictilisib seems to be 
drug-dependent. Whereas the effectiveness of vismodegib and sonidegib cannot be 
enhanced by pictilisib the effectiveness of HhAntag apparently is. These results are partly 
contradictory to the results obtained from cultured Ptch+/- ERMS cells (e.g. all SMO inhibitors 
evoke synergistic anti-proliferative effects when combined with pictilisib) and could depend 
on drug pharmacokinetics or the tumor microenvironment that is missing in cell cultures. 
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6 Discussion 
The importance of HH signaling in RMS was first discovered when the PTCH germline 
mutations were found to be causal for the development of multiple tumors in patients with 
Gorlin syndrome, among them ERMS56-58. Until now expression of HH signaling components 
was shown in the majority of all sporadic RMS with higher degree of pathway activation in 
ERMS and fusion-gene negative ARMS compared to fusion-gene positive ARMS21,22,113. 
However, in sporadic RMS the HH signaling activity is most likely driven by other 
mechanisms than mutations in components of the HH pathway. Two clinical trials 
investigating the effectiveness of SMO inhibitors in RMS were performed and showed that 
the drugs are generally tolerated. Follow-up trials are missing so far.  
Our group has shown that the effectiveness of SMO inhibitors in cell lines derived from 
sporadic RMS strongly depends on the cell line investigated and that effectiveness is not 
necessarily associated with a downregulation of HH signaling activity121. Therefore, it was 
first hypothesized that besides canonical HH signaling, non-canonical activation via 
PI3K/AKT/mTOR signaling may play a role in sporadic RMS tumorigenesis and 
maintenance. Indeed, the majority of sporadic RMS show phosphorylation of AKT or S6207-209 
and cross-talk between PI3K/AKT/mTOR and HH signaling is well described108. Second, it 
was hypothesized that the antitumoral effects of SMO inhibitors may rely on off-target effects. 
Here, we investigated these hypotheses in more depth and we analyzed the effectiveness of 
SMO inhibitors alone and in combination with PI3K/AKT/mTOR inhibitors in cell lines derived 
from sporadic ERMS and in the Ptch+/- mouse model for ERMS. Together, we show that the 
effectiveness of SMO inhibitors depends on the mode of HH signaling activation. Whereas 
the drugs rather induce GLI1-independent antitumoral effects in cell lines derived from 
sporadic ERMS, their anticancer effects correlate with Gli1 expression levels in Ptch+/- ERMS 
cells and in vivo in ERMS of the Ptch+/- mouse model. In either case combination with 
PI3K/AKT/mTOR inhibitors can be beneficial.  
6.1 Effectiveness of SMO inhibitors on ERMS cell lines with low HH 
activity 
Previous work of our group showed that SMO inhibitors can induce apoptosis and reduce 
proliferation of RMS cell lines. Whereas sonidegib and HhAntag showed strong antitumoral 
effects, cyclopamine as well as vismodegib did either not affect or even enhance proliferation 
of the cell lines121. However, the observed antitumoral effects were not always associated 
with a downregulation of HH signaling activity, e.g. 30 µM sonidegib reduced proliferation 
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and induced apoptosis of RD cells but did not affect GLI1 expression. Since this was 
indicative for off-target effects, a RD cell line with a stable SMO knockdown118 was incubated 
with the SMO inhibitors cyclopamine, vismodegib, sonidegib and HhAntag. 
So far, a SMO knockdown was described in CCA and Rh36 cells where it did not affect 
proliferation168. However, the SMO knockdown in RD cells apparently reduced tumor growth 
in xenograft models and sphere formation in vitro118. When analyzing the latter model, we 
found a strong, but incomplete reduction of SMO protein levels (see Fig. 5). This was 
accompanied by reduced HH signaling activity. Because this cell line showed very low basal 
levels of SMO expression, we expected that SMO inhibitors would be less effective 
compared to control cells with higher basal SMO expression. However, against this 
expectation, the experiments revealed that RD SMOlow cells are more sensitive towards 
cyclopamine, sonidegib or HhAntag compared to RD SMOhigh cells. Indeed, RD SMOlow 
cells stopped to grow or even died when they were incubated with these SMO inhibitors. 
Thus, pharmacological inhibition of the remaining SMO activity in RD SMOlow cells induced 
strong anti-proliferative effects. This could reflect a situation, in which cells with very low HH 
signaling activity (i.e. RD SMOlow cells) are more sensitive to small changes in HH signaling. 
In other words, in tumor cells with low HH signaling activity even a small pharmacological 
inhibition of signaling leads to dramatic induction of effectiveness. A similar behavior was 
shown in vivo for vismodegib in preclinical models for medulloblastoma and colorectal 
cancer135, for the B-RAF inhibitor PLX4032 in melanoma244 and for the B-RAF inhibitor GDC-
0879 in melanoma and colorectal cancer245. A possibility to prove this hypothesis would 
require the measurement of SMO activity. This could for example be done with a phospho-
specific SMO antibody that shows the activation status of SMO as described246.  
The lack of any effect of vismodegib in both RD SMOlow cells and RD SMOhigh cells is hard 
to explain, because it is opposite to previous observed data from our group showing that 
vismodegib enhances BrdU incorporation of RD cells121. It is also opposite to another report 
showing that vismodegib reduces viability of RD cells120. However, one possible explanation 
might be an acquired SMO mutation in the RD subclone used for generation of the SMO 
knockdown, which might induce a selective resistance against vismodegib. Indeed, in the 
literature a D477G mutation in SMO has been described that causes resistance towards 
vismodegib while only mildly reducing the effectiveness of cyclopamine, sonidegib or 
HhAntag232,233. However, the explanation is rather unlikely, since the parental RD cells do not 
harbor this mutation (personal communication of Heidi Hahn with Javed Khan, Genetic 
Branch, NIH). Finally, the different cellular response to one out of four investigated SMO 
inhibitors might indicate that these drugs indeed exert off-target effects. Thus, vismodegib - 
as all other SMO inhibitors - downregulated GLI1 expression moderately (see Fig. 14A) but 
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did not affect proliferation of RD cells. If SMO would be the only target for all four drugs, one 
would expect similar cellular responses to either drug. 
Another explanation for the lack of effectiveness of vismodegib is the fact that it binds to 
other structures in the binding pocket of SMO, which might be compromised in the used cell 
lines41,247. Another possibility might be that proliferation of RD cells is not only regulated by 
the SMO/GLI axis but by other mechanisms that were not further investigated here. In 
contrast to vismodegib, cyclopamine, sonidegib and HhAntag, vismodegib might influence 
these mechanisms.  
6.2 Modulation of canonical HH signaling in ERMS cell lines 
Our data here demonstrates that it is not possible to strongly activate canonical HH signaling 
in RD and RUCH-2 cells by stimulation with SHH. This was surprising, because human 
sporadic RMS samples express HH ligands and show activity of HH signaling21,120. However, 
in human RMS, DHH and IHH are the predominant HH ligands and DHH and IHH depletion 
downregulates GLI1 protein levels in RD cells120. Thus, these two HH ligands would have 
been more reliable for the experiment. Nevertheless, the fact that SAG, which binds to the 
upper part of the ligand binding pocket of SMO41, also did not activate HH signaling activity, 
rather argues for a relative unresponsiveness of RD and RUCH-2 cells towards ligand-based 
stimulation of the pathway. Furthermore, autocrine secretion of DHH and IHH should have 
stimulated the HH pathway in an autocrine loop. However, the incubation of the cells with 
SMO inhibitors did in general not block the pathway. Similarly, when investigating the impact 
of SMO inhibitors on the transcriptional activity of GLI proteins using a luciferase-based GLI 
reporter system in RD cells, we found that none of the compounds inhibited the expression of 
the reporter (see Fig. 8). These data are furthermore in contrast to the data showing that 
vismodegib or sonidegib moderately and HhAntag significantly reduced GLI1 expression in 
RD cells (see Fig. 14). 
Together, our data – although partly in contrast to the current literature – strongly suggest 
that canonical HH signaling does not play a major role in cell lines that are derived from 
sporadic human ERMS. In addition, the fact that some SMO inhibitors i.e. HhAntag 
significantly inhibited GLI1 transcription, but did not affect GLI activity, argues for an off-
target effect of this compound. Furthermore, the observation that vismodegib – in contrast to 
cyclopamine, sonidegib or HhAntag - does not affect growth of RD SMOlow and RD 
SMOhigh cells, also indicates off-target effects as already described above.   
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6.3 Non-canonical modulation of HH signaling via PI3K/AKT/mTOR in 
ERMS cell lines 
In general it was shown that GLI1 expression and thus HH signaling activity can be regulated 
in sporadic ERMS, as also shown above. Furthermore it is known that the 
RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways, that are active in RMS, can regulate 
HH signaling. Due to these facts we next investigated the potential cross-talk between the 
HH, RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways in cell lines derived from sporadic 
ERMS.  
In order to analyze the impact of RAS/RAF/MEK/ERK signaling, RD cells were treated with 
the MEK inhibitor UO126. The drug significantly upregulated GLI1 expression level in a 
concentration-dependent manner (see Fig. 11A). Similar results have been described for 
pancreas carcinoma, in which RAS signaling negatively regulates GLI2 and GLI3 through 
DYRK1B97. In contrast, treatment of RD cells with PI3K/AKT/mTOR inhibitors efficiently 
downregulated GLI1 expression (see Fig. 11B). This could be explained by an AKT-mediated 
inactivation of PKA and GSK3β, which inhibits the negative influence of these proteins on 
GLI activity54,248. Another possible explanation is that S6K1 phosphorylates and thereby 
releases GLI1 from its negative regulator SUFU108. 
To sum up, non-canonically regulated HH signaling in human ERMS cell lines by both 
RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signaling is more pronounced than canonical 
activation. Since the MEK inhibitor UO126 induced AKT phosphorylation, which might have 
contributed to the upregulation of GLI1 (see results section 5.1.3.2), we here tried to analyze 
a potential regulation of HH signaling by AKT in more detail. Indeed, a correlation between 
PI3K/AKT and HH signaling has also been demonstrated in esophageal 
adenocarcinoma108,184,235, melanoma76, breast cancer185 and during osteoblast 
differentiation107. However, in RD cells that were transfected with constitutively active and 
dominant negative forms of AKT, overexpression of either protein did not modulate GLI1 
expression (see Fig. 13). Since no changes in phosphorylation of the mTOR target S6 were 
observed as described in the literature, and since the general expression of exogenous 
proteins in RD cells was quite low (see Fig. 12), we currently think that this experiment 
should be repeated using a retroviral transduction system for stable expression of the AKT 
isoforms.  
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6.4 Effects of SMO and/or PI3K/AKT/mTOR inhibitors in ERMS cell 
lines 
6.4.1 Functionality of PI3K/AKT/mTOR signaling inhibitors depends on feedback 
regulatory loops  
At first, all PI3K/AKT/mTOR inhibitors were functional. PI-103, pictilisib and MK-2206 
efficiently downregulated pAKT levels, and everolimus and rapamycin efficiently inhibited the 
phosphorylation of the mTOR target S6 (see Figs.10B and 15). 
Furthermore, everolimus and rapamycin enhanced phosphorylation of AKT in RD cells. This 
phenomenon has already been described237. Thus, upon mTOR inhibition, an IGF-1R-
dependent activation of PI3K and subsequent phosphorylation of AKT at Ser473 occurs. Due 
to this negative feedback loop, the use of mTOR inhibitors for RMS clinical trials (phase II 
and III clinical trials are ongoing, as described in section 1.1.1) should be carefully 
reconsidered. 
PI-103 and pictilisib efficiently inhibited the phosphorylation of S6 in RD and RUCH-2 cells. 
However, MK-2206 lacked this effect as was observed for several other cancer cell lines238-
240. One possible explanation of the missing inhibition of S6 phosphorylation is the possibility 
of an AKT-independent regulation of mTORC1. However, this would be contrary to what was 
observed upon pictilisib treatment, which efficiently downregulated pAKT and pS6. Together, 
the two PI3K inhibitors PI-103 and pictilisib showed higher functionality than AKT or mTOR 
inhibitors.  
6.4.2 Anticancer effects of SMO inhibitors alone and in combination with 
PI3K/AKT/mTOR inhibitors 
Next, the impact of a combined treatment with SMO and PI3K/AKT/mTOR inhibitors on HH 
signaling activity and on proliferation and apoptosis was investigated in RD and RUCH-2 
cells. As already stated, PI3K/AKT/mTOR inhibitors more efficiently reduced HH signaling 
compared to SMO inhibitors (see Fig. 14). These data indicate that non-canonical HH 
signaling via the PI3K/AKT/mTOR signaling pathway plays a more prominent role in both 
ERMS cell lines compared to canonical HH signaling. In addition the data showed that 
inhibition of canonical HH signaling was not strengthened when SMO inhibitors were 
combined with PI3K/AKT/mTOR inhibitors. Similar results have been shown in a recent 
paper when using vismodegib in combination with PI-103249.  
We next investigated the impact of the drugs on proliferation (see Figs. 16 and 17) and 
apoptosis (see Fig. 18). In the settings where cells were treated with single drugs, 
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vismodegib or sonidegib did not affect proliferation, whereas HhAntag reduced it. In addition, 
sonidegib and HhAntag – in contrast to vismodegib - induced apoptosis in RD cells. PI-103 
and pictilisib efficiently blocked proliferation of RD and RUCH-2 cells and induced apoptosis 
in RD cells. MK-2206 blocked proliferation of RUCH-2 cells. In contrast, everolimus and 
rapamycin did not affect proliferation of either cell line. Although these effects are very hard 
to explain with the markers used in this thesis, it is possible that downregulation of pAKT and 
pS6 are required for efficient growth inhibition of RD cells. Thus, MK-2206 or everolimus and 
rapamycin, that did not reduce pS6 or pAKT, respectively, had no anti-proliferative or pro-
apoptotic effects in RD cells. On the other hand, MK-2206 blocks proliferation of RUCH-2 
cells but not of RD cells, which goes along with a reduction of GLI1 expression in RUCH-2, 
but not in RD. This may indicate that the lack of pS6 reduction might be compensated by 
GLI1 reduction in RUCH-2 cells. However, this is pure speculation. 
When SMO inhibitors were combined with PI3K/AKT/mTOR inhibitors, cooperative 
antitumoral effects were observed for several combination treatments. However, these were 
dependent on the used SMO inhibitor and on the cell line investigated. Thus, in RD cells, 
combination treatments with vismodegib generally did not evoke cooperative anti-proliferative 
or pro-apoptotic effects, whereas the combination sonidegib plus pictilisib induced a 
synergistic reduction of proliferation at concentrations of 50 µM plus 10 µM. Additionally, 
combinations of 30 µM sonidegib plus PI-103, pictilisib or MK-2206 evoked strong and 
cooperative pro-apoptotic effects. Unfortunately, these effects were not observed at a 
concentration of 10 µM sonidegib and GLI1 expression, pAKT and pS6 levels and caspase 3 
cleavage were only measured in samples treated with 10 µM sonidegib. Thus, it was not 
possible to correlate these factors with the cooperative pro-apoptotic effects. Nevertheless, 
single treatment of RD cells with PI-103, pictilisib or MK-2206 induced cleavage of caspase 3 
and apoptosis (see Figs. 15 and 18), suggesting that the cooperative pro-apoptotic effects 
may be caspase-dependent.  
Also the combination of HhAntag plus pictilisib evoked cooperative anti-proliferative effects 
and the combination of 12.5 µM HhAntag plus 2.5 µM pictilisib acted synergistically (see Fig. 
17C). However, the cooperative anti-proliferative effects were not accompanied by any 
changes in GLI1 expression, pAKT, pS6 or cleavage of caspase 3. Thus, the reason for the 
cooperative effects has to be based on other factors. HhAntag also evoked strong pro-
apoptotic effects when combined with MK-2206. This was indeed accompanied by an 
enhanced cleavage of caspase 3. However, it remains unclear why the pro-apoptotic effects 
only occurred upon combination treatment with MK-2206 and not with PI-103 or pictilisib. 
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Similar to what was seen in RD cells, combination of vismodegib plus PI3K/AKT/mTOR 
inhibitors did not enhance the anti-proliferative effects in RUCH-2 cells (see Fig. 16). This 
was also true for sonidegib. Although the combination of sonidegib plus rapamycin 
cooperatively reduced proliferation, the overall effect of this combination was rather weak 
compared to e.g. single treatment with pictilisib. In contrast, combination of HhAntag plus PI-
103 induced strong and cooperative anti-proliferative effects. However, this effect also could 
not be traced back to GLI1, pAKT or pS6 levels and remains to be analyzed in the future. 
Furthermore the combination of HhAntag plus pictilisib did not enhance the anti-proliferative 
effects of either single treatment in RUCH-2. However, since pictilisib already reduced 
proliferation towards the lower detection limit and since the combination of HhAntag plus 
pictilisib enhanced cleavage of caspase 3 (see Fig. 15C), this combination may indeed exert 
very potent antitumoral effects, at least in RUCH-2 cells. Furthermore, the combination of 
HhAntag plus MK-2206 induced strong and cooperative anti-proliferative effects (see Fig. 
16C). Because this went along with a more pronounced reduction of pS6 levels and an 
increase in cleavage of caspase 3 compared to either single treatment (Fig. 15C), the 
cooperative effects could be due to enhancement of apoptosis. This is similar to a recently 
published observation showing that MK-2206, which alone does not affect pS6 levels, 
cooperatively reduces pS6 levels in mouse embryonic fibroblasts when combined with 
rapamycin240. In addition, the authors of this report also state that, similar to what we have 
observed, only the parallel reduction of pAKT and pS6 inhibits cell growth. In RUCH-2 cells, 
cooperative anti-proliferative effects were also seen when HhAntag was combined with 
rapamycin (see Fig. 16C). This was accompanied by a reduction of pAKT (see Fig. 15C). 
Since rapamycin only mildly reduced pAKT levels and HhAntag strengthened this effect, 
HhAntag may enhance effectiveness of rapamycin via downregulation of AKT activity. 
However, the combination HhAntag plus everolimus, which also reduced the level of pAKT, 
did not show cooperative anti-proliferative effects. Thus, the cooperative anti-proliferative 
effect of the combination rapamycin plus HhAntag may be based on other mechanisms than 
pAKT levels.  
Together, cell lines derived from sporadic ERMS show PI3K/AKT/mTOR-mediated non-
canonical activation of HH signaling. In addition, antitumoral effects in these cells are 
generally induced by PI3K/AKT/mTOR inhibitors, but not by SMO inhibitors. Although the 
antitumoral effects of PI3K/AKT/mTOR inhibitors are accompanied by inhibition of non-
canonical HH signaling, inhibition of the latter pathway is most probably not much involved in 
the antitumoral effects. Thus, HhAntag, MK-2006 and the mTOR inhibitors rapamycin or 
everolimus strongly inhibited GLI1 expression but did not affect proliferation. This is similar to 
another study showing that application of the GLI1/2 inhibitor GANT-61 is not effective in RD 
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cells249. Together these data indicate that targeting the HH pathway alone is not very useful 
in therapy of sporadic ERMS. 
In addition, the combination of SMO inhibitors plus PI3K/AKT/mTOR inhibitors is generally 
not superior to single drug treatment in cell lines derived from sporadic ERMS. The 
exceptions were the combinations of HhAntag plus PI-103, MK-2206 or rapamycin, which 
cooperatively inhibited cellular proliferation of at least RUCH-2 cells. This fact also indicates 
that cooperative antitumoral effects of SMO inhibitors and PI3K/AKT/mTOR inhibitors are 
highly drug- and cell line-specific. 
6.5 Effects of SMO and/or PI3K inhibitors on Ptch+/- ERMS cells and 
tumors 
So far, the data showed that human cell lines that are derived from sporadic ERMS are 
rather unresponsive to activation or inhibition of canonical HH signaling. These cell lines in 
most likelihood do not harbor mutations that cause activation of HH signaling upstream of 
SMO, because PTCH mutations or mutations in other components of the HH pathway are 
very rare in sporadic ERMS or ARMS22,115,116 (see also section 1.2.4; RD cells are PTCH 
wildtype168). Therefore, we next investigated the effects of SMO inhibitors and also of PI3K 
inhibitors in ERMS that are caused by mutations upstream of SMO in e.g. PTCH. PTCH 
germline mutations in patients with Gorlin syndrome are causal for the development of 
several HH-associated cancer types, among them RMS34,57,58. Thus, canonical HH signaling 
is probably a driver for RMS in some cases. Since we had no access to a human ERMS cell 
line with a PTCH driver mutation and since a knockdown of PTCH in ERMS e.g. RD cells, in 
which non-canonical HH signaling is predominant, would not have reflected the situation in 
vivo, we used ERMS-like tumors of Ptch+/- mice34. In addition to active Hh signaling, this 
model shows active Pi3k/Akt/mTor signaling242. Tumors derived from this mouse model were 
used to assess the effectiveness of SMO inhibitors and also of the PI3K inhibitor pictilisib 
alone or in combination. For this purpose, primary short-term ERMS cultures were incubated 
in vitro and ERMS-bearing Ptch+/- mice were treated orally with the drugs. 
6.5.1 Effects of different SMO inhibitors in vitro and in vivo 
In contrast to RD cells that are wildtype for PTCH and also to RUCH-2 cells (which are in all 
likelihood also PTCH wildtype), treatment of primary Ptch+/- ERMS cells with vismodegib, 
sonidegib or HhAntag significantly reduced Gli1 expression levels (see Fig. 19). This shows 
that the canonical Hh signaling pathway can be efficiently modulated in this model and that 
all three drugs indeed inhibit Smo to a similar extent. The SMO inhibitors also strongly 
reduced Gli1 expression in vivo (see Fig. 24). This proves favorable bioavailability and 
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functionality of all drugs when applied orally, at least in mice. In contrast to primary ERMS 
cells, sonidegib seems to be more potent than vismodegib in the mouse, although its dosage 
was lower (80 mg/kg daily) than that of vismodegib (100 mg/kg daily). This may indicate an 
enhanced bioavailability of sonidegib when compared to vismodegib. A recent comparison 
between the two drugs in a preclinical mouse model for basal cell carcinoma showed similar 
results. Although mice underwent topical drug administration, this report suggests a more 
favorable uptake of sonidegib into the bloodstream compared to vismodegib, indicated by a 
higher plasma concentration232. This could explain the stronger inhibition of Gli1 expression 
by sonidegib when compared to vismodegib in ERMS isolated from treated mice (please 
note that a direct comparison of Gli1 expression between vismodegib- or sonidegib- and 
HhAntag-treated ERMS was not possible, because vismodegib or sonidegib were given for 
21 days, whereas HhAntag was given for only 14 days; see also section 5.3.1). 
Additionally, vismodegib, sonidegib and HhAntag efficiently reduced cell growth in vitro (see 
Fig. 21) and tumor growth in vivo (see Fig. 22). In primary ERMS cells vismodegib was less 
effective than sonidegib and HhAntag. In contrast, vismodegib and HhAntag showed a 
similar predicted tumor growth inhibition in vivo, whereas sonidegib was more effective and 
induced tumor regression. Although the treatment duration of the HhAntag cohorts was 
longer than that of the vismodegib or sonidegib cohorts (drugs were given for 35 and 21 
days, respectively), the vehicle-treated tumors of all cohorts show a similar growth behavior 
in the prediction model. This suggests that the predicted tumor growth of all cohorts can 
probably be compared with each other. Thus, sonidegib seems to be more effective in vivo 
than vismodegib or HhAntag. This was also reflected by the analysis of Ki67+ cells that were 
significantly downregulated in the sonidegib-treated tumors compared to the vehicle control 
(see Fig. 23). 
Besides the growth prediction models, the effectiveness of the drugs was evaluated by 
RECIST analysis (PD: progressive disease, SD: stable disease, PR: partial response)230,231. 
The analysis showed that all three SMO inhibitors reduced the number of animals showing 
PD and enhanced the number of animals showing SD or PR. Also in this analysis, sonidegib 
was the most effective drug (see Table 18), and thus the results are in line with the growth 
prediction models. The effectiveness of sonidegib and vismodegib can be explained by Hh 
signaling inhibition (see Fig. 24). Indeed, a positive correlation between Gli1 expression 
levels and tumor growth was found for ERMS of all animals treated with vismodegib or 
sonidegib (see Fig. 25A, analysis could not be performed for HhAntag because no tumor 
material was available at the end of treatment; please see section 5.3.1). However, this 
correlation was not found in primary Ptch+/- ERMS cells. In cultured ERMS cells, vismodegib 
or sonidegib reduced Gli1 expression levels to a similar extend (see Fig. 19), but sonidegib 
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had a more pronounced anti-proliferative potential when compared to vismodegib (see Fig. 
21). There are several explanations for this difference. First, in the in vitro setting the 
concentrations of the drugs were all the same, whereas in the in vivo setting the 
administered doses and most probably the bioavailability of vismodegib and sonidegib is 
different, as already described above.  
Furthermore, vismodegib or sonidegib apparently moderately reduced pAkt levels in vivo 
(see Fig. 27; not significant). The same was seen for sonidegib or HhAntag in vitro (see Fig. 
20; not significant). Thus, it is possible that Hh signaling interacts with Pi3k/Akt/mTor 
signaling. On the other hand the decreased Akt phosphorylation could reflect off-target 
effects of the drugs. 
In summary, all SMO inhibitors show a very strong antitumoral potency in ERMS that show 
canonical Hh signaling activity due to Ptch mutations. 
6.5.2 Pictilisib-mediated effects on Hh signaling and growth of Ptch+/- ERMS 
Because the PI3K inhibitor pictilisib efficiently downregulated HH signaling and proliferation 
in RD and RUCH-2 cells (see chapter 5.1.4 and 228), this drug was also employed in Ptch+/- 
ERMS. As expected, the drug efficiently downregulated pAKT in vitro and in vivo (see Figs. 
20 and 27). Similar to RD and RUCH-2 cells, pictilisib also reduced Gli1 expression in 
cultured Ptch+/- ERMS cells (see Fig. 19). Thus, we hypothesized that Hh signaling in Ptch+/- 
ERMS is not only activated by the Ptch mutation but also by the Pi3k/Akt/mTor pathway. 
However, this was different in the in vivo situation where pictilisib did not affect Gli1 
expression at all (see Fig. 24). One possible explanation for this difference could be external 
stimuli from the tumor microenvironment that hamper the Pi3k/Akt/mTor-mediated Hh 
signaling regulation in vivo. If e.g. immune cells or endothelial cells secrete these stimuli they 
are probably missing when the Ptch+/- ERMS cells are cultured in vitro.  
Beyond that, pictilisib enhanced the expression level of the negative Hh regulator Hhip in 
vitro and in vivo (see Figs. 19 and 24). The upregulation of Hhip expression and 
downregulation of Gli1 expression is at the first glance contradictory, because both genes 
are positively regulated by Hh signaling. However, we also did not observe a correlation 
between Gli1 and Hhip expression levels in Ptch+/- ERMS cells and tissue samples that were 
treated with SMO inhibitors. In addition, Hhip can be epigenetically silenced in Hh-associated 
cancer types250-253. Thus, it is possible that Hhip is also epigenetically silenced in Ptch+/- 
ERMS, e.g. by DNA methyltransferase 1 (Dnmt1)-mediated hypermethylation of its promoter 
region. Furthermore, in bladder254, lung255 and liver cancer256 active Pi3k/Akt signaling 
stabilizes Dnmt1, e.g. through inhibition of GSK3β. Hence, pictilisib treatment may decrease 
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Dnmt1 levels in ERMS, which could result in upregulation of Hhip expression. Because 
hypermethylation of the Hhip promoter region would prevent Gli transcription factors from 
binding, this hypothesis would also explain two additional observations. First, it would explain 
the discrepancy between Gli1 and Hhip expression levels in pictilisib-treated Ptch+/- ERMS 
cells and tumors. Second, it would also explain why SMO inhibitors did not affect Hhip 
expression levels although they were in general shown to be functional (see Figs. 19 and 
24). To proof this hypothesis one should assess Dnmt1 protein levels in pictilisib-treated 
ERMS (tissue and cells) and methylation marks in the Hhip promoter region by bisulfite 
sequencing. One could also perform chromatin immunoprecipitation (ChIP) with sequencing 
to analyze potential binding of Gli transcription factors at the Hhip promoter under solvent- or 
pictilisib-treated conditions.  
Treatment with pictilisib additionally upregulated the expression level of Gli2, at least in the in 
vitro settings (see Fig. 19). As the Gli2 promoter is methylated and can even be 
hypermethylated257, Gli2 expression upon pictilisib treatment could also be the result of an 
inhibition of the Akt-Dnmt1 axis. 
Similar to SMO inhibitors, pictilisib also reduced proliferation (see Fig. 21) and induced 
caspase 3 cleavage (see Fig. 20) in cultured ERMS cells in a concentration-dependent 
manner. In line with that, the drug reduced tumor growth in vivo. Regarding to RECIST 
analysis, the effectiveness of pictilisib was similar to that of vismodegib or HhAntag (see 
Table 18). In line with the latter result, pictilisib treatment reduced the number of Ki67+ cells 
within the tumor to a similar extent as vismodegib or HhAntag (see Fig. 23). 
Whereas caspase 3 cleavage was enhanced by pictilisib treatment in cultured cells, it was 
not affected in vivo (see Fig. 26). However, pictilisib efficiently downregulated pAkt levels in 
both settings. Thus, again, signals from the tumor microenvironment may have prevented 
pictilisib-mediated apoptosis induction in the in vivo setting. Indeed, the tumor 
microenvironment is often characterized by e.g. hypoxic conditions that also can prevent 
RMS cell lines from drug-induced apoptosis258.  
Together the data indicate that pictilisib is also an efficient anticancer drug for ERMS that are 
caused by Ptch mutations, although its effectiveness is independent of Hh signaling 
modulation. We have shown that the anticancer effects of pictilisib in vivo are based on an 
inhibition of cancer cell proliferation. In combination with the high effectiveness of this drug in 
cell lines derived from sporadic ERMS (see section 6.4), our data support the idea that, 
indeed, inhibition of PI3K may be superior to SMO inhibition. This is mainly based on the fact 
that anticancer effects of pictilisib are independent of the existence of PTCH mutations in 
ERMS.  
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6.5.3 Combination effects of SMO inhibitors plus pictilisib  
Both SMO inhibitors and pictilisib evoked strong antitumoral effects in Ptch+/- ERMS. To see 
whether the combination of the drugs was more potent, they were also applied together. This 
could be important e.g. for patients with PTCH-associated RMS, because the use of SMO 
inhibitors in the clinics is frequently accompanied by severe side effects and is therefore 
especially problematic for young patients (see also introduction section 1.3.2). An enhanced 
effectiveness in the frame of a combination therapy may thus allow for lowering the dose of 
SMO inhibitors and for avoiding adverse effects. Furthermore, SMO inhibitors can induce 
tumor resistance, either by activating canonical (e.g. SMO mutations) or non-canonical (e.g. 
PI3K/AKT/mTOR-mediated) HH signaling160,165. Therefore, the combination of SMO inhibitors 
with the PI3K inhibitor pictilisib may potentially circumvent some of these resistance 
mechanisms. 
When cultured ERMS cells were treated with SMO inhibitors plus pictilisib, the reduction of 
Gli1 expression was strengthened and was even cooperative for sonidegib or HhAntag plus 
pictilisib (see Fig. 19). This fostered the hypothesis that Hh signaling in Ptch+/- ERMS is also 
regulated by the Pi3k/Akt/mTor signaling cascade. However, this effect was not observed in 
vivo (see Fig. 24). Because pictilisib alone also does not affect Gli1 expression in vivo, 
Pi3k/Akt/mTor-signaling probably does not regulate Hh signaling in this setting (already 
discussed above; see section 6.5.2).  
Furthermore, combination treatment with sonidegib plus pictilisib rescued the pictilisib-
mediated upregulation of Hhip expression back to basal level in cultured Ptch+/- ERMS cells 
(see Fig.19). Combination treatments with vismodegib or HhAntag plus pictilisib also lowered 
the pictilisib-mediated upregulation of Hhip expression, but to a lesser extent. Similar results 
were obtained in the in vivo setting (see Fig. 24). This phenomenon can be explained with 
the aforementioned hypothesis of Akt/Dnmt1-mediated epigenetic silencing described in 
section 6.5.2. Thus, pictilisib may induce demethylation of the Hhip promoter region, which 
subsequently becomes accessible for Gli repressor isoforms that are generated upon 
treatment with SMO inhibitors. A similar scenario can be suggested for the pictilisib-mediated 
upregulation of Gli2 expression, which was reduced to basal level upon the combination 
treatments with sonidegib or HhAntag plus pictilisib (see Fig. 19). However, this hypothesis 
remains pure speculation so far. 
Besides Hh signaling inhibition, all combination treatments were generally very effective 
regarding tumor growth reduction. In the prediction model, sonidegib alone or HhAntag plus 
pictilisib were the most potent treatments (see Figs. 22D - 22F). This was also shown by 
RECIST analysis, which indicated that combination treatment with HhAntag plus pictilisib 
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was the most effective among all treatments (see Table 18). These data are basically also in 
line with the reduced number of proliferating Ki67+ tumor cells (see Fig. 23), and with the 
synergistic anti-proliferative effects in vitro (see Fig. 21).  
Furthermore, in tumors that have been treated with pictilisib alone the Gli1 expression level 
did not correlate with tumor growth inhibition (Fig. 25C). Thus, the anticancer effects of 
pictilisib in vivo must be driven in an Hh-independent way. In contrast, all Ptch+/- ERMS 
treated with SMO inhibitors or with SMO inhibitors plus pictilisib showed a significant 
correlation between Gli1 expression and tumor growth inhibition (see Fig. 25A). This 
correlation indicates the impact of Hh signaling on proliferation of Ptch+/- ERMS. Furthermore, 
in those tumors in which Hh signaling and proliferation were strongly suppressed by a SMO 
inhibitor, addition of pictilisib was of no benefit (e.g. the anticancer effects of sonidegib were 
not enhanced when combined with pictilisib). In contrast, in tumors in which Hh signaling and 
proliferation were only moderately suppressed by a SMO inhibitor, pictilisib was beneficial 
(e.g. the combination of HhAntag plus pictilisib was more efficient than HhAntag alone). This 
implicates that SMO inhibitors could indeed be used in low doses for clinical trials - at least in 
Ptch+/- ERMS - when they are combined with PI3K inhibitors.  
Finally, the data may indicate that pictilisib targets a different cancer cell population than the 
SMO inhibitors. Thus, whereas SMO inhibitors reduce growth of cells showing canonical Hh 
pathway activation, pictilisib may reduce growth of cells that show active Pi3k signaling. 
Perhaps pictilisib also reduces growth of tumor cells that show non-canonical Hh signaling. 
However, these cells must be very rare in Ptch+/- ERMS, because pictilisib does not block 
Gli1 expression in the in vivo setting. It is also possible that these cells have a growth 
advantage in the in vitro setting e.g. mediated by factors in the culture medium, because the 
effect of pictilisib on non-canonical Hh signaling in cultured Ptch+/- ERMS is very strong. 
Together these results show that SMO inhibitors can be very effective anticancer drugs for 
Ptch+/- ERMS. Those drugs, which strongly inhibit HH signaling, are especially effective. In 
addition, when the respective SMO inhibitor only moderately inhibits HH signaling and 
proliferation, the combination with pictilisib is beneficial. The latter fact also implies that 
pictilisib may be beneficial to attenuate side effects of SMO inhibitors, because the SMO 
inhibitors could be applied at a lower dose when combined with pictilisib. However, the 
effectiveness of SMO inhibitors in Ptch+/- ERMS cannot be translated to PTCH wildtype cell 
lines from sporadic ERMS (see section 6.4). Thus, the use of SMO inhibitors in ERMS 
patients, especially in those without PTCH mutation, should be very carefully considered and 
requires thorough pretesting, e.g. in patient-derived xenograft models. 
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Abbreviations 
µCT Micro computed tomography 
AKT Protein kinase B 
AKT-CA Constitutively active AKT 
AKT-DN Dominant negative AKT 
AMPK 5'Adenosine monophosphate-activated protein kinase 
ANOVA  Analysis of variance 
ARMS Alveolar RMS 
ATCC American type culture collection 
B6 C57BL/6N 
BAD Bcl-2-associated death promoter 
Balb BALB/c 
BCA Bicinchoninic acid 
Bcl-2 B-cell lymphoma 2 
BOC Brother of CDO 
BrdU 5-Bromo-2’-deoxyuridine 
BSA Bovine serum albumin 
BSA Bovine serum albumin 
Casp3 cl Cleaved form of caspase 3 
Casp3 pro Pro form of caspase 3 
cDNA Complementary DNA 
CDO Cell adhesion molecule-related/down-regulated by oncogenes 
ChIP Chromatin immunoprecipitation 
CI Combination index 
CK1 Casein kinase 1 
CMV Cytomegalovirus 
Control-CM Control conditioned medium 
Cu
2+
 Cupric ions 
DAB Diaminobenzidine 
dATP Deoxyadenosine triphosphate 
dCTP Deoxycytidine triphosphate 
dGTP Deoxyguanosine triphosphate 
DHH Desert HH 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
DNA Desoxyribonucleic acid 
DNMT1 DNA methyltransferase 1 
dNTPs Deoxyribonucleotide triphosphates 
DTT Dithiothreitol 
dTTP Deoxythymidine triphosphate 
DYRK Dual-specificity tyrosine-phosphorylation-regulated kinase 
E. coli Escherichia coli 
EDTA Ethylendiaminetetraacetic acid 
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EGF Epidermal growth factor 
EGFP Enhanced green fluorescent protein  
EGFR EGF receptor 
EMA European medicines agency 
ERK Extracellular signal-regulated kinase 
ERMS Embryonal RMS 
EtOH Ethanol 
FCS Fetal calf serum 
FDA Food and drug administration 
FELASA Federation of european laboratory animal science associations 
FGF Fibroblast growth factor 
FGFR FGF receptor 
FITC Fluorescein isothiocyanate  
FOXO1 Forkhead box protein O1 
GAS1 Growth arrest-specific 1 
gDNA Genomic DNA 
GLI Glioma-associated oncogene homolog 
GLI
R
 GLI repressor form 
GSK3β Glycogen synthase kinase 3β 
HA Hemagglutinin 
HE Haematoxylin and eosin 
HH Hedgehog 
HHIP HH interacting protein 
HPRT Hypoxanthine-guanine phosphoribosyltransferase 
HRP Horse radish peroxidase 
HSC70 Heat-shock protein 70 
IGF1/2 Insulin-like growth factor 1/2 
IGF-1R IGF factor 1 receptor 
IgG Immunoglobulin G 
IHH Indian HH 
IRS1 Insulin receptor substrate 1 
JNK c-Jun N-terminal kinases 
LB Lysogeny broth 
LOH Loss of heterozygosity 
mAb Monoclonal antibody 
MAPK Mitogen-activated protein kinase 
MCT Methylcellulose tween 
MDM2 Mouse double minute 2 homolog 
MEK Mitogen-activated protein kinase kinase 
MolTaq Taq polymerase (named after Thermus aquaticus) 
mRNA Messenger RNA 
mTOR Mammalian target of rapamycin 
mTORC1/2 mTOR complex  
NC Nitrocellulose 
P/S Penicillin, Streptomycin 
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pAb Polyclonal antibody 
pAKT Phosphorylated AKT 
PAX Paired box 
PBS Phosphate buffered saline 
PBST PBS-tween 
PCR Polymerase chain reaction 
PD Progressive disease 
PDK 3-phosphoinositide-dependent protein kinase 
pDNA Plasmid DNA 
pERK Phosphorylated ERK 
PFA Paraformaldehyde 
PI Propidium iodide 
PI3K Phosphatidylionsitide 3-kinase 
PIP2 Phosphatidylinositol-4,5-bisphosphate 
PIP3 Phosphatidylinositol-3,4,5-trisphosphate 
PKA Protein kinase A 
PR Partial response 
PRAS40 Proline-rich AKT substrate of 40 kDa 
pS6 Phosphorylated S6 
PTCH Patched 
PTEN Phosphatase and tensin homolog 
PVDF Polyvinylidene 
qRT PCR Quantitative real-time PCR 
Rac1 RAS-related C3 botulinum toxin substrate 1 
RAF Rapidly accelerated fibrosarcoma 
RAS Rat sarcoma 
RECIST Response evaluation criteria in solid tumors 
RhoA RAS homolog gene family member A 
RMS Rhabdomyosarcoma 
RNA Ribonucleic acid 
rRNA Ribosomal RNA 
RTK Receptor typrosine kinase 
S6K1 S6 kinase 1 
SAG SMO agonist 
SD Stable disease 
SDS Sodiumdodecylsulfate 
SEM Standard error of the mean 
SHH Sonic HH 
SHH-CM SHH conditioned medium 
SMO Smoothened 
SOX Sex-determining region Y-related high mobility group-box 
SUFU Suppressor of fused 
TBE Tris-boric acid-EDTA 
TBP TATA-box binding protein 
TBS Tris-buffered saline 
Abbreviations 128 
 
 
 
TBST TBS-triton 
TGFβ Transforming Growth Factor-β 
TSC1/2 Tuberous sclerosis protein 
UV ultraviolet 
VAC Vincristine, actinomycin D and cyclophosphamide 
VEGF Vascular endothelial growth factor 
VEGFR VEGF receptor 
WST-1 Water soluble tetrazolium salt-1 
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